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A. List of abbreviations 
AGC       Protein kinase A (PKA)/PKG/PKC-like 
ATP       Adenosine triphosphate 
C. elegans     Caenorhabditis elegans (roundworm) 
D. melanogaster   Drosophila melanogaster (fruit fly) 
HM       Hydrophobic motif 
Hpo       Hippo 
KD       Kinase-dead 
LATS      Large tumor suppressor 
M/Met      Methionine 
MOB       Mps-one binder 
MST       Mammalian sterile-20 like 
NDR       Nuclear Dbf2 related 
NTR       N-terminal regulatory domain 
OA       Okadaic acid 
S. cerevisiae    Saccharomyces cerevisiae  (budding yeast) 
S. pombe      Schizosaccharomyces pombe (fission yeast) 
STK       Serine/Threonine kinase 
S/Ser       Serine 
T/Thr       Threonine 
Trc       Tricornered 
WT       Wild-type 
YAP       YES-associated protein 
Less frequently used abbreviations are defined upon their first use in the text. 
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B. Summary 
Protein kinases are important regulators of signal transduction pathways in both 
unicellular and multicellular organisms. They play critical roles in biological 
processes such as cell growth, division, differentiation, adhesion, motility and cell 
death. Given their central role in mediating cellular function and physiological 
responses, perturbation of protein kinase signaling can cause many diseases, including 
cancer and diabetes. Out of the 518 protein kinases encoded by the human genome, 
approximately 60 belong to the AGC group of Ser/Thr protein kinases, including the 
NDR kinase family. Members of this family are highly conserved from yeast to men 
and regulate important processes such as mitotic exit, cell polarity, neuronal and 
epithelial morphology, growth, proliferation and apoptosis. Despite the fact that NDR 
kinase family members regulate important cellular processes, direct downstream 
targets have only been identified recently. Furthermore, the regulation of NDR kinase 
signaling by upstream kinases of the Ste20-like family or co-activator proteins of the 
MOB family is also remarkably conserved. The human genome encodes for four 
NDR kinases: NDR1, NDR2, LATS1 and LATS2. Whereas the molecular 
mechanisms of NDR kinase regulation have mostly been worked out using human 
NDR1/2 kinases, biological functions have just started to emerge. Human NDR 
kinases were implicated in regulating centrosome duplication, mitotic chromosome 
alignment and apoptosis signaling. Additionally, the human MOB family consists of 
six distinct members (hMOB1A, -1B, -2, -3A, -3B and -3C), with hMOB1A/B the 
best studied due to their tumor suppressive functions through regulation of 
NDR/LATS kinases. The roles of the other MOB proteins are not as well defined. 
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 We investigated the role of human MOB proteins in NDR/LATS kinase regulation. 
We found that three hMOB proteins did not bind to or activate all human NDR 
kinases and that hMOB2 was an NDR-specific binder. Furthermore, we describe 
competitive binding of hMOB1A/B and hMOB2 towards the NTR of human NDR1/2. 
Interestingly, in contrast to hMOB1A/B, hMOB2 is bound to unphosphorylated 
NDR1/2. Moreover, RNAi-mediated depletion of hMOB2 protein resulted in 
increased NDR activity. Consistent with these findings, hMOB2 overexpression 
impaired not only okadaic acid-induced activation of NDR but also the functional 
roles of NDR in death receptor-induced apoptosis and centrosome duplication. In 
summary, our data indicate that hMOB2 is a negative regulator of human NDR1/2 
kinases. 
 Additionally, we established a basis for the discovery of additional human NDR 
kinase substrates. We employed the chemical genetic method developed by Shokat 
and colleagues to create analog-sensitive variants of NDR1/2 kinases. Subsequently, 
we have tried to identify direct targets of analog-sensitive NDR1(M166G) by 
performing in vitro kinase assays on cell lysates and immunocomplexes in the 
presence of a radiolabeled ATP analog and observed a specific and reproducible 
pattern of labeled bands in reactions containing NDR1(M166G) immunocomplexes. 
Our data together with the recent identification of the first in vivo substrate of human 
NDR1/2 kinases, p21, should stimulate further efforts to dissect the downstream 
signaling of mammalian NDR kinases. 
 
 
 
1. Introduction 
1.1. Protein kinases: Critical regulators of signal transduction 
Protein kinases are key regulators of intracellular signaling pathways and mediate 
most of the signal transduction in eukaryotic cells. All protein kinases catalyze the 
transfer of the γ-phosphate group of ATP to the hydroxyl group of serine, threonine or 
tyrosine amino acid side chains [1]. The phosphorylation by protein kinases can alter 
the substrates properties such as activation/deactivation of enzyme activity, change in 
subcellular localization or increase/decrease in protein stability. Therefore, protein 
kinases play critical roles in cell growth, division, differentiation, motility, adhesion 
and death in unicellular and multicellular organisms and proper regulation of their 
activity is crucial for the normal physiology of organisms [2]. Hence, perturbation of 
protein kinases by mutation, altered expression, or general dysregulation can cause 
many human diseases such as cancer or diabetes [3]. 
 The human protein kinase complement of the human genome, also known as the 
kinome, encodes for ~518 protein kinases and constitutes one of the biggest gene 
family of the human genome [2]. To 
gain insight into kinase function and 
evolution, all 518 protein kinases 
were classified into a hierarchy of 
phylogenetic groups, families and 
subfamilies based on the catalytic 
domain sequence [2]. The biggest 
kinase group is represented by 
tyrosine kinases, followed by the 
Figure 1. Dendrogram of 491 eukaryotic protein 
kinase domains from 478 genes. Major groups are 
labeled and colored (Taken from (2)). 
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CAMK, the AGC and then the CMGC group of kinases (Figure 1). The catalytic 
domain (kinase domain) consists of 250-300 amino acids defining 12 conserved 
subdomains which are thought to fold into a common bilobal catalytic core structure 
since residues that contribute to nucleotide binding, phosphoryl transfer or ion binding 
are highly conserved [1]. Furthermore, since deregulated protein kinase signaling is 
associated with the development of human diseases, members of this class of enzymes 
are emerging as attractive drug targets [4].  
 
1.2. The NDR kinase family 
The human genome encodes 63 protein kinases that are classified as members of 
the AGC group of serine/threonine kinases [2]. These kinases, along with their 
regulatory mechanisms by phoshporylation, are highly conserved throughout 
eukaryotic evolution and contain notable members such as isoforms of protein kinase 
A (PKA), PKC or PKB [5].  
 NDR kinases represent a less well-studied family of the AGC group. The human 
genome encodes four related NDR kinases: NDR1 (STK38), NDR2 (STK38L), 
LATS1 and LATS2 [6]. Members of the NDR family are highly conserved 
throughout evolution and can be found in organisms such as S. cerevisiae (Dbf2p, 
Dbf20p and Cbk1p), S. pombe (Sid2p and Orb6p), C. elegans (SAX-1 and LATS) and 
D. melanogaster (Warts and Trc) as well as other fungi, plants and protozoans [6]. 
Genetic and biochemical studies showed that NDR kinases amongst all species are 
crucial regulators of important functions such as mitosis, cytokinesis, cell polarity and 
morphogenesis, apoptosis, proliferation, centrosome duplication and other 
developmental processes [7].  
 
 2 
1.2.1. Characteristics of NDR kinases 
The primary structure of NDR kinases is conserved from yeast to men (Figure 2) 
[6]. The highly conserved kinase domain can be subdivided into 12 subdomains based 
on structural features and conserved residues [1]. AGC kinases share typical features 
such as phosphorylation sites in the activation segment located at subdomain VIII of 
the kinase domain and at the hydrophobic motif which is found in a non-catalytic 
region positioned C-terminally of the kinase domain [5]. All NDR kinases contain 
both typical characteristics of AGC kinases required for activation but are unique 
among the AGC group because they exhibit two distinct features only present in the 
NDR family: an N-terminal regulatory domain (NTR) also known as the 
S100B/hMOB1 association domain (SMA) and an insert of about 30-60 amino acids 
 Figure 2. Primary structure of selected NDR kinases. Eight members of NDR family kinases 
from unicellular to multicellular organisms are shown (H.s. Homo sapiens, D.m. Drosophila 
melanogaster, C.e. Caenorhabditis elegans, A.t. Arabidopsis thaliana, T.b. Trypanosoma brucei). 
The N-terminal regulatory domain (NTR, grey), the kinase domain (green) with the activation 
segment (yellow) and the hydrophobic motif (brown) are shown. In addition, the auto-inhibitory 
sequence (red) and conserved phosphorylation sites (blue dots) are indicated. Taken from (7). 
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between subdomains VII and VIII of the kinase domain (Figure 2). The NTR is 
responsible for the interaction with S100B and hMOB1 proteins [8, 9]. Furthermore, 
the NTR contains a significant number of basic and hydrophobic residues which were 
shown to be essential for the interaction of hMOB1A with human NDR1/2 and 
LATS1/2 [8, 10-12]. Interestingly, MOB1 proteins contain a negatively charged area 
suggesting that the NDR/MOB, LATS/MOB complex formation is based on 
electrostatic interactions, which was supported by the analysis of a MOB1 structure in 
complex with an N-terminal peptide of NDR [13]. However, this structure did not 
include the full-length NTR and therefore the exact mechanism of how hMOB1 
proteins interact with NDR remains largely unknown. 
 The primary sequence of the 30-60 residues insert between kinase subdomains VII 
and VIII seems to differ between NDR family members. However, all the inserts 
contain a stretch of basic residues located towards subdomain VIII [6]. These 
positively charged residues precede the activation segment and seem to inhibit NDR 
kinase activity since mutations of these residues to alanine lead to a significant 
increase in NDR1/2 kinase activity [8]. Therefore, this motif is also referred to as an 
auto-inhibitory sequence (AIS).  
 
1.2.2. Regulation of NDR kinases 
Regulation by phosphorylation 
As mentioned above, many AGC kinases require phosphorylation on two highly 
conserved regulatory motifs for full activation [5]. Thus, all NDR kinases contain 
those main regulatory phosphorylation sites: the activation segment (Ser281 of human 
NDR1) and the hydrophobic motif phosphorylation site (Thr444 of human NDR1). In 
contrast to other AGC kinases, the activation segment is not targeted by an upstream 
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kinase but is regulated by autophosphorylation [14, 15]. Whether this 
autphosphorylation is mediated by a cis-acting or trans-acting mechanism has yet to 
be investigated, although work on the budding yeast NDR kinase Cbk1p suggests that 
the activation loop modification occurs through intramolecular autophosphorylation 
[16]. Still, similar to other AGC kinases, the hydrophobic motif of NDR kinases is 
targeted by upstream kinases [6]. The importance of phosphorylation of the 
hydrophobic motif is best illustrated by a structural study performed on PKB, another 
AGC kinase [17, 18]. The phosphorylated hydrophobic motif engages a hydrophobic 
groove within the N-terminal lobe of the kinase domain and this intramolecular 
association results in a global disorder-to-order transition and ultimately kinase 
activation [17, 18]. Furthermore, this mechanism of activation is likely to be 
transferrable to other AGC kinases, since replacement of the entire hydrophobic motif 
of human NDR2 kinase by the hydrophobic motif of PRK2 (which mimics 
hydrophobic motif phosphorylation) results in a constitutively active NDR kinase [14]. 
Congruently, the activation loop phosphorylation site and the HM phosphorylation 
site are essential for kinase activity, since mutation to alanine abolishes kinase activity 
of human NDR kinases [14]. Both phosphorylation sites are targets of the 
serine/threonine phosphatase PP2A. Treatments with okadaic acid (OA, potent 
inhibitor of PP2A) increase phosphorylation of yeast, fly and human NDR kinases 
[19-22]. In addition, recombinant PP2A completely inactivates human NDR [21]. 
Interestingly, in higher eukaryotes, a third phosphorylation site located within the 
NTR is conserved (Thr74 of human NDR1) [14, 21]. Mutation of this site to alanine 
reduces kinase activity of human NDR1 and also abolishes binding to hMOB1A [8]. 
Therefore, it remains to be shown whether this phosphorylation site has intrinsic 
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functions on kinase activity or whether the effect is a consequence of MOB1-binding 
loss.  
 
Regulation by NDR kinases by the Ste20-like kinase family 
Genetic studies in yeast lead to the first insights in the nature of upstream kinases 
regulating NDR kinase family members. It was shown that the Ste20-like kinases 
Cdc15p, Kic1p, Sid1p and Nak1p function upstream of the NDR kinases Dbf2p, 
Cbk1p, Sid2p and Orb6p [20, 23-26]. Yet, only Cdc15p was shown to directly 
phosphorylate and activate Dbf2p [20]. Genetic and biochemical studies in D. 
melanogaster also demonstrated that the Ste20-like kinase Hippo (Hpo) functions 
upstream of the NDR family kinase Warts (Wts) and that Hpo interacts and 
phosphorylates Wts [27-32]. Interestingly, Hippo also phosphorylates and activates in 
fruit flies the second NDR family kinase, Tricornered (Trc), on the HM [33]. This 
finding indicates that in higher eukaryotes multiple NDR kinases can be regulated by 
a single Ste20-like kinase. 
The first Ste20-like kinase that was shown to phosphorylate specifically the 
hydrophobic motif phosphorylation site of NDR kinases was identified as mammalian 
sterile20-like kinase 3 (MST3) [34]. MST3 phosphorylates the HM of NDR1/2 
kinases (Thr444/442) in vitro and in vivo [34]. The human MST family of protein 
kinases consists of 5 members: MST1, MST2, MST3, MST4 and YSK/SOK1. Recent 
work also demonstrated that kinases other than MST3 can act as HM-kinases of 
human NDR/LATS kinases. MST1 and MST2 were shown to phosphorylate human 
LATS1/2 [19]. Interestingly, MST1 also phosphorylates and activates NDR1/2 [35, 
36]. Furthermore, MST2 phosphorylates NDR1/2 in vitro [36] and was suggested to 
function as the upstream kinase in cell culture [37]. Overall, genetic and biochemical 
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work undertaken in different organisms has linked Ste20-like kinases and NDR 
family kinase which indicates that the function of Ste20-like kinase as upstream 
activators of NDR kinase is a part of conserved signaling pathways across species. 
However, given that one Ste20-like kinase can regulate more than one NDR kinase 
and that one NDR family kinase can be regulated by multiple Ste20-like kinases 
indicates a significant complexity of the Ste20-like-NDR signaling pathways in higher 
eukaryotes. Therefore, multiple Ste20-like kinases might govern the different 
functions of a single NDR kinase. 
 
Regulation of NDR kinases by MOB proteins 
The N-terminal regulatory domain represents a unique feature of the NDR kinase 
family. The NTR is essential for the interaction with the MOB (Mps one-binder) 
family of proteins. MOB proteins are small globular proteins with no enzymatic 
activity and can be found in unicellular organisms to human (Phylogenetic tree of 
MOB proteins from yeast, Drosophila and humans can be found on page XX). Also 
conserved is the interaction of MOB proteins with the NTR of NDR kinases [6]. 
Structures of yeast, human and frog MOB1 proteins have been resolved [13, 38] and 
in combination with the knowledge of key residues in human NDR1/2 and LATS1/2 
that are required for hMOB1A binding [8, 11, 39], it is likely that the positively 
charged NTR of NDR kinases interacts with a negatively charged surface on MOB1 
proteins. In yeast, Mob1p binds to and is necessary for the activation of 
Dbf2p/Dbf20p and Sid1p kinases [20, 40, 41]. Similarly, the second MOB protein in 
yeast Mob2p binds to and activates Cbk1p and Orb6p [42, 43]. Interestingly, yeast 
MOB proteins and NDR kinases form restricted heterodimers in which the subunits 
are not interchangeable [42, 44]. In multicellular organisms, binding of MOB proteins 
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is not restricted to a single NDR kinase. In D. melanogaster, MOB as tumor 
suppressor (Mats)/dMOB1 physically interacts with Wts and is necessary for Wts 
activity [45, 46]. Mats/dMOB1 function seems to be evolutionary conserved since the 
human homolog hMOB1A can rescue the loss of Mats/dMOB1 in Drosophila [46]. In 
addition, Mats interacts genetically with the second NDR kinase, Trc [47]. Moreover, 
Trc physically interacts with a second MOB protein in flies, dMOB2 [47]. 
 The human genome encodes six MOB genes, human MOB1A/B, hMOB2 and 
hMOB3A/B/C [35] and one closely related gene (Phocein) which is part of a 
phosphatase complex [48]. Whereas hMOB1A/B and hMOB2 were shown to 
physically interact and impact human NDR/LATS kinase activity [8, 11, 12, 39, 49], 
recent studies provide evidence that hMOB3A/B/C proteins do not interact with or 
activate all four NDR/LATS kinases [10, 35, 50]. Interestingly, whereas hMOB1A/B 
interact and activate all four human NDR/LATS kinases, hMOB2 was shown to 
interact only with NDR1/2 [8, 10-12, 49, 50].  
Whereas it is known that MOB proteins interact with and are essential for the 
function of yeast and fly NDR kinase family members, most insight into the 
regulation of NDR activity and functions by MOB proteins was gained by studies on 
hMOB1A/B. Key residues in the NTR of NDR1/2 and LATS1/2 important for 
hMOB1A/B binding were identified [8, 11, 39]. hMOB1A/B are essential for the 
functions of human NDR1/2 in apoptosis and centrosome duplication [35, 36]. 
Furthermore, interfering with hMOB1A/B-NDR complex formation impaired 
activation and NDR1/2 function in the context of centrosome duplication [35]. 
Moreover, mutation of the conserved basic residues in the NTR of LATS1 negatively 
affects LATS1 kinase activity and activation [11]. In addition to the association with 
NDR kinases, hMOB1A/B proteins are also capable to interact with human MST1/2, 
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functioning possibly as adaptor proteins between NDR/LATS and MST kinases [36, 
45, 51]. Moreover, hMOB1A/B proteins facilitate and are required for efficient HM 
phosphorylation of human NDR1/2 by MST kinases [34-36] .Accordingly, a tripartite 
complex of MST1, hMOB1A/B and NDR1/2 has been described [36]. Furthermore, 
human MST1/2 kinases as well as the fly Hpo kinase phosphorylate hMOB1A/B and 
Mats/dMOB1, respectively, thereby increasing MOB1 protein affinity towards 
NDR/LATS or Wts kinases [45, 51]. In addition, hMOB1A/B binding to NDR1/2 
kinases is thought to release the kinase from autoinhibition by the AIS [8]. The 
obtained data so far suggest a model of NDR activation in which hMOB1A/B is 
Figure 3. Current model of human NDR family kinase activation by MST kinases and hMOB1 
proteins. Initially, MST1/2 phosphorylate hMOB1which results in efficient complex formation with 
NDR kinases. Binding of hMOB1 to NDR kinases facilitates activation-loop autophosphorylation 
and hydrophobic motif phosphorylation by MST1/2 kinases. Fully active NDR kinases then 
phosphorylate substrates as YAP for LATS1/2. Note that for phosphorylation by MST1, NDR1/2 
reside in complex with hMOB1 whereas it is not necessary for LATS1/2. Taken from (52). 
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phosphorylated by MST1/2 which results in efficient complex formation of hMOB1 
proteins and human NDR1/2 kinases, which in turn facilitates the phosphorylation of 
NDR1/2 by MST kinases [52] (Figure 3). Another level of human NDR kinase 
regulation by MOB1 proteins seems to be spatial relocalization. Artificial targeting of 
hMOB1 proteins to the plasma membrane results in rapid and robust activation of 
NDR1/2 or LATS1/2 [11, 39]. Indeed, membrane targeting of Mats/dMOB1 in D. 
melanogaster also leads to Wts activation and membrane-targeted Trc rescues the 
effect of trc mutant flies [22, 53]. These observations indicate that NDR/LATS kinase 
activation via relocalization to the plasma membrane, is an important step in the 
activation process and is most likely conserved in vivo. Interestingly, MOB1 proteins 
contain a positively charged surface [38] which would allow interaction with 
negatively charged phospholipids at the plasma membrane. However, the mechanisms 
by which NDR kinases are recruited to and activated at the plasma membrane by 
MOB1 proteins remain to be elucidated. 
 Much less is known about the role of MOB2 proteins in NDR kinase signaling. 
The NDR kinase family appears to be divided in terms of MOB2 binding. Whereas 
the NDR branch (human NDR1/2, Trc, Cbk1p and Orb6p) interacts with MOB2 
proteins, the LATS branch (human LATS1/2, Wts, Dbf2p and Sid2p) does not 
associate with MOB2 [11, 12, 20, 42-44, 46, 47, 49]. Conflicting data exist about the 
function of NDR-MOB2 interactions. In yeast, the interaction between Cbk1p/Orb6p 
and Mob2p proteins are essential for yeast NDR kinase activity and functions [42, 54]. 
In Drosophila, the role of dMOB2 appears to be different. dMOB2 and trc physically 
interact and co-localize, yet, kinase activity was not addressed in this setting [47]. 
Moreover, mutations in the dMOB2 gene did not enhance the trc phenotype, whereas 
mutations in the Mats/dMOB1 gene did so [47]. Intriguingly, forced overexpression 
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of a truncated version of dMOB2, which shares high sequence similarity with the 
human MOB2 protein, resulted in a weak Trc dominant-negative phenotype [47]. This 
observation indicates that dMOB2 might have inhibitory properties towards Trc 
kinase. Apart from that, a recent study implicates dMOB2 in photoreceptor 
morphogenesis in Drosophila [55]. Whether this function is dependent on NDR 
kinases such as Trc has yet to be elucidated. Comparable to Drosophila MOB2, the 
role of mammalian MOB2 in the regulation of NDR kinases is not clear. Two studies 
suggest that human MOB2 serves as an activator of human NDR1/2 kinases in vitro 
[37
ins (such as 
uman MOB3A/B/C) has yet to be clarified in multicellular organisms.  
Re
, 49]. However, these findings were not confirmed in a cellular setting.  
Altogether, MOB proteins are essential regulators of NDR kinases across species. 
While MOB1 proteins appear to be activators in all species tested so far, the role for 
MOB2 proteins in the course of NDR kinase activation in higher eukaryotes remains 
less defined. Furthermore, the function of the additional MOB prote
h
 
gulation of NDR kinases by scaffolding proteins 
Large scaffolding proteins are thought to provide higher specificity for signal 
transmission and are also conserved regulators of NDR kinase activity and function. 
In yeast, C. elegans, D. melanogaster and mammals, scaffold proteins which impact 
on NDR kinases were identified [24, 37, 56-59]. In yeast, scaffold proteins Tao3p and 
Mor2p are required for Cbk1p and Orb6p functions [24, 58]. In C. elegans, the 
scaffold protein SAX-2 was shown to genetically interact with the NDR kinase SAX-
1 [57]. More is known about the role of Furry in the regulation of Trc in D 
melanogaster. Furry genetically and physically interacts with Trc and is essential for 
Trc kinase activity [56, 60, 61]. Furthermore, the region of Trc necessary for the 
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interaction with Furry was investigated [60]. More recently, murine Furry was cloned 
and was shown to physically interact with human NDR1/2 and hMOB2 and was 
suggested to regulate human NDR kinase activity [37]. However, the functional 
significance of this interaction has yet to be investigated in the context of NDR 
reg
 of large scaffolding proteins in the regulation of NDR 
inase activity and function. 
1.2
 and dendritic 
ling, centrosome duplication and embryonic development (Table 1).  
ulation during apoptosis or centrosome duplication.  
In the case of LATS kinases in flies and humans, different scaffolding proteins are 
described. The relatively small scaffold protein human WW45 and its fly homolog 
Salvador (Sav) contain a WW domain necessary for its interaction with LATS kinases 
and were shown to be important for functions of human LATS1/2 and fly Warts [19, 
29, 32, 62]. Although no clear yeast ortholog of WW45 proteins has been described, 
the Furry-like and WW45 proteins share the common function of linking the Ste20-
like upstream kinases with the respective NDR kinases. Nevertheless, more work is 
needed to understand the role
k
 
.3. Functions of NDR kinases 
The functions of NDR kinase family members were first identified using genetic 
studies in yeast. Dbf2p is a central player of the mitotic exit network (MEN) in S. 
cerevisiae and Sid2p regulates the septation initiation network (SIN) in S. pombe [63], 
while the other members Cbk1p and Orb6p are critical regulators of morphogenesis in 
S. cerevisiae and S. pombe [64, 65]. Since then, NDR kinases across all species were 
shown to be implicated in important biological functions including regulation of 
proliferation, cell growth, apoptosis, neuronal growth, differentiation
ti
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Functions of NDR kinases in yeast 
 As mentioned above, the NDR kinases Dbf2p and Sid2p are essential for the 
functionality of MEN and SIN in budding and fission yeast [63, 66]. Briefly, in S. 
cerevisiae, regulation of MEN includes activation of the small GTPase Tem1p, after 
which the Cdc15p protein kinase is stimulated, followed by activation of the 
Dbf2p/Mob1p complex. The Dbf2p/Mob1p complex then phosphorylates Cdc14p 
leading to Cdc14p phosphatase relocalization from the nucleolus to the cytoplasm 
[67], where it dephosphorylates CyclinB-Cdk complex finally allowing exit from 
mitosis. A very similar pathway exists in S. pombe consisting of the small GTPase 
Spg1p, the protein kinases Sid1p and Cdc7p, the Sid2p/Mob1p complex and the 
phosphatase Clp1p. Interestingly, also in fission yeast, the activated Sid1p/Mob1p 
complex phosphorylates Clp1p therefore controlling retention of Clp1p in the 
cytoplasm [68]. Human LATS1 has also been implicated in the regulation of mitotic 
exit [12]. However, the precise mechanisms remain undefined and more detailed work 
needs to be undertaken to assess whether NDR kinases are implicated in a mammalian 
mi
sis by spatially 
restricting the localization and the activity of the GTPase Cdc42 [70].  
totic exit network. 
The second NDR kinases in yeast, Cbk1p in budding yeast and Orb6p in fission 
yeast, are part of a morphogenesis network In S. cerevisiae, Cbk1p is an essential 
component of the RAM (regulation of Ace2p activity and cellular morphogenesis) 
signaling cascade that regulates polarized growth. The Cbk1p/Mob2p complex 
directly phosphorylates the transcription factor Ace2p leading to its retention in the 
nucleus in the daughter cell, therefore controlling transcriptional asymmetry [69]. 
Orb6p in S. pombe is required for the coordination of morphological changes with 
cell cycle progression. It is thought that Orb6 controls cell morphogene
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 Table 1. Selected functions of NDR family kinases. Modified from (7).References for the 
indicated functions can be found in the text. 
NDR kinases in neuronal growth and differentiation 
Work in C. elegans and D. melanogaster identified a role for NDR kinases in the 
regulation of neuronal growth, morphology and differentiation. In C. elegans, the 
NDR kinase SAX-1 (sensory axon defects-1), in conjunction with the large scaffold 
protein SAX-1, regulates neurite outgrowth and dendritic tiling [57, 71]. Dendritic 
tiling is a organizational phenomenon for a same type of neurons to maximally cover 
a receptive field with minimal redundancy [72]. The role for NDR kinases in dendritic 
tiling is conserved in Drosophila [72]. The Jan lab has shown that Trc together with 
Furry regulate dendritic tiling in D. melanogaster [61]. Importantly, they could also 
demonstrate that this function is dependent on Trc kinase activity which is directly 
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regulated by Furry [56, 61]. Moreover, using genetic and biochemical approaches, 
they could demonstrate that Trc as well as Wts are phosphorylated and activated by 
Hippo in the context of dendritic tiling [33]. Hippo regulates Trc for proper neurite 
outgrowth and tiling, whereas Wts is regulated to ensure maintenance. Thus, they 
demonstrated for the first time that one single Ste20-like kinase can regulate two 
different NDR kinase family members [33]. Interestingly, this indicates that two 
distinct NDR family members can regulate two different aspects of the same 
biological process. Furthermore, the target of rapamycin complex 2 (TORC2) has 
been implicated in regulating Trc activation in the process of dendritic tiling [22]. 
Besides regulating dendritic tiling, the NDR kinase Trc, together with Furry, also 
control cell morphogenesis such as post-mitotic wing hair development [47, 56]. 
 Overall, the work from invertebrates identified an important role for the NDR 
kinases such as Tricornered and Warts in neuronal growth and differentiation. 
Unfortunately, the downstream targets of Trc or Warts in the context of dendritic 
tiling are unknown. Furthermore, mammalian NDR kinases involvement in neuronal 
processes such as dendritic tiling has yet to be investigated. Interestingly, one report 
identified the NDR2 transcript to be upregulated in the amygdala in fear-conditioned 
mice and that in cultured cells NDR2 was involved in neuronal growth and neurite 
outgrowth therefore indicating a conserved role for NDR in neuronal morphology 
[73]. 
 
Tumor suppression from flies to humans: the Hippo pathway 
The NDR kinase Wts was first identified in screens for tumor suppressors in 
Drosophila [74, 75] and subsequently been shown to act as a tumor suppressor in 
mice [76]. Later, the Ste20-like kinase Hippo was found to act upstream of Wts and 
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also the MOB protein Mats/dMOB1 was shown to regulate Wts tumor suppressive 
function [28, 31, 46]. Since then, numerous proteins were shown to be implicated in 
the regulation of this emerging tumor suppressor pathway collectively called the 
Hippo pathway (Figure 4). This pathway has attracted broad interest in both clinical 
and basic research. Most of the components of the pathway are highly conserved 
across species and have been extensively reviewed in the last years [52, 77-85]. 
 Four tumor suppressors were found to constitute the core kinase cassette of hippo 
signaling in flies: the NDR family kinase Wts, the Ste20-like kinase Hippo and the 
adaptor proteins Sav and Mats/dMOB1 [78, 85]. Biochemically, these proteins form a 
cascade in which the Hippo-Salvador complex phosphorylates and activates the 
Warts/Mats complex which in turn phosphorylates and inactivates the transcriptional 
co-activator Yorkie [27, 28, 45]. Yorkie was the first identified substrate of all NDR 
kinases across species. Phosphorylation of Yorkie on Ser 168 leads to 14-3-3 
mediated nuclear exclusion [86]. In the nucleus, Yorkie interacts with TEAD family 
transcription factor Scalloped and promotes the transcription of genes such as 
dCyclinE, diap1 (drosophila inhibitor of apoptosis 1) or the bantam microRNA to 
regulate apoptosis and cell proliferation [87-90]. Genetic screens or candidate gene-
based approaches lead to the identification of many other genes involved in the 
regulation of the core cassette of the hippo pathway. These include the FERM domain 
containing proteins Merlin/Nf2 and Expanded, the protocadherins Fat and Dachsous, 
the apical transmembrane protein Crumbs, the WW and C2 domain containing protein 
Kibra, the protein phosphatase 2A complex dSTRIPAK and the CK1 family kinase 
Discs Overgrown ([78, 85] and Figure 4). 
 As mentioned before, most of the components of the fly Hippo pathway are 
conserved in mammals. The core cassette of the mammalian Hippo pathway consists 
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of the Hippo orthologs MST1/2, the mammalian Salvador protein WW45, the 
Mats/dMOB1 homologs hMOB1A/B, the mammalian Wts kinases LATS1/2 and the 
transcriptional co-activator proteins and Yorkie homologs YAP and TAZ [52, 78, 85]. 
Although most of the additional regulators identified in Drosophila are conserved in 
mammals, their function in regulating the mammalian Hippo pathway has yet to be 
determined [85]. Furthermore, recent evidence revealed an interplay between the 
Hippo pathway and other established signaling cascades such as the Wnt, Notch and 
Hedgehog pathway [79, 85]. Interestingly, work on the Hippo pathway in mammalian 
systems revealed additional complexity and in some cases also divergence from the 
Drosophila network. For instance, LATS1/2 phosphorylate YAP and TAZ on five 
Figure 4. Signaling diagram of the hippo signaling network in Drosophila and mammals. 
Corresponding proteins in Drosophila and mammals are matched in colors and shapes. Direct 
biochemical interactions are indicated by solid lines or drawn as proteins in direct contact with each 
other. Dashed lines indicate genetic interactions for which no direct protein-protein interactions have 
been reported. Arrowed or blunted ends indicate activation or inhibition, respectively. Also shown 
are selected target genes. Yki- or YAP/TAZ-interacting transcription factors other than Scalloped 
(Drosophila) or TEAD (mammals) are collectively listed in a box. Adapted from (78). 
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sites homologous to Ser168 in Yorkie. Although Ser127 in YAP (the Ser168 
homology site in Yorkie) seems to be the main regulator of nuclear translocation, 
there is also evidence that for certain functions all five phosphorylation sites are 
important [86, 91, 92]. Moreover, recent studies demonstrate a role for 
phosphorylated YAP and TAZ proteins in regulating Wnt and TGF-β-SMAD 
signaling in the cytoplasm [93, 94], mainly by direct binding to Dishevelled or SMAD 
proteins. Furthermore, YAP was shown to bind other transcription factors than the 
ones part of the TEAD family. In apoptosis signaling, YAP also binds to and activates 
the p53 family member p73 [95]. Also, RASSF (Ras-association domain family) 
proteins were shown to differentially regulate MST1/2 kinases in mammals. Whereas 
RASSF1A binds to MST1/2 through their SARAH domain and stimulates kinase 
activity of MST1/2 [96], another isoform, RASSF6, was shown to act similarly to the 
sole Drosophila ortholog dRASSF and was shown to inhibit MST1/2 signaling [97, 
98].  
Using genetically modified mice, tumor suppressive roles could be confirmed for 
some components of the mammalian Hippo pathway such as LATS1 [76], RASSF1A 
[99], Merlin/Nf2 [100, 101] and MST1/2 [102]. Interestingly, neither MST1 nor 
MST2 single knock-outs display cancer phenotypes and the MST1/2 double knock-
out are embryonic lethal [103], indicating a functional redundancy between MST1 
and MST2. However, the tissue-specific double knock-out in the liver results in tumor 
formation [102, 104]. Furthermore, the Hippo pathway might also diverge in 
mammals form Drosophila in terms of tissue or cell type-dependent actions of the 
components. In mouse embryonic fibroblast (MEF) cells, ablation of MST1 and 
MST2 does not affect LATS1/2 phosphorylation [102]. More interestingly, an 
alternative YAP-Ser127 kinase might exist in mouse liver [105]. Genetic ablation of 
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MST1/2 in this tissue had no effect on LATS1/2 phosphorylation but abolished YAP 
Ser127 phosphorylation [102]. In addition, Zhou et al. tested the presence of 
additional Ser127 activity in biochemical fractions of MST1/2 knock-out livers and 
found that a second peak distinct from LATS1/2 existed in the liver [102]. This data 
indicate that in the mouse liver a different YAP kinase is present which probably 
could be NDR1/2 [105]. However, NDR1/2 phosphorylate YAP in vitro but fail to do 
so in tissue cultured cells [91]. More work is needed to decipher the tissue and cell 
dependent components of the mammalian Hippo pathway. Still, studies in Drosophila 
and mammals have firmly established the Hippo pathway as a central mechanism 
controlling organ size and tissue homeostasis and that dysregulation of this pathway 
underlies various diseases such as cancer.  
 In addition to the regulation of YAP and TAZ, mammalian LATS1 and LATS2 
kinases have also been implicated in other functions independent of the Hippo 
pathway (Table 1) [7].  
 
The roles of NDR1 and NDR2 in mammals 
 The mechanisms of biochemical regulation of NDR kinase family members have 
mainly been worked out using human NDR1/2 kinases. However, the biological 
functions of human NDR1/2 kinases have only been identified recently. Hergovich 
and colleagues identified a role for NDR1/2 kinases in centrosome duplication [106]. 
Significantly, overexpression of NDR1 or NDR2 lead to overduplication of 
centrosomes and RNAi (RNA interference)-mediated depletion of NDR1 resulted in 
impaired centrosome duplication [106]. Further work demonstrated that the function 
of NDR1/2 at the centrosome depends on intact interaction with hMOB1A/B and the 
regulation of HM phosphorylation by the MST1 kinase [35]. Moreover, another study 
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performed by the Hemmings lab provided evidence that NDR1/2 kinases are activated 
by hRASSF1A and MST1 upon FAS-mediated apoptosis [36]. RNAi-mediated 
depletion of NDR1/2 lead to reduced apoptosis upon stimulation of death receptors 
and also this function of NDR1/2 appears to be dependent of hMOB1A/B binding 
[36]. NDR1/2 were also implicated in the alignment of chromosomes during mitosis 
[37]. Chiba and colleagues investigated the role of the mammalian homolog of Furry 
and could indicate a role for human NDR1/2-Furry in microtubule dynamics and 
stability. Although this finding is potentially interesting, the study displays major 
inconsistencies with previously published work. They could not reproduce the 
centrosome duplication phenotype in NDR-depleted cells and hMOB1A was not able 
to stimulate NDR1/2 kinase activity in their assay [37]. More recently, Cornils and 
colleagues described for the first time a tumor-suppressive role for NDR kinases in 
vivo [107]. Firstly, mice homozygous for knock-outs of NDR1 do not have any major 
phenotypes possibly due to a functional redundancy of the two isoforms NDR1 and 
NDR2 [107]. Indeed, in tissues that express mainly NDR1under wild-type conditions, 
NDR2 is upregulated upon knock-out of NDR1. Significantly, mice lacking NDR1 
are more prone to develop T-cell lymphomas than wild-type littermates. Furthermore, 
the study indicates that the analyzed lymphomas display loss of the second isoform 
NDR2. Therefore, the loss of both NDR isoforms in mammals results in resistance to 
apoptosis and ultimately leads to tumor development [107]. Based on the functional 
compensation of NDR1 and NDR2, expression of both isoforms in human cancers 
should be investigated in order to gain more insight on the role of NDR1/2 in tumor 
development. 
Altogether, although the biochemical regulation of human NDR1/2 kinases has 
been well established, the physiological roles of mammalian NDR1/2 is just starting 
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to unravel. However, still more work using genetically modified mice carrying tissue-
specific disruptions of NDR1/2 is needed in order to further define the roles of 
NDR1/2 in normal physiology and tumor development and therefore complement 
aforementioned studies undertaken in tissue-cultured cells.  
 
1.2.4. Substrates of NDR Kinases 
 Although the functions of NDR kinase family members have been worked out in 
detail first in S. cerevisiae and S. pombe, and that it was subsequently shown across 
species that these kinases are regulators of important functions, direct substrates have 
only been recently identified (Table 2). 
In budding yeast, Dbf2p phosphorylates three serines adjacent to the nuclear 
localization signal (NLS) of the protein phosphatase Cdc14p thereby abrogating its 
NLS activity leading to cytoplasmic localization [67]. All three phosphorylation sites 
match a previously identified consensus phosphorylation motif for the activated 
Dbf2p-Mob1p complex, RxxS [67, 108]. Similarly, in fission yeast the Sid2p-Mob1p 
complex phosphorylates Clp1p, the Cdc14p homolog in S. pombe [68]. However, 
Sid2p needs to phosphorylate six serines which however also lie within RxxS 
consensus sites. In contrast, Clp1p phosphorylation by Sid2p creates binding sites for 
the 14-3-3 protein Rad24, leading to its cytoplasmic retention during cytokinesis [68]. 
However, whether this kinase-substrate pair is conserved in higher eukaryotes has yet 
to be investigated since the phosphorylation sites in Cdc14p or Clp1p are not 
conserved in the two human homologs CDC14A/B. 
Recently, direct substrates for the second NDR kinase in budding yeast, Cbk1p, 
were identified. The study performed by the Weiss lab suggests that Cbk1p exhibits 
strong preference to phosphorylate the sequence HxRRxS determined by positional 
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scanning peptide arrays [69]. Furthermore, they provide evidence that Cbk1p controls 
transcriptional asymmetry through phosphorylation of the transcription factor Ace2p 
on four sites containing the consensus motif HxK/RK/RXS. Phosphorylation of 
Ace2p by Cbk1p blocks its interaction with nuclear export machinery thereby 
resulting in accumulation in the nucleus and increased function [69]. Moreover, a 
second substrate of Cbk1p was described, a RNA-binding protein Ssd1. Cbk1p 
phosphorylates Ssd1 on at least eight sites matching the previously determined 
consensus for Cbk1p [109]. Thereby, Cbk1p regulates the translation and transcription 
of daughter cell-specific genes via inhibition of Ssd1. No substrate has been identified 
for the second NDR kinase in S. pombe. However, one study suggests that Orb6p 
could control cellular morphogenesis by directly phosphorylating the Cdc42 guanine 
nucleotide exchange factor Gef1 [70]. It still needs to be determined whether Gef1 is 
a direct substrate of Orb6p in vivo.  
 The first in vivo substrate of NDR kinases across species was identified by the 
investigation of interaction partners of the Wts kinase in Drosophila [27]. The 
transcriptional co-activator Yorkie is phosphorylated by Wts on Ser168. The 
phosphorylation site, as well as the underlying regulatory mechanisms, seems to be 
conserved in mammals [86]. Drosophila Wts phosphorylates Yorkie on Ser168 and 
LATS1/2 phosphorylate the Yorkie homologs YAP and TAZ on at least five sites, one 
of them, Ser127 in YAP and Ser89 in TAZ, is the Ser168 homology site of Yorkie [86, 
91, 92, 110]. Phosphorylation on this site creates a 14-3-3 binding site and exclusion 
from the nucleus. Interestingly, all phosphorylation sites lie within the HxRxxS 
consensus [86, 91, 92, 110]. Although the fly NDR kinases Wts and Tricornered 
cooperate in establishment and maintenance of dendritic tiling, no substrates in this 
particular function have yet been identified (Table 2). 
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 In mammals, LATS1/2 phosphorylate YAP and TAZ as mentioned above. 
Recently, LATS2 was shown to phosphorylate the pro-apoptotic protein ASPP1 
(apoptosis-stimulating protein of p53-I) [111]. However, the phosphorylation site as 
well as the functional relevance of this modification in the pro-apoptotic function of 
ASPP1 remains to be shown. Although functions of human NDR1/2 were identified, 
direct substrates for human NDR1/2 kinases have not be identified. Only very 
recently the first in vivo substrate of NDR1/2 in the context of cell cycle regulation 
was identified as the cyclin-dependent kinase inhibitor p21/Waf1/Cip1 (Cornils and 
Kohler, see Appendix). NDR1/2 directly phosphorylate p21 on Ser146 leading to its 
degradation and proper G1/S progression of the cell cycle (see Appendix). 
 Table 2. Selected substrates of NDR kinases from budding yeast (S. cerevisiae), fission yeast (S. 
pombe), fruit fly (D. melanogaster) and human (H. sapiens). Phosphorylation motifs of the respective 
substrate are indicated (H, Histidine; R, Arginine; S, Serine; x; any aminoacid). Identification 
indicates the method used to identify the respective substrate. References can be found in the text. 
*this study, see Appendix.  
 
 Overall, the substrates of NDR kinases from yeast to men were identified mainly 
by a candidate substrate approach [112] (Table 2). No study so far has used an 
unbiased approach for the identification of NDR kinase substrates. Therefore, it seems 
important to apply such an approach in order to find additional NDR kinase targets 
which will further clarify our understanding of how NDR kinases execute their 
different roles across species. 
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2. Scope of the Thesis 
 The aim of the study was to functionally characterize the human MOB (hMOB) 
family in the context of human NDR kinase regulation. Although the regulation of 
human NDR kinase family members by hMOB1/A/B is well studied, the function of 
the remaining human MOB proteins is not that well characterized (hMOB2, 
hMOB3A/B/C). We describe differential interactions of human MOB proteins with 
NDR/LATS kinases. Whereas hMOB3 proteins did not interact with or activate 
NDR/LATS kinases, hMOB2 restrictively interacted with NDR1/2. Concentrating on 
the function of hMOB2, we demonstrated an inhibitory role for a MOB protein for the 
first time. hMOB2 competes with hMOB1A/B for binding to the NTR of NDR1/2 
kinases thereby interfering with hMOB1A-mediated activation. Although NDR1/2 
kinases were shown to form active complexes with hMOB1A/B proteins, we observed 
that hMOB2-NDR1/2 represents an inactive complex. Indeed, our data indicates that 
endogenous hMOB2 has inhibitory properties towards NDR1/2 since RNAi-mediated 
knock-down of hMOB2 resulted in increased NDR phosphorylation and activity. 
Congruently, overexpression of hMOB2 impaired activation and function of human 
NDR1/2 kinases in apoptosis and centrosome duplication. 
 An additional aim was the identification of novel substrates for human NDR1/2 
kinases. We employed a chemical genetic strategy to create analog-sensitive NDR 
kinases which can be used to specifically label direct targets using an analog ATP. By 
performing kinase assays on immunocomplexes of analog-sensitive NDR1, we 
observed a specific and reproducible pattern of labeled bands. The development of 
such an unbiased method for NDR and the recent identification of the first in vivo 
substrate of human NDR1/2 kinases will certainly stimulate future efforts to discover 
novel downstream targets of human NDR kinases. 
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 3. Results 
 
 
 
 
3.1. Human MOB2 inhibits human NDR1/2 kinases 
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 3.1.1. Summary 
 
MOB proteins are integral components of signaling pathways controlling 
important cellular processes such as mitotic exit, centrosome duplication, apoptosis 
and cell proliferation in eukaryotes. The human MOB protein family consists of six 
distinct members (human MOB1A [hMOB1A], -1B, -2, -3A, -3B and -3C), with 
hMOB1A/B being the best studied due to their putative tumor suppressive functions 
through the regulation of NDR/LATS kinases. The roles of the other MOB proteins 
are less well defined. Accordingly, we characterized all six human MOB proteins in 
the context of NDR/LATS binding and their ability to activate NDR/LATS kinases. 
hMOB3A/B/C proteins neither bind nor activate any of the four human NDR/LATS 
kinases. We found that both hMOB2 and hMOB1A bound to the N-terminal region of 
NDR1. However, our data suggest that the binding modes differ significantly. Our 
work revealed that hMOB2 competes with hMOB1A for NDR binding. hMOB2, in 
contrast to hMOB1A/B, is bound to unphosphorylated NDR. Moreover, depletion of 
hMOB2 by RNA interference (RNAi) resulted in increased NDR kinase activity. 
Consistent with these findings, hMOB2 overexpression interfered with the functional 
roles of NDR in death-receptor signaling and centrosome overduplication. In 
summary, our data indicate that hMOB2 is a negative regulator of human NDR 
kinases in biochemical and biological settings. 
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MOB proteins are integral components of signaling pathways controlling important cellular processes, such
as mitotic exit, centrosome duplication, apoptosis, and cell proliferation in eukaryotes. The human MOB
protein family consists of six distinct members (human MOB1A [hMOB1A], -1B, -2, -3A, -3B, and -3C), with
hMOB1A/B the best studied due to their putative tumor-suppressive functions through the regulation of
NDR/LATS kinases. The roles of the other MOB proteins are less well defined. Accordingly, we characterized
all six human MOB proteins in the context of NDR/LATS binding and their abilities to activate NDR/LATS
kinases. hMOB3A/B/C proteins neither bind nor activate any of the four human NDR/LATS kinases. We found
that both hMOB2 and hMOB1A bound to the N-terminal region of NDR1. However, our data suggest that the
binding modes differ significantly. Our work revealed that hMOB2 competes with hMOB1A for NDR binding.
hMOB2, in contrast to hMOB1A/B, is bound to unphosphorylated NDR. Moreover, RNA interference (RNAi)
depletion of hMOB2 resulted in increased NDR kinase activity. Consistent with these findings, hMOB2
overexpression interfered with the functional roles of NDR in death receptor signaling and centrosome
overduplication. In summary, our data indicate that hMOB2 is a negative regulator of human NDR kinases in
biochemical and biological settings.
The first MOB (Mps one binder) protein was identified in
Saccharomyces cerevisiae more than a decade ago (22, 25).
Since then, members of the MOB protein family have been
found in unicellular organisms to mammals. Initially, the bio-
logical roles of MOB proteins were mainly investigated using
budding and fission yeasts, revealing that Mob1p plays a vital
role in the control of mitotic exit (3, 8, 23). Drosophila MOB1
(dMOB1)/Mats (MOB as tumor suppressor) emerged as an
integral part of the Hippo tumor-suppressing pathway control-
ling cell proliferation and apoptosis from recent work in Dro-
sophila melanogaster (24, 37). Interestingly, the functions of
MOB proteins seem to be evolutionarily conserved, since the
lethality and overgrowth phenotypes in Drosophila mats mu-
tants can be rescued by the human homolog human MOB1A
(hMOB1A) (24). This suggests that the Hippo signaling path-
way is highly conserved from flies to humans (9, 12, 30, 31, 40).
However, the biological roles of hMOB1A/B seem to be more
diverse, as they function in cellular proliferation (29), apop-
tosis (36), and centrosome duplication (13). Mob2p in budding
and fission yeasts is an essential part of a signaling network
responsible for polarized cell growth and transcriptional asym-
metry (6, 20, 38). In flies, the biological functions of dMOB2
and dMOB3 are less understood. However, dMOB2 seems to
play a role in wing hair morphogenesis (10). In mammals, the
biological roles of MOB2 proteins have so far proved elusive.
A conserved property of MOB proteins is the association
with and activation of the NDR (nuclear-Dbf2-related) kinases
of the AGC family (16, 28). In yeast, Mob1p binds to and is
necessary for the activation of Dbf2/Dbf20 and Sid2 kinases
(19, 22, 26). Similarly, Mob2p binds to and activates Cbk1 and
Orb6 (20, 38). Furthermore, yeast MOB proteins and NDR
kinases form restricted heterodimers of signaling complexes in
which the subunits are not interchangeable (18, 20). In con-
trast, in multicellular organisms, the binding of MOB proteins
is not restricted to a unique NDR kinase. For example, three
MOB proteins exist in flies: dMOB1/Mats, dMOB2, and
dMOB3 (10). dMOB1/Mats was shown to interact physically
with warts, the fly homolog of human LATS1/2, and to be
necessary for warts activity (24, 37). Moreover, dMOB1/Mats
also genetically interacts with the second NDR kinase in flies,
tricornered (trc) (10). Furthermore, it was shown in coimmu-
noprecipitation experiments that dMOB2 physically associates
with trc (10).
The molecular mechanisms by which MOB proteins bind to
and activate NDR kinases are best understood in mammals.
hMOB1A binds to and activates human NDR1/2 kinases by
stimulating autophosphorylation on the activation segment (2).
Similarly, hMOB1A also binds to and activates LATS1 and -2
(4, 15, 39). In contrast, hMOB2 was shown to bind to NDR1
and NDR2, but not to LATS1 (4, 15). Importantly, hMOB1A/B
are also required for efficient phosphorylation of the hydro-
phobic motif (T444/442) of NDR1/2 kinases by MST1 kinase
(mammalian STE-20-like 1) (13, 36). Spatial relocalization of
NDR kinases seems to be a further level of regulation, because
membrane targeting of hMOB1 proteins leads to rapid activa-
tion of NDR1/2 and LATS1 kinases (11, 15). Indeed, mem-
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brane targeting of dMOB1/Mats in Drosophila activates warts
kinase and inhibits tissue growth by increasing apoptosis and
reducing proliferation (17). Further, membrane-targeted tri-
cornered kinase rescues the dendritic tiling defect in trc mu-
tant flies (21). These observations indicate that activation of
NDR kinases by relocalization to the plasma membrane is an
important step in NDR/LATS kinase activation and function.
Here, we study for the first time all six human MOB proteins
(hMOB1A/B, hMOB2, and hMOB3A/B/C) with respect to
their abilities to bind and activate all four human NDR ki-
nases. Surprisingly, we found that three out of the six MOBs
neither bind to nor activate human NDR1/2 or LATS1/2 ki-
nases. By focusing on the NDR1/2-specific binder hMOB2, we
found that hMOB2 competes with hMOB1A/B for NDR bind-
ing. Furthermore, we provide evidence that overexpression of
hMOB2 impairs NDR1/2 activation in a binding-dependent
manner and affects functions of NDR, such as centrosome
duplication and apoptotic signaling. Significantly, RNA inter-
ference (RNAi)-mediated reduction of the hMOB2 protein
resulted in increased NDR kinase activity. These data indicate
that hMOB2, in contrast to hMOB1A/B, plays an inhibitory
role in the regulation of human NDR1/2 kinases.
MATERIALS AND METHODS
Construction of plasmids. Human NDR1 and NDR2 and hMOB1A, hMOB1B,
hMOB2, hMOB3A, hMOB3B, and hMOB3C cDNAs were subcloned into
pcDNA3, pGEX-4T1, or pMal-2c using BamHI and XhoI restriction sites. Ac-
cession numbers for hMOB3 reference cDNAs are 3A, NM_130807; 3B,
NM_024761; and 3C, NM_201403. The cloning of hMOB3 cDNAs has been
described previously (13). Plasmids containing human LATS1 and LATS2 were
described elsewhere (14). pcDNA3 derivatives contained a hemagglutinin (HA)
or a myc epitope alone or the myristolyation/palmitylation motif of the Lck
tyrosine kinase (MGCVCSSN) combined with a myc epitope (mp-myc). Mutants
of NDR1 and hMOB2 were generated by site-directed mutagenesis according to
the manufacturer’s instructions (Stratagene). Deletion mutants of NDR1 were
cloned via PCR. Individual PCR products were digested with BamHI and XhoI
and cloned into pcDNA3 derivatives. To generate a construct expressing the N
terminus of NDR1 or NDR2 with a C-terminal tag, the coding sequences for
amino acids 1 to 83 of NDR1/2 were amplified by PCR, digested by NheI and
KpnI, and cloned into pcDNA3.1-myc-RFP as described elsewhere (27). To
generate hMOB3 proteins containing a C-terminal myc tag, hMOB3A/B/C
cDNAs were cloned into pcDNA3.1-myc-RFP as described above, and the red
fluorescent protein (RFP) was removed by PCR. To generate tetracycline-reg-
ulated mammalian expression vectors, cDNAs encoding myc-hMOB2(wt) or
myc-hMOB2(H157A) were digested with KpnI and XhoI and ligated into
pENTR 3C (Invitrogen). N-terminally tagged hMOB2 cDNAs were finally
inserted into pT-Rex-DEST30 using Gateway technology (Invitrogen). To
obtain pTER-shMOB2 vectors that express short hairpin RNAs (shRNAs)
against human MOB2, the following oligonucleotide pairs were inserted into
pTER using BglII and HindIII: 5-GATCCCGCTGGTGACGGATGAGGA
CTTCAAGAGAGTCCTCATCCGTCACCAGCTTTTTGGAAA-3 (target-
ing sequences of the hMOB2 coding sequence are underlined) and 5-AGC
TTTTCCAAAAAGCTGGTGACGGATGAGGACTCTCTTGAAGTCCT
CATCCGTCACCAGCGG-3. The generation of the pTER-shLuc control
vector has been described previously (14). All constructs were confirmed by
sequence analysis.
Cell culture, transfections, and chemicals. COS-7, HEK 293, U2-OS, and
HeLa cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% fetal calf serum. Exponentially growing COS-7 cells
were plated at consistent confluence (1  106 cells/10-cm dish) and transfected
the next day using Fugene 6 (Roche) as described by the manufacturer. Expo-
nentially growing HEK 293 cells were transfected in solution at consistent con-
fluence (5  106 cells/10-cm dish) using jetPEI (PolyPlus Transfections) accord-
ing to the manufacturer’s instruction. Exponentially growing U2-OS cells were
plated at consistent confluence and transfected the next day using Lipofectamine
2000 (Invitrogen) as described by the manufacturer. Aphidicolin was from Cal-
biochem, and okadaic acid (OA) was purchased from Alexis Biochemicals (Enzo
Life Sciences). Apoptosis of U2-OS cells was induced by the addition of activat-
ing anti-Fas antibody clone CH-11 (0.5 g/ml) in combination with cyclohexi-
mide (CHX) (10 g/ml).
Generation of stable cell lines. To generate inducible cell lines, U2-OS T-Rex
cells were transfected with pT-Rex-DEST30 vectors encoding hMOB2 variants.
Cell clones were selected by growth in the presence of 1 mg/ml G418 (Gibco) and
50 g/ml hygromycin B (Invivogen). Stable transformants were maintained in
DMEM supplemented with 0.5 mg/ml G418 and 50 g/ml hygromycin B. Ex-
pression of myc-hMOB2 variants was induced by the addition of 2 g/ml tetra-
cycline.
Antibodies. The generation and purification of anti-T444-P, anti-S281-P, anti-
NDR2, anti-NDRNT, anti-NDRCTD, and anti-hMOB1A/B antibodies has been
described previously (13, 14, 35, 36). It is important to note that the anti-T444-P
antibody recognizes the phosphorylated hydrophobic motifs of both NDR iso-
forms, NDR1 (T444-P) and NDR2 (T442-P). Anti-HA 12CA5 and 42F13, anti-
myc 9E10, and anti--tubulin YL1/2 were used as hybridoma supernatants.
Further, anti-HA antibody (Y-11) and anti--actin were purchased from Santa
Cruz and anti-Fas (CH-11) from Millipore. Anti-LATS1 antibody was purchased
from Cell Signaling and anti-cleaved poly(ADP-ribose) polymerase (PARP)
from BD Bioscience. Anti-p63(G1/296) antibody was from Alexis Biochemicals
(Enzo Life Sciences). Anti-hMOB2 antibody was raised against purified, bacte-
rially produced full-length hMOB2 fused C terminally to maltose-binding protein
(MBP). Rabbit injections and bleed collections were done by Eurogentec. Anti-
protein antibody was purified by preabsorbing the bleeds against 10 mg of
immobilized MBP and then binding them to 5 to 10 mg of GST-hMOB2 co-
valently coupled to glutathione-Sepharose 4B beads. Antibodies were eluted with
0.2 M glycine (pH 2.2).
Immunoblotting and immunoprecipitation. Immunoblotting experiments were
performed as described previously (11). For immunoprecipitation, cells were
harvested, pelleted at 1,000  g for 3 min, and washed with cold phosphate-
buffered saline (PBS) before lysis in immunoprecipitation (IP) buffer (20 mM
Tris, 150 mM NaCl, 10% glycerol, 1% NP-40, 5 mM EDTA, 0.5 mM EGTA, 20
mM -glycerophosphate, 50 mM NaF, 1 mM Na3VO4, 1 mM benzamidine, 4 M
leupeptin, 0.5 mM phenylmethylsulfonyl fluoride [PMSF], 1 M microcystine,
and 1 mM dithiothreitol [DTT] at pH 8.0). Lysates were centrifuged for 10 min
at 16,000  g at 4°C before being precleared with protein A-Sepharose. The
beads were washed twice with IP buffer, once with IP buffer containing 1 M NaCl,
and finally once with IP buffer before samples were analyzed by SDS-PAGE. To
analyze the association of NDR1/2 or LATS1/2 and hMOB species by coimmu-
noprecipitation, cells coexpressing HA-NDR or HA-LATS and myc-hMOB spe-
cies were subjected to immunoprecipitation using anti-HA 12CA5 antibody as
described above, omitting the wash with 1 M NaCl IP buffer, before analysis by
SDS-PAGE and immunoblotting. For immunoprecipitation of endogenous pro-
teins, cells were processed for immunoprecipitation as described above. Lysates
were preincubated with control rabbit IgG, anti-hMOB2, anti-NDR2, anti-
LATS1, or anti-T444-P antibody overnight, and then protein A-Sepharose was
added for 3 h and the beads were washed four times in IP buffer containing 150
mM NaCl before analysis by SDS-PAGE. To analyze the association of NDR1
mutants and hMOB2, coimmunoprecipitation experiments were performed as
described above, including one wash with IP buffer containing 1 M NaCl. Char-
acterization of hMOB2 mutants by IP was performed in low-stringency buffer (30
mM HEPES, pH 7.4, 20 mM -glycerophosphate, 20 mM KCl, 1 mM EGTA, 2
mM NaF, 1 mM Na3VO4, 1% TX-100) supplemented with protease inhibitors.
HA-NDR kinase assay and HA-LATS kinase assay. Analysis of HA-NDR or
HA-LATS kinase activities after immunoprecipitation was performed as de-
scribed previously (11, 15).
HA-LATS autophosphorylation assay. Analysis of immunoprecipitated HA-
LATS autophosphorylation was also carried out as reported previously (15).
Fractionation of cells. Cytosolic and membrane-associated proteins were sep-
arated by S100/P100 fractionation as described previously (11).
Immunofluorescence microscopy. Cells were processed for immunofluores-
cence analysis as defined elsewhere (14).
RESULTS
Human NDR and LATS kinases do not interact with
hMOB3A, -B, or -C protein. MOB proteins are evolutionarily
highly conserved from yeast to humans. Unfortunately, human
MOB proteins have been named inconsistently in the literature
(Table 1). Alignments, as well as phylogenetic analysis of the
human MOB family (data not shown), revealed a close rela-
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tionship of hMOB3 proteins with hMOB1A. Many biochemi-
cal properties of hMOB1A and -B have been described (2, 11,
15), suggesting that hMOB3A/B or -C proteins might display
some of these properties. In order to test whether hMOB3
proteins can physically interact with human NDR or LATS
kinases, HA-NDR1/2 or HA-LATS1/2 were coexpressed with
N-terminally myc-tagged hMOB proteins prior to being pro-
cessed for immunoprecipitation and subsequent immunoblot-
ting (Fig. 1). As expected, we observed interactions between
HA-NDR1 and myc-hMOB2 (Fig. 1A, top, lane 1) as well as
HA-NDR2 and myc-hMOB2 (Fig. 1B, top, lane 1). To our
surprise, none of the hMOB3 proteins interacted with HA-
NDR1 (Fig. 1A, top, lanes 2 to 4) or HA-NDR2 (Fig. 1B, top,
lanes 2 to 4) in these settings. In addition, hMOB3A, -B, and
-C did not associate with HA-LATS1 or HA-LATS2 (Fig. 1C
and D, top, lanes 2 to 4). In full agreement with the existing
literature (4, 15), we confirmed that HA-LATS1 and myc-
MOB2 do not interact in cells (Fig. 1C, top, lane 5) and also
demonstrated that myc-hMOB2 cannot associate with HA-
LATS2 (Fig. 1D, top, lane 5), thus illustrating that hMOB2 is
a specific binder of NDR1/2. Significantly, these data were fully
confirmed using hMOB proteins containing a C-terminal myc
tag (data not shown).
Membrane-targeted variants of hMOB3 proteins do not ac-
tivate human NDR and LATS kinases. We have demonstrated
that hMOB3A, -B, and -C do not bind to NDR1/2 or LATS1/2
in our settings (Fig. 1). In order to exclude possible postlysis
effects we applied a second experimental setting as described
previously (11, 15). Briefly, fusion of the myristoylation/palmi-
toylation motif (mp) from the Lck kinase to the N terminus
of myc-tagged hMOB1A (mp-myc-hMOB1A) led to efficient
plasma membrane localization. Importantly, the resulting activa-
tion of NDR/LATS is dependent on hMOB1A-NDR/LATS in-
teraction and takes place within the cells before subsequent ma-
nipulations, such as cell lysis and immunoprecipitation. To
address whether membrane-targeted variants of hMOB3 pro-
teins are able to activate either human NDR1/2 or LATS1/2
kinases, we transfected HEK 293 cells with the respective
NDR/LATS kinase and membrane-targeted hMOBs. As re-
ported previously (11), mp-myc-MOB1A robustly activated
HA-NDR1, as reflected in increased Thr444 phosphorylation
at the hydrophobic motif of NDR1 (Fig. 2A, top, lane 2),
paralleled by increased kinase activity (Fig. 2B, lane 2). Coex-
pressing membrane-targeted hMOB3 variants produced no in-
crease in phosphorylation (Fig. 2A, top panel, lanes 3 to 5) or
kinase activity (Fig. 2B, lanes 3 to 5). Comparable results were
obtained when cells were transfected with HA-NDR2 and mp-
myc-hMOB3A, -B, or -C (Fig. 2C, top, lanes 3 to 5, and D,
lanes 3 to 5). This is consistent with the coimmunoprecipitation
TABLE 1. Human MOB proteins
Protein %identity
No. of
amino acids Alternative names
hMOB1A 100 216 MOB1, MOBKL1B, MOBK1B,
MOB4B, hMats1
hMOB1B 95 216 MOB1, MOBKL1A, MOB4A,
hMats2, MOB1
hMOB2 38 237 HCCA2, hMOB3
hMOB3A 50 217 MOBKL2A, MOB-LAK,
MOB1C, hMOB2A
hMOB3B 51 216 MOBKL2B, MOB1D, hMOB2B
hMOB3C 49 216 MOBKL2C, MOB1E, hMOB2C
FIG. 1. Human NDR and LATS kinases do not interact with hMOB3A/B/C proteins. (A and B) Lysates of HEK 293 cells coexpressing the
indicated combinations of HA-tagged NDR1 wild-type (wt), HA-tagged NDR2(wt), and myc-tagged hMOB species were analyzed by IP using
anti-HA 12CA5 antibody. Complexes were assayed by immunoblotting using anti-myc antibody (top) or anti-HA antibody (middle). Input lysates
were analyzed by immunoblotting using anti-myc antibody (bottom). hMOB2 served as a positive control. (C and D) Lysates of HEK 293 cells
coexpressing the indicated HA-tagged LATS1(wt) or LATS2(wt) and myc-tagged human MOB species were analyzed as described for panels A
and B, except that hMOB1A served as the positive control and hMOB2 as the negative control.
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FIG. 2. Membrane-targeted variants of hMOB3A/B/C do not activate human NDR and LATS kinases. (A) Lysates of HEK 293 cells
coexpressing the indicated combinations of HA-tagged NDR1(wt) and membrane-targeted human MOB proteins (mp-myc-hMOB) were analyzed
by IP using anti-HA 12CA5 antibody. Complexes were assayed by immunoblotting using anti-T444-P antibody (top) or anti-HA antibody (middle).
Input lysates were immunoblotted with anti-myc antibody (bottom). (B) In parallel, complexes were subjected to kinase assays. The results of two
independent experiments are shown. The error bars indicate standard deviations. (C) Lysates of HEK 293 cells coexpressing the indicated
combinations of HA-tagged NDR2(wt) and mp-myc-hMOB proteins were analyzed as described for panel A. (D) In parallel, complexes were
subjected to kinase assays as described for panel B. (E) Lysates of HEK 293 cells coexpressing the indicated combinations of HA-tagged
LATS1(wt) and mp-myc-hMOB species were analyzed by IP using anti-HA 12CA5 antibody before being assayed by immunoblotting using
anti-HA antibody (middle) or an autophosphorylation assay (top). Input lysates were analyzed by immunoblotting with anti-myc antibody. (F) In
parallel, complexes were subjected to peptide kinase assays. The result from one representative experiment performed in duplicate is shown.
(G) Lysates of HEK 293 cells coexpressing the indicated combinations of HA-tagged LATS2(wt) and mp-myc-hMOB species were analyzed as
described above for panel E. (H) In parallel, complexes were subjected to peptide kinase assays. The results from two independent experiments
are shown. The error bars indicate standard deviations.
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experiments (Fig. 1A and B) and indicates that hMOB3s can-
not interact with human NDR1/2 kinases in cultured mamma-
lian cells despite the significant similarity to hMOB1A. Fur-
thermore, we addressed whether membrane-targeted hMOB3
variants are able to activate HA-LATS1 or HA-LATS2 (Fig.
2E to H). As already reported (15), HA-LATS1 was substan-
tially activated by mp-myc-hMOB1A (Fig. 2E and F, lanes 2),
as illustrated by increased autophosphorylation and kinase ac-
tivity, whereas mp-hMOB3 proteins were unable to activate
HA-LATS1 (Fig. 2E and F, lanes 4 to 6). We observed similar
results in the case of HA-LATS2 (Fig. 2G and H). In combi-
nation with the coimmunoprecipitation experiments (Fig. 1),
these findings strongly suggest that none of the three hMOB3
proteins physically interacts with or activates human NDR1/2
or LATS1/2 kinases.
hMOB2 binds to the amino terminus of human NDR1/2
kinases in a mode distinct from hMOB1A/B binding. We have
shown that hMOB3s do not associate with human NDR1/2
kinases (Fig. 1 and 2), despite their higher degree of similarity
to hMOB1A/B than to hMOB2 (Table 1). Interestingly,
hMOB2 appears to be an NDR-specific binder, since it did not
bind to human LATS1 (4, 15) or LATS2 (Fig. 1 and 2) but
readily bound to NDR1 and 2 (Fig. 1). Therefore, we investi-
gated the interaction of hMOB2 with NDR1/2 in more detail
using a series of NDR1 mutants (Fig. 3A and Table 2). We
deleted the N or C terminus of NDR1 to determine which region
was necessary for the interaction with hMOB2 (Fig. 3B).
NDR1(wt) and NDR1(1-380) coprecipitated hMOB2 (Fig. 3B,
top, lanes 2 and 4), whereas NDR1 lacking the conserved N-
terminal regulatory domain (NTR), HA-NDR1(NTR), did not
(Fig. 3B, top, lane 3). Conversely, we addressed whether the N
terminus of NDR (amino acids 1 to 83) was sufficient for
association with hMOB2. Indeed, NDR1(1-83)-myc-RFP in-
teracted with HA-hMOB2 (Fig. 3C, top, lane 2), and NDR2(1-
83)-myc-RFP also bound HA-hMOB2 (Fig. 3D, top, lane 2).
Remarkably, hMOB1A/B binds to the same N-terminal region
of NDR (2). Therefore, since the key residues essential for
interaction between NDR1/LATS1 kinases and hMOB1A
have been described (2, 15), we investigated whether hMOB2
utilized the same conserved binding motif. Interestingly, point
mutations in the NDR1 N terminus that abolish or diminish
the interaction with hMOB1A did not impair binding of
hMOB2 (Fig. 3E, top, lanes 5 and 6, and Table 2). Since
hMOB2 appeared to bind to NDR separately from hMOB1A,
we aimed to define the N-terminal region on human NDR1
necessary for the hMOB2 interaction via N-terminal mutagen-
esis of NDR1 (Fig. 3F). We observed that NDR1 lacking the
first 26 amino acids [NDR1(26)] still interacted with hMOB2
(Fig. 3F, top, lane 3), whereas an NDR1 mutant lacking the
first 33 residues [NDR1(33)] was no longer able to bind to
hMOB2 (Fig. 3F, top, lane 2), arguing that the amino acids
between residues 27 and 33 of human NDR1 are necessary for
the interaction. We sought to further analyze this region and
mutated 5 residues within this stretch to alanines (HA-NDR1
5A: Leu27, Glu28, Asn29, Phe30, and Ser32, respectively) and
examined whether this mutant was still able to bind to hMOB2
(Fig. 3G). Unexpectedly, the NDR1 mutant carrying 5 point
mutations bound to hMOB2 but lost the ability to bind to
hMOB1A (Fig. 3G, top, lanes 4 and 5). Neither single point
mutations in this stretch nor multiple mutations led to the loss
of hMOB2 interaction (Table 2). Therefore, we attempted to
create an NDR1 mutant incapable of binding to hMOB2 by
mutating residues in the N terminus that differ significantly
from the N-terminal region of LATS1. However, this effort
remained ineffective, since all tested mutants bound to
hMOB2 (Table 2), leaving a defined binding motif of hMOB2
on NDR1 yet to be determined. Nevertheless, these data dem-
onstrate that while hMOB2 and hMOB1 proteins utilize iden-
tical regions of human NDR1/2 kinases to bind, the interac-
tions differ significantly between these two hMOB isoforms.
hMOB2 competes with hMOB1A for binding to NDR and
interferes with the activation of endogenous NDR by okadaic
acid. We showed that hMOB2, like hMOB1A, binds to the N
terminus of NDR (Fig. 3), suggesting that hMOB1A and
hMOB2 might function competitively in binding NDR kinases.
Thus, we examined whether the coimmunoprecipitation of
myc-tagged hMOB1A by HA-NDR1 is affected by expressing
increasing amounts of myc-hMOB2 (Fig. 4A). In the absence
of myc-hMOB2, a substantial amount of myc-hMOB1A coim-
munoprecipitated with HA-NDR1 (Fig. 4A, top, lane 2). On
the other hand, coexpression of increasing amounts of myc-
hMOB2 led to a significant decrease in myc-hMOB1A coim-
munoprecipitating with HA-NDR1 (Fig. 4A, lanes 3 to 6),
despite the fact that the overall amount of expressed myc-
hMOB1A was not changed (Fig. 4A, bottom, lanes 2 to 6).
Interestingly, hMOB2 displaced hMOB1A even though it was
expressed at a lower level than hMOB1A (Fig. 4A, lanes 3 and
4). This indicates that hMOB2 can efficiently compete with
hMOB1A for binding to NDR1.
Activation of NDR kinases by the protein phosphatase 2A
inhibitor OA was shown to depend on intact interaction of
NDR1/2 and hMOB1 proteins (2). Since hMOB2 is able to
partially displace hMOB1A from NDR, we investigated the
effect of hMOB2 expression on OA-induced activation of en-
dogenous NDR species (Fig. 4B and C). As expected, treat-
ment of HEK293 cells with OA strongly increased Thr-444
phosphorylation of NDR (Fig. 4B, top, lane 3) and elevated
the kinase activity of endogenous NDR2 (Fig. 4C, lane 3).
Interestingly, expression of hMOB2(wt) impaired NDR phos-
phorylation (Fig. 4B, top, lane 4) and led to an 50% reduc-
tion in endogenous NDR2 activity (Fig. 4C, lane 4). Overall,
these data suggest that hMOB2 competes with hMOB1 for
NDR binding and interferes with OA-induced activation of
NDR, in contrast to hMOB1, which was previously shown to
enhance OA-induced activation (2).
hMOB2 interferes with the activation of ectopic and endog-
enous NDR kinases by membrane-targeted hMOB1A in a
binding-dependent manner. Next, we investigated whether the
competition with hMOB1 and the inhibitory effect on NDR
activation by hMOB2 depended on an intact NDR-hMOB2
interaction. For this, we generated an hMOB2 variant deficient
in NDR binding (Fig. 5A). Mutating His157 to alanine abol-
ished binding to NDR1 and -2 despite similar expression levels
(Fig. 5A, top, compare lanes 2 and 3, 5 and 6). Subsequently,
we investigated whether hMOB2 can interfere with the activa-
tion of NDR by membrane-targeted hMOB1A in an interac-
tion-dependent manner (Fig. 5B and C). As previously re-
ported (11), mp-myc-hMOB1A potently activates HA-NDR1
(Fig. 5B and C). Intriguingly, myc-tagged hMOB2(wt) expres-
sion almost completely abolished the activation of HA-NDR1
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FIG. 3. hMOB2 binds to the N terminus of NDR but in a manner distinct from that for hMOB1A/B. (A) Primary structures of human NDR1
and overview of HA-tagged NDR1 mutant derivatives. (B) Lysates of COS-7 cells containing the indicated combinations of HA-tagged NDR1
forms and myc-tagged hMOB2(wt) were analyzed by IP using anti-HA antibody. Complexes were analyzed by immunoblotting using anti-myc (top)
or anti-HA (middle) antibody. Input lysates were analyzed using anti-myc antibody. NTR denotes deletion of amino acids 1 to 83 of NDR1, the
NTR (N-terminal regulatory domain). (C) Lysates of HEK 293 cells coexpressing the indicated combinations of HA-tagged hMOB2(wt), the N
terminus of NDR1 (amino acids 1 to 83) fused N terminally to myc-RFP, or myc-RFP alone were analyzed by IP using anti-HA antibody.
Complexes were assayed by immunoblotting using anti-myc (top) and anti-HA (middle) antibodies. The lysates were analyzed using anti-myc
antibody. (D) Lysates of HEK 293 cells coexpressing combinations of HA-tagged hMOB2(wt), the N terminus of NDR2 (amino acids 1 to 83)
containing a C-terminal myc-RFP tag, or myc-RFP alone were analyzed as described for panel C. (E) Lysates of COS-7 cells coexpressing
HA-tagged NDR1(wt), NDR1(NTR), NDR1(E73A), NDR1(T74A), NDR1(R78A), and myc-tagged hMOB2(wt) were analyzed by IP using
anti-HA antibody. Complexes were analyzed by immunoblotting using anti-myc or anti-HA antibody. Input lysates were assayed by immunoblotting
using anti-myc antibody. (F) Lysates of HEK 293 cells coexpressing HA-tagged NDR1(wt), NDR1 containing a deletion of amino acids 1 to 33
[NDR1(33)], NDR1(26), and myc-tagged hMOB2(wt) were analyzed by IP using anti-HA antibody. Complexes were assayed using anti-myc or
anti-HA antibody. Input lysates were assayed by immunoblotting using anti-myc antibody. (G) Lysates of HEK 293 cells containing the indicated
combinations of HA-tagged NDR1(wt), NDR1 5A mutant, myc-tagged hMOB1A, or hMOB2 were analyzed by IP using anti-HA antibody. NDR1
5A mutant denotes mutation of amino acids Leu27, Glu28, Asn29, Phe30, and Ser32 to alanine. Complexes were assayed by immunoblotting using
anti-myc (top) or anti-HA (middle) antibody. Input lysates were assayed by immunoblotting using anti-myc antibody (bottom).
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by mp-myc-hMOB1A (Fig. 5B and C, lanes 3), even though the
expression of mp-myc-hMOB1A remained unchanged (Fig.
5B, bottom, lane 3). However, coexpression of myc-tagged
hMOB2(H157A), which cannot bind to NDR1/2 kinases, did
not interfere with mp-myc-hMOB1A-driven activation of HA-
NDR1 (Fig. 5B and C, lanes 4). In conclusion, the negative
effect of hMOB2 on NDR1 activation by membrane-targeted
hMOB1A is likely to be binding dependent.
We have previously shown that expression of membrane-
targeted hMOB1A in U2OS cells leads to the membrane re-
cruitment and activation of endogenous NDR1 species (11).
To address the effect of hMOB2 on membrane recruitment
and activation of endogenous NDR species, HEK 293 cells
transfected with mp-myc-hMOB1A, myc-hMOB2(wt), or myc-
hMOB2(H157A) were separated into cytoplasmic and mem-
branous fractions prior to analysis by immunoblotting (Fig.
5D). While in untransfected cells native phospho-T444/442
proteins were found almost exclusively in the cytoplasmic frac-
tion (Fig. 5D, lane 1), in cells expressing mp-myc-hMOB1A
NDR, phosphospecies were enriched at the membrane (Fig.
5D, lane 4). Congruently, endogenous NDR1/2 was recruited
to the membrane by mp-myc-hMOB1A (Fig. 5D, lane 4).
Upon coexpression of myc-tagged hMOB2(wt) the phos-
phosignal of endogenous NDR species at the membrane dis-
appeared (Fig. 5D, lane 6), although we still observed residual
NDR2 in the membranous fraction (Fig. 5D, lane 6). To ad-
dress whether this effect was dependent on the interaction
between hMOB2 and endogenous NDR species, we coex-
pressed NDR binding-deficient hMOB2(H157A) with mp-
myc-hMOB1A. Confirming the result with overexpressed HA-
NDR1 (Fig. 5B), myc-hMOB2(H157A) did not interfere with
FIG. 4. hMOB2 competes with hMOB1A and interferes with okadaic
acid-induced activation of endogenous NDR kinases. (A) hMOB1A-
NDR1 and hMOB2-NDR1 interactions are mutually exclusive. Lysates
of HEK 293 cells coexpressing HA-tagged NDR1(wt) and myc-tagged
hMOB1A and hMOB2 were analyzed by IP using anti-HA antibody.
Complexes were assayed by immunoblotting using anti-myc (top) and
anti-HA (middle) antibodies. Input lysates were analyzed by immuno-
blotting using anti-myc antibody. (B) HEK 293 cells transfected with
empty vector () or hMOB2(wt) were treated with 1 M OA for 45
min before input lysates were processed for immunoblotting with the
indicated antibodies. (C) In parallel, samples were subjected to immu-
noprecipitation using rabbit IgG or anti-NDR2 antibody before pep-
tide kinase assays were performed. Data from at least two independent
experiments with two replicates per experiment are shown. The error
bars represent standard deviations.
TABLE 2. Summary of coimmunoprecipitation experiments
NDR1 mutation
Binding toa:
hMOB2 hMOB1A
Y31A 	 
R41A 	 
R44A 	 (	)
T74A 	 
R78A 	 
K24A 	 	
T26A 	 ND
T26F 	 ND
L27A 	 ND
E28A 	 	
N29A 	 ND
F30A 	 ND
S32A 	 ND
A36K 	 ND
E40A 	 	
V51E 	 ND
E54R 	 ND
D59A 	 ND
E60A 	 	
E61A 	 	
R63A 	 	
E73A 	 	
TVT23/25/26FFF 	 ND
FY30/31HV 	 ND
EE39/40AA 	 ND
Q45K/K47Q 	 ND
EEE53-55RRR 	 ND
EEKR60-63AAAA 	 ND
KRR62/63/65QDM 	 ND
H69D/R71D 	 ND
SAHAR67-71KMLCQ 	 ND
a HA-tagged NDR1 mutants were coexpressed with either myc-hMOB2 or
myc-hMOB1A in HEK 293 or COS7 cells before coimmunoprecipitation exper-
iments were performed. 	, interaction; , no interaction; (	), impaired inter-
action; ND, not determined.
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either membrane recruitment of endogenous NDRs by mp-
myc-hMOB1A (Fig. 5D, lane 8) or the activation of endoge-
nous NDR at the membrane (Fig. 5D, top, lane 8). We con-
clude that hMOB2 competes with hMOB1A for NDR binding
and can interfere with the activation of human NDR kinases in
a binding-dependent manner.
Endogenous hMOB2 physically interacts with human NDR,
but not with LATS1. In overexpression settings, hMOB2 readily
coimmunoprecipitates with human NDR1/2 kinases (Fig. 1). In
order to address the interaction of endogenous proteins, we
raised a rabbit polyclonal antibody against hMOB2 (Fig. 6A
and B). The affinity-purified anti-hMOB2 antibody detected a
band at approximately 27 kDa, the predicted molecular size of
the hMOB2 protein, which was reduced in cells expressing
shRNA against hMOB2 (Fig. 6A, top). Furthermore, the anti-
hMOB2 detected only recombinant glutathione S-transferase
(GST)-hMOB2, but none of the other hMOBs (Fig. 6B, top).
Endogenous hMOB2 coprecipitated with NDR2 when an anti-
NDR2 antibody was used for immunoprecipitation, but not
with control antibody (Fig. 6C, top). Conversely, when an anti-
hMOB2 antibody was used to immunoprecipitate endogenous
hMOB2, endogenous NDR2 coprecipitated in HEK293 cells
(Fig. 6D, top). Similar results were observed using HeLa cell
lysates (data not shown). Moreover, endogenous hMOB2
could not be coimmunoprecipitated using an anti-LATS1 an-
tibody (Fig. 6E, top, lane 3). Therefore, our data show for the
first time that endogenous hMOB2 is a specific binder of
NDR1/2 kinases.
hMOB2 is found preferentially in unphosphorylated NDR
complexes, while hMOB1A/B is associated with active NDR
kinases. Given that we observed a putative negative role for
hMOB2 in the course of NDR activation and that endogenous
hMOB2-NDR complexes are readily detectable (Fig. 4, 5, and
6), we examined endogenous total NDR-hMOB complexes
and active NDR-hMOB complexes by immunoprecipitation
experiments using anti-NDR2 and anti-T444-P antibodies (Fig.
7). The anti-T444-P antibody recognizes only phosphorylated
hydrophobic motifs of active NDR1/2 kinases (14). HEK 293
cells were subjected to immunoprecipitation with the two dif-
ferent anti-NDR antibodies described above and to subse-
quent immunoblotting experiments. When the anti-NDR2 an-
tibody was used, a small fraction of the immunoprecipitated
NDR2 protein was phosphorylated at the hydrophobic motif
(T444-P), indicating that mostly inactive NDR species were
immunoprecipitated (Fig. 7, lane 2). In contrast, using the
anti-T444-P antibody to immunoprecipitate active NDR spe-
cies, we obtained a significant amount of phospho-T444 species
despite the small amount of total NDR2 pulled down (Fig. 7,
FIG. 5. hMOB2 interferes with the activation of human NDR ki-
nases by membrane-targeted hMOB1A in an NDR binding-dependent
manner. (A) COS-7 cell lysates expressing HA-tagged NDR1(wt)
(lanes 1 to 3), HA-NDR2(wt) (lanes 4 to 6), myc-tagged hMOB2(wt),
or myc-hMOB(His157Ala) were lysed in low-stringency lysis buffer
and then subjected to IP using anti-HA 12CA5 antibody. Complexes
were analyzed by immunoblotting with anti-HA (middle) and anti-myc
(top) antibodies. Input lysates were analyzed by immunoblotting using
anti-myc and anti--tubulin antibodies (bottom). (B) Lysates of COS-7
cells containing the indicated combinations of HA-tagged NDR1(wt),
membrane-targeted hMOB1A (mp-myc-hMOB1A), and myc-tagged
hMOB2(wt) and hMOB2(H157A) were analyzed by immunoprecipi-
tation using anti-HA antibody. Complexes were assayed by immuno-
blotting and probed with anti-T444-P, anti-S281-P, and anti-HA anti-
bodies. The input lysate was analyzed by immunoblotting using anti-
myc antibody. (C) In parallel, complexes were subjected to peptide
kinase assays. The results from two independent experiments are
shown. The error bars indicate standard deviations. (D) HEK 293
cells transfected with membrane-targeted hMOB1A (mp-myc-
hMOB1A) and the indicated myc-tagged hMOB2 constructs were
subjected to S100/P100 (S, cytoplasm; P, membrane) fractionation
before being immunoblotted with anti-T444-P, anti-NDR2, anti-
myc, anti-CLIMP63 (p63) (a marker for membranous fraction), and
anti--tubulin (a marker for the cytoplasmic fraction) antibodies.
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lane 3). Interestingly, endogenous hMOB2 was enriched using
anti-NDR2 antibody (Fig. 7, lane 2), whereas when anti-
T444-P antibody was used to pull down active NDR species,
hMOB2 was not detectable (Fig. 7, lane 3). On the other hand,
hMOB1A was almost exclusively detected in phosphorylated
complexes of NDR (Fig. 7, compare lanes 2 and 3). This
finding is in agreement with previous reports demonstrating
enhanced complex formation of hMOB1A/B and NDR kinases
upon activation (36). Overall, we conclude that hMOB2 pref-
erentially associates with unphosphorylated NDR and, in con-
trast, hMOB1A/B associates with phosphorylated NDR.
Reduction of hMOB2 protein results in increased NDR1/2
kinase activity. hMOB2 is found in complex with unphosphor-
ylated NDR kinases (Fig. 7), and ectopically expressed
hMOB2 competes with hMOB1A/B, interfering with the acti-
vation of human NDR kinases (Fig. 4 and 5). Therefore, we
addressed the role of endogenous hMOB2 by RNAi. HEK293
cells, untransfected or transfected with plasmids encoding
shRNAs against firefly luciferase (Fig. 8A, lane 2) or hMOB2
(Fig. 8A, lane 3), were analyzed by immunoblotting and kinase
assays on endogenous NDR proteins performed in parallel
(Fig. 8A and B). hMOB2 protein levels were reduced upon
transfection with shMOB2, whereas hMOB1A/B levels were
not changed (Fig. 8A, lane 3). Interestingly, knockdown of
hMOB2 proteins resulted in an increase of phosphorylated
NDR species (Fig. 8A, top, lane 3), despite a slight reduction
in total NDR protein (Fig. 8A, lane 3). The increase of phos-
phorylated NDR was reflected in a significant increase in ki-
nase activity when a peptide kinase assay using immunopre-
cipitated NDR2 was performed (Fig. 8B, lane 3). Therefore,
we conclude that endogenous hMOB2 has inhibitory proper-
ties. However, the precise mechanism by which hMOB1A/B
FIG. 6. Endogenous hMOB2 interacts with NDR, but not with LATS1, in tissue-cultured cells. (A) Characterization of anti-hMOB2 rabbit
polyclonal antibody. HEK 293 cells transfected with short hairpin targeting either firefly luciferase (shLuc) or hMOB2 (shMOB2) were analyzed
72 h after transfection by immunoblotting using affinity-purified anti-hMOB2 antibody (top) and anti--tubulin antibody (bottom). Molecular
masses are indicated. (B) Recombinant GST-tagged human MOB proteins were separated by SDS-PAGE and analyzed by immunoblotting using
anti-hMOB2 (top) and anti-GST (bottom) antibodies. (C) Interaction of endogenous hMOB2 and NDR2. Whole-cell extracts of HEK 293 cells
were subjected to immunoprecipitation using control rabbit IgG or anti-NDR2 antibody. Complexes were analyzed by immunoblotting using
anti-hMOB2 (top) and anti-NDR2 (middle) antibodies. Input lysates were probed with anti-hMOB2 antibody. (D) Endogenous NDR2 was
coimmunoprecipitated with hMOB2. Lysates of HEK 293 cells were assayed by immunoprecipitation using control rabbit IgG or anti-hMOB2
antibody. Complexes were assayed by immunoblotting using anti-NDR2 (top) or anti-hMOB2 (bottom) antibody. Antibody heavy chains are
marked with an asterisk. Input lysates were analyzed with anti-NDR2 antibody. (E) Endogenous hMOB2 coimmunoprecipitates with NDR2, but
not with LATS1. Lysates of HEK 293 cells were subjected to immunoprecipitation with the indicated antibodies and analyzed by immunoblotting
using anti-NDR2, anti-LATS1, and anti-hMOB2 antibodies. Antibody heavy chains are marked with an asterisk.
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and hMOB2 complex formation with NDR is regulated re-
mains unknown, since analysis of HEK293 cells treated with OA
showed that hMOB2 protein levels remained unchanged (Fig.
8C) during the course of NDR activation (Fig. 8C, top) whereas
hMOB1A protein levels increased with time during the treatment
(Fig. 8C). Further, we did not observe significant changes in
either hMOB2 or hMOB1A/B protein levels during the course of
NDR activation upon induction of apoptosis (Fig. 8D).
hMOB2 expression affects biological functions of human NDR
kinases. Recent studies suggest that binding of hMOB1A/B to
human NDR1/2 kinases is necessary for apoptosis signaling
(36) and efficient centrosome duplication (13) in human cells.
Our findings show that hMOB2 is preferentially located in
inactive complexes with NDR (Fig. 7) and competes with
hMOB1A/B for NDR binding, thereby interfering with activa-
tion of NDR (Fig. 5 and 6). Therefore, we tested whether
hMOB2 binding to NDR kinases affects NDR function in
apoptosis and centrosome duplication. To examine the effect
of hMOB2 on apoptotic signaling, we generated U2-OS cell
lines expressing myc-hMOB2(wt) or myc-hMOB2(H157A) in a
tetracycline-inducible manner (Fig. 9). Cells were treated with
or without tetracycline for 24 h before anti-Fas antibody in
combination with cycloheximide was added. Cells were har-
vested at the time points indicated and analyzed by immuno-
blotting (Fig. 9). Unexpectedly, the hMOB2(H157A) variant
displayed reduced protein stability, since no residual protein
could be detected after the addition of a combination of anti-
Fas antibody and CHX or CHX alone (data not shown). Over-
expression of hMOB2(wt) resulted in reduced phosphorylation
of the hydrophobic motif of NDR1 (T444) after 4 and 6 h of
treatment compared with control cells (Fig. 9, top, compare
FIG. 7. Endogenous hMOB2 preferentially associates with inactive
NDR kinases. Whole-cell extracts of HEK 293 cells were subjected to
IP using the indicated antibodies and analyzed by immunoblotting with
anti-T444-P, anti-NDR2, anti-hMOB2, and anti-hMOB1A/B. Input
lysates were assayed by immunoblotting using the antibodies listed
above. Antibody heavy chains are marked with an asterisk.
FIG. 8. Reduction of hMOB2 protein results in increased NDR1/2 activity. (A) HEK 293 cells were transfected with plasmids encoding shLuc
or shMOB2 and were processed 72 h later for immunoblotting with the indicated antibodies. (B) In parallel, samples were subjected to IP using
rabbit IgG or anti-NDR2 antibody before peptide kinase assays were performed. Data from at least two independent experiments with two
replicates per experiment are shown. The error bars represent standard deviations. (C) HEK 293 cells were treated with 1 M OA for the indicated
times before being processed for immunoblotting with the indicated antibodies. A background band is marked by an asterisk. (D) Apoptosis was
induced in U2-OS cells by adding Fas antibody in combination with CHX for the indicated time and analyzed as for panel C.
4516 KOHLER ET AL. MOL. CELL. BIOL.
lines 2 and 3 to 6 and 7). Concurrently, we investigated
whether this decrease in NDR activation was matched by a
reduction in apoptotic markers. Indeed, the signal for cleaved
PARP was reduced in cells overexpressing hMOB2(wt) com-
pared with control cells (Fig. 9, compare lanes 3 and 4 to 7 and
8). These results indicate that hMOB2(wt) can interfere with
the physiological activation of NDR kinases and consequently
also interfere with NDR kinase apoptotic function.
We then sought to determine whether hMOB2 can also
affect NDR functions in centrosome duplication. As previously
reported (1), centrosomes overduplicate in U2-OS cells upon
S-phase arrest. Therefore, U2-OS cells transiently expressing
empty vector, myc-tagged hMOB2(wt), or hMOB2(H157A)
were arrested in S phase for 72 h and then analyzed by
immunoblotting and immunofluorescence (Fig. 10A and B).
As expected centrosome overduplication was observed in
control cells (Fig. 10C) but was reduced by overexpression
of hMOB2(wt) (Fig. 10C, lane 3). Overexpression of the NDR
binding-deficient mutant hMOB2(H157A) had no effect (Fig.
10C, lane 4), despite expression and localization patterns sim-
ilar to those of hMOB2(wt) (Fig. 10A and B). Overall, these
results suggest that wild-type hMOB2 also negatively affects
centrosome overduplication during S phase in an NDR bind-
ing-dependent manner. Therefore, two biological functions of
human NDR kinases can be negatively regulated by increased
hMOB2 expression.
DISCUSSION
MOB proteins are critical regulators of kinases of the NDR
family and are conserved from yeast to humans (16). In bud-
ding yeast, two distinct complexes of MOB-NDR modules ex-
ist, Mob1p-Dbf2p and Mob2p-Cbk1p. Moreover, MOB pro-
teins are essential activating subunits of the respective NDR
kinases (19, 20, 22, 38). In multicellular organisms, such as
Drosophila, dMOB1/Mats is required for the function of both
warts and trc kinase (10, 24), indicating that MOB1 proteins do
not specifically bind to a single NDR kinase, as in yeast. Also,
in human cells, hMOB1A/B bind to and activate all four
NDR kinases (2, 4, 13, 15, 29) and are essential for the
function of NDR1/2 kinases in apoptosis and centrosome
duplication (13, 36).
FIG. 9. Overexpression of hMOB2(wt) impairs death receptor-in-
duced activation of NDR kinases and interferes with apoptosis signal-
ing. U2-OS cells expressing myc-hMOB2(wt) in a tetracycline-induc-
ible manner were incubated without (lanes 1 to 4) or with (lanes 5 to
8) tetracycline for 24 h before apoptosis was induced by the addition of
Fas antibody in combination with CHX. Cells were harvested after 0,
4, 6, and 12 h and processed for immunoblotting using the indicated
antibodies.
FIG. 10. Ectopic expression of hMOB2(wt) impairs centrosome overduplication. (A and B) U2-OS cells transfected with myc-tagged
hMOB2(wt) or hMOB2(H157A) were treated with aphidicolin (2 g/ml) for 72 h before being processed for immunoblotting (A) or immuno-
fluorescence assay (B) with the indicated antibodies. The insets show enlargements of centrosomes in red. Myc-hMOB2 variants are in green. DNA
is stained blue. (C) Histograms showing percentages of cells with excess centrosomes (3, more than three per mononucleated cell). Shown are
cumulative data from at least three independent experiments with at least two replicates of 100 cells counted per experiment. The error bars
indicate standard deviations.
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However, human cells express six MOB proteins (Table 1)
and four NDR kinases. We show here that hMOB3A, -B, and
-C do not physically interact with or activate any of the four
NDR/LATS kinases (Fig. 1 and 2). Despite their significant
homology to hMOB1 proteins compared with hMOB2 (Table
1), hMOB3 proteins display significant sequence variation in or
around amino acids previously shown to be important in con-
ditional mutants in budding yeast MOB1p (32). Such variation
might explain why hMOB3 proteins did not associate with
NDR/LATS kinases. In support of this, it was shown recently
that overexpression of hMOB3 proteins did not significantly
affect centrosome duplication, a known function of NDR1/2
kinases (13). Therefore, the physiological binding partners and
functions of hMOB3 proteins remain undefined.
Our data demonstrated that hMOB2 is a specific interaction
partner of human NDR1/2 and not LATS1/2 (Fig. 1 and 2).
Accordingly, we focused our investigation on hMOB2 and
NDR1/2. Our findings demonstrate that hMOB2 binds to the
N-terminal regulatory domain of NDR1/2 kinases (Fig. 3), the
same region reported earlier for hMOB1A/B (2). Interestingly,
mutational analysis of the N-terminal region of NDR1/2 re-
vealed that the mode of binding of hMOB2 differs significantly
from that of hMOB1A/B, because mutations in the NDR1/2
protein that interfere with hMOB1 binding (2) do not affect
hMOB2 association (Fig. 3 and Table 2). hMOB2 binds
NDR1/2, most likely through multiple contact points, since the
interaction could not be ablated by single or combined point
mutations (Fig. 3 and Table 2). Therefore, structural analysis
of NDR1/2 kinases in complex with hMOB1 and hMOB2 pro-
teins will be required in the future to examine differences in
the two modes of interaction and also the mechanistic differ-
ences in activation/inhibition of these two complexes.
Additionally, we described for the first time competitive
binding of hMOB2 and hMOB1 proteins to the N terminus of
human NDR1/2 kinases (Fig. 4). Moreover, hMOB2 impaired
okadaic acid-induced activation of endogenous NDR species
(Fig. 4B), indicating distinct functions for different human
MOB proteins in the regulation of NDR1/2 kinases, since
hMOB1A was shown to potentiate NDR activity in a similar
experiment (2). In addition, these data are strengthened by the
concurrent use of a phosphospecific antibody to the hydropho-
bic motif phosphorylation (anti-T444-P) and by our biological
experiments. However, in the literature, conflicting reports on
the effects of hMOB2 overexpression on NDR activity describe
overexpressed hMOB2 activating NDR1/2 kinases upon OA
stimulation (5, 7). This could be due to the assays used to
measure NDR kinase activity. In both studies, the nonspecific
kinase substrates myelin basic protein and histone H1 were
used. Therefore, the presence of an associated kinase may have
contributed to the increase in phosphorylation of these sub-
strates, whereas in our assays, an established NDR kinase
substrate peptide was used (11, 13, 33, 34).
hMOB2 interferes with the activation of ectopic and endog-
enous NDR1/2 kinases by membrane-targeted hMOB1A in an
NDR binding-dependent manner (Fig. 5), since an hMOB2
variant incapable of binding to NDR1/2 did not affect activa-
tion of NDR (Fig. 5). The expression of hMOB2(wt) retained
NDR in the cytoplasm, and also, a fraction of mp-hMOB1A
was observed in the cytoplasmic fraction (Fig. 5D). Therefore,
it is possible that hMOB2 inhibits activation of NDR by mp-
hMOB1A by retention of the NDR-MOB1 complex, or even
by retaining mp-hMOB1A itself in the cytoplasm. However,
the analysis of this observation requires further investigation.
Moreover, we analyzed endogenous complexes of NDR1/2 and
hMOB1A/B or hMOB2 (Fig. 6 and 7). In full agreement with
previous work (36), we showed that phosphorylated endoge-
nous NDR species associate with hMOB1A/B. Interestingly,
unphosphorylated NDR proteins coimmunoprecipitated with
hMOB2, in contrast to active NDR species, which were found
to be associated mostly with hMOB1A/B (Fig. 7). This finding
uncovers a novel and distinct role of hMOB2 in the regulation
of NDR1/2 kinases.
Strikingly, by RNAi depletion of hMOB2 in HEK293 cells,
we found evidence that the endogenous role of hMOB2 is to
inhibit NDR kinases, since knockdown of hMOB2 increased
phosphorylation and kinase activity of endogenous NDR
species (Fig. 8A and B). We did not observe an effect on
hMOB1A/B protein, but we detected a decrease in total NDR
protein. Therefore, it is tempting to speculate that hMOB2
might also play a role in NDR protein stability. Nevertheless,
we describe for the first time an endogenous inhibitory func-
tion of a human MOB protein. We tried to address the mech-
anism through which hMOB1A/B and hMOB2 regulate NDR
activation and inhibition by analyzing the abundance of
hMOB1A/B and hMOB2 during the activation of NDR ki-
nases (Fig. 8C and D and 10A). Whereas the hMOB2 protein
level did not change during both treatments, hMOB1A/B pro-
tein increased during okadaic acid stimulation (Fig. 8), despite
activation of NDR in both treatments (Fig. 8). Therefore,
the endogenous mechanism through which hMOB1A/B and
hMOB2 regulate activation/inhibition of NDR kinases remains
unknown, since the total protein level might not represent the
composition of NDR-MOB complexes during the course of
activation. Future research in this direction is warranted.
We subsequently addressed the putative inhibitory func-
tion of hMOB2 in the context of two biological functions of
NDR1/2 kinases, the proapoptotic role of NDR and the contri-
bution of NDR to centrosome duplication (13, 36). Importantly,
both functions depend on the interaction of hMOB1A/B proteins
and NDR1/2 kinases.
First, inducible expression of hMOB2 interfered with the
activation of NDR1 in U2-OS cells after anti-Fas treatment
and in turn delayed apoptotic progression, as assessed by
cleaved PARP (Fig. 9). Since cleaved PARP is a marker for
apoptotic cells, this indicates that hMOB2 expression delayed
the onset of apoptosis and most likely reduced the total apop-
totic cell population in our settings. Furthermore, ectopic
hMOB2 impaired centrosome overduplication in an NDR
binding-dependent manner (Fig. 10). Significantly, the expres-
sion of kinase-dead NDR1 had a comparable effect on centro-
some overduplication in a similar assay (13). This is indicative
of an inhibitory effect of hMOB2 on NDR1 activity, which in
turn was necessary for centrosome duplication in our experi-
mental settings.
Interestingly, the role of the MOB2 protein in flies, dMOB2,
appears to also differ from that of dMOB1/Mats, because mu-
tations in the dMOB2 gene do not significantly enhance a
phenotype of trc mutants or overexpression of a dominant-
negative trc kinase (10). More precisely, overexpression of a
truncated form of dMOB2 (amino acids 148 to 354) leads to a
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phenotype similar to the trc mutant in fly wings (10), suggest-
ing a dominant-negative role of dMOB2 in NDR kinase reg-
ulation in flies. Intriguingly, the truncated variant of dMOB2
shares high similarity with the full-length human MOB2 pro-
tein (data not shown). Therefore, it is tempting to speculate
that dMOB2 has competitive properties similar to those of
hMOB2 shown in our study. Determining whether dMOB2
negatively regulates trc kinase by competing with dMOB1/
Mats is a question for future studies.
Our data show for the first time that hMOB2 has inhibitory
effects on NDR1/2 functions. hMOB2 is found in unphosphor-
ylated NDR complexes, and when overexpressed, hMOB2 can
compete with hMOB1A/B, possibly physically displacing en-
dogenous hMOB1A/B from NDR. hMOB2-NDR1/2 com-
plexes that accumulate also appear to be inactive/quiescent. As
a result, the activation of NDR1/2 by hMOB1A/B and possibly
also by upstream kinases, such as MST1, could be impaired.
Future challenges will be to address whether hMOB2 hinders
NDR activation by mechanisms other than competition and
steric restriction of the access of hMOB1 to the N terminus of
NDR1/2, which in turn will have to be addressed by highly
defined quantitative biochemical and biological assays. More-
over, the role of dMOB2 in flies has yet to be clarified. In light
of our findings, the investigation by Drosophila geneticists of a
negative function of dMOB2 on tricornered, warts, or even
hippo kinase, will be of considerable interest.
In conclusion, our data indicate a novel role for hMOB2
in the regulation of NDR1/2 kinases. In contrast to hMOB1,
hMOB2 is present in unphosphorylated NDR complexes.
RNAi-mediated reduction of hMOB2 resulted in increased
NDR activity. Overexpression negatively affects biological
functions of NDR kinases, such as apoptotic progression and
centrosome duplication. Altogether, our data indicate that
hMOB2 plays an inhibitory role in the regulation of human
NDR1/2 kinases.
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 Figure S1. Alignment of human hMOB proteins and phylogenetic analysis of the 
MOB protein family. (A) Phylogenetic relationships between proteins of the MOB 
family from human, fruit fly and yeast species. Only the residues of the conserved 
MOB-phocein domain (pFam accession number PF03637) corresponding to residues 
29-205 of hMOB1A were aligned and used for the phylogenetic analysis. The tree 
was constructed with quicktree using the neighbor-joining method. The numbers for 
interior branches represent bootstrap values. Only values higher than 50 are shown. 
Protein accession numbers form top to bottom: human MOB1A (Homo sapiens), 
Q9H8S9; human MOB1B, NP_775739; fruit fly dMOB1/Mats (Drosophila 
melanogaster), NP_651041; human MOB3A, CAE45267; human MOB3B, 
CAE45268; human MOB3C, CAE45269; fruit fly MOB3 (dMOB3), AAF52892; 
budding yeast MOB1 (Saccharomyces cerevisiae, scMOB1), P40484, and MOB2 
(scMOB2), P43563; fission yeast MOB1 and 2 (Schizosaccharomyces pombe, 
spMOB1, NP_595191; spMOB2, NP_587851) human MOB2, NP_443731; fruit fly 
MOB2 (dMOB2), NP_729715. (B) Alignment of amino acid sequences of full-length 
MOB proteins. Alignment was performed using default parameters of ClustalW2 and 
illustrated using Jalview. Residues 17-85 and 95-121 of scMOB1 are not shown in the 
alignment. 
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 Figure S2. Kohler et al. 
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 Figure S2. Human NDR and LATS kinases do not interact with C-terminally 
tagged hMOB3A/B/C proteins. (A) and (B) Lysates of HEK 293 cells co-expressing 
the indicated combinations of HA-tagged NDR1 wild-type (wt), HA-tagged 
NDR2(wt) and hMOB species containing a C-terminal myc-tag were analyzed by 
immunoprecipitation (IP) using anti-HA 12CA5 antibody. Complexes were assayed 
by immmunoblotting using anti-myc antibody (top panel) or anti-HA antibody 
(middle panel). Input lysates were analyzed by immunoblotting using anti-myc 
antibody and a-α-tubulin antibody. hMOB2 served as positive control. (C) and (D) 
Lysates of HEK 293 cells co-expressing the indicated HA-tagged LATS1(wt) or 
LATS2(wt) and hMOB species containing a C-terminal myc-tag were analyzed as 
described in A and B, except that hMOB1A served as positive control. 
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 Figure S3. The hMOB2(H157A) mutant displays reduced protein stability. U2-
OS cells expressing hMOB2(wt) or hMOB2(H157A) in a tetracycline inducible 
manner were incubated without or with tetracycline for 24 h before treatment with 
DMSO (lanes 1, 4, 7 and 10), cycloheximide (CHX) (lanes 2, 5, 8 and 11) or CHX in 
combination with activating anti-Fas antibody (lanes 3, 6, 9 and 12). Cells were 
harvested 4 h and processed for immunoblotting using anti-myc and anti-actin 
antibodies. 
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 Figure S4. Kohler et al. 
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Figure S4. Alignment of the amino acid sequence of human MOB2 and fly 
dMOB2(dC). The truncated dMOB2(dC) protein (aa148-354) as described in (He et 
al. 2005) shares 47% identity and 61% similarity with full-length human MOB2. 
 
 
 
 
 
  
 
 
 
 
3.2. Discovery of Novel Human NDR Kinases Substrates: 
A Chemical Genetic Approach 
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 3.2.1. Introduction 
 
The identification of kinase-substrate pairs has so far been the bottleneck of 
protein kinase research mainly because the highly conserved structural similarity of 
the kinase domain prevents prediction of substrate specificity for a single kinase.  
Shokat and colleagues developed a method by which with the help of a mutation a 
subtle structural distinction between wild-type and mutant kinases is created therefore 
facilitating the identification of novel substrates [1]. The method is based on the 
mutation of a highly conserved bulky hydrophobic residue in the ATP-binding pocket 
present in most of all protein kinases [2]. Changing this so-called gatekeeper residue 
in the active site of the kinase (usually a methionine, leucine, phenylalanine or 
threonine) to alanine or glycine grants access to a hydrophobic groove within the 
ATP-binding pocket, therein allows binding of bulky ATP analogs with substituent 
groups appended to the N6-amine such as N6-(benzyl)-ATP. Since wild-type kinases 
are not able to utilize ATP analogs, the addition of a single analog-sensitive kinase to 
cell extracts in the presence of a radiolabeled ATP analog ([γ−32P] N6-(benzyl)-ATP) 
should ultimately result in specific labeling of direct substrates which can 
subsequently be identified by mass spectrometry [3-6].  
Additionally, the analog-sensitive kinase is exclusively sensitized to the orthogonal 
inhibitors 1Na-PP1, 1NM-PP1 or 3-MB-PP1. Since wild-type kinases remain 
insensitive to the addition of these orthogonal inhibitors, the chemical genetic analysis 
offers single-kinase inhibition, and unlike genetic disruption of protein kinase 
function, cell-permeable inhibitors act quickly, reversibly and do not allow the cell to 
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compensate for the missing kinase activity. This allows for direct investigation of the 
cellular kinase activity-dependent functions of the modified protein kinase [7-9]. 
Although NDR1/2 kinases are well characterized in terms of regulation and 
functions, downstream signaling events remain elusive. Indeed, the first NDR 
substrate was only described recently (Cornils et al., see Appendix). Therefore, we 
aimed to employ the chemical genetic method to NDR kinases in order to identify 
novel substrates. Hence, we created analog-sensitive variants of NDR1/2 kinases by 
the mutation of the gate-keeper residues Met166 and Met167, respectively. 
Subsequently, we have tried to identify direct substrates of analog-sensitive NDR1/2 
variants by performing assays on cell extracts and immunocomplexes in the presence 
of a radiolabeled ATP analog.  
 
 
3.2.2. Results 
 
Generation of an active analog-sensitive NDR1-hMOB complex to screen for 
novel substrates in cell extracts. We have characterized a recombinant analog-
sensitive NDR1 kinase, MBP-NDR1 PIF M166G (Kohler R Masterthesis 2006). 
However, this recombinant kinase diplayed reduced basal activity when compared to 
wild-type NDR1 and therefore the discovery of novel substrates in cell lysates was 
likely to be hindered by the limited kinase activity of recombinant NDR1 M166G 
from bacteria. 
For the discovery of novel substrates of Cdk1 and Cdk7, analog-sensitive kinases 
were expressed and purified from insect cells using the baculovirus system [3, 4, 10]. 
We thus changed to the baculoviral system and purified polyhistidine-tagged 
 52 
NDR1(M166G) in dimeric complexes with either hMOB1A or hMOB2 or 
NDR1(M166G) without hMOB proteins instead containing the PIFtide (6xHis-
NDR1(M166G) PIF) rendering it constitutively active (Fig. 1A). The recombinant 
proteins were essentially pure and we could demonstrate the distinct NDR/hMOB 
complexes by Coomassie stain or immunoblotting (Fig. 1A). The activity of these 
NDR1(M166G) variants was then compared to the previously used MBP-
NDR1(M166G) PIF from E. coli using a peptide kinase assay and radiolabeled ATP-
analog [γ−32P] N6-(benzyl)-ATP (Fig. 1B). As apparent from this panel, the analog-
sensitive NDR1 kinases from Sf9 cells displayed 6-16 fold increase in kinase activity 
compared to the MBP-NDR1(M166G) PIF (Fig. 1B, lanes 2-4 vs lane 1). 
Interestingly, the NDR1(M166G)/hMOB1A complex showed comparable kinase 
activity to the constitutively active NDR1(M166G) PIF (Fig. 1B, lanes 2 and 3). 
Therefore, the NDR1/hMOB1A complex was used for further experiments since it 
possibly reflected a physiological NDR1 kinase better than the artificial PIFtide 
containing chimeric kinase. Furthermore, the complex of NDR1(M166G)/hMOB2 
displayed reduced activity when compared to NDR1(M166G)/hMOB1A (Fig. 1B, 
compare lanes 2 and 4), which is in full agreement with our recently published 
manuscript [11]. Significantly, we could further increase the activity of the 
NDR1(M166G)/hMOB1A complex by adding the upstream kinase MST3 (Fig. 1C). 
The incubation of NDR1(M166G)/hMOB1A together with GST-MST3 purified from 
okadaic acid (OA)-treated HEK 293 cells before assaying kinase activity resulted in a 
robust increase in phosphorylation of the hydrophobic motif T444 as well as kinase 
activity (~100-fold) measured by peptide kinase assay (Fig. 1C, lane 2). To 
demonstrate that this increase in activity was specific to the analog-sensitive NDR1 
kinase, the orthogonal inhibitor 1NM-PP1 was added to the kinase reaction after 
 53 
incubation with GST-MST3, which abolished NDR1 kinase activity in the peptide 
kinase assay (Fig. 1C, lane 3).  
Figure 1. Generation and characterization of active recombinant NDR1(M166G)/ hMOB complexes. (A) 
Purification of NDR1(M166G)/hMOB complexes. Purified polyhistidine-tagged NDR1(M166G) variants from 
Sf9 cells were analyzed by SDS-PAGE followed by Coomassie staining and in parallel by immunoblotting 
using anti-NDR, anti-hMOB1A/B and anti-hMOB2 antibodies. (B) Recombinant NDR1(M166G)/hMOB1A 
complex displays high activity. 500 ng of purified proteins and complexes from (A) were assayed for kinase 
activity in a peptide kinase assay using [γ-32P] N6-(benzyl)-ATP. The results in duplicates are shown relatively 
to the activity of MBP-NDR1(M166G) PIF purified from E. Coli. (C) Activation of NDR1(M166G)/hMOB1A 
by MST3 in vitro. NDR1(M166G) in complex with hMOB1A was incubated with or without GST-MST3 
purified from okadaic acid (OA)-activated HEK 293 cells. Aliquots of the reactions were analysed by 
immunoblotting using anti-T444P, anti-NDR and anti-GST antibodies. In parallel, kinase assays on NDR 
substrate peptide containing [γ-32P] N6-(benzyl)-ATP were performed in duplicates with or without the 
orthogonal inhibitor 1NM-PP1. (D) Screening membrane extracts for direct substrates. Activated 
NDR1(M166G)/hMOB complexes (+) treated as in (C) were mixed with 100 μg membrane extracts in the 
presence of [γ-32P] N6-(benzyl)-ATP, an ATP regenerating system and with or without the orthogonal inhibitor 
1NM-PP1. Labeled bands were analysed by SDS-PAGE and exposed to a Phosphor screen ad visualized with a 
Phosphorimager. 
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We generated a highly active analog-sensitive NDR1/hMOB1A complex, and the 
usage of an ATP regeneration system as previously described [3] greatly reduced the 
background in our assays (Fig 1D, Lane 1). However, when we screened for direct 
substrates in cell lysates or subcellular fractions such as membranous, nuclear or 
cytosolic fractions, we did not observe a reproducible pattern of labeled bands. As a 
representative experiment we show here membranous fraction of HEK 293 cells 
assayed with activated dimeric NDR1(M166G)/hMOB complexes (Fig. 1D). We did 
not observe strong background staining (Fig. 1D, lane 1), however, the only bands in 
the reaction that responded to the orthogonal inhibitor 1NM-PP1 treatment were 
NDR1(M166G) at ~58 kDa and a faint band at ~20 kDa (Fig 1. lanes 2 and 3). In 
conclusion, although we successfully optimized the activity of our analog-sensitive 
NDR1 kinase, we did not observe a reproducible pattern of phosphorylated bands that 
could possibly lead to the discovery of novel substrates.  
 
Kinase assays on HA-NDR1(M166G) immunocomplexes reveal a distinct 
pattern of labeled bands specific for the activity of the analog-sensitive NDR 
kinase. The labeling reactions performed with activated NDR1(M166G)/hMOB1A 
and cell extracts did not lead to the discovery of directly phosphorylated proteins. (Fig. 
1). Therefore, we sought to leverage another approach which did not involve 
production of recombinant analog-sensitive kinases and assays in cell extracts. We 
adapted the method described by Eblen et al., which consists of a kinase assay on 
immunocomplexes of the respective analog-sensitive kinase, in order to identify novel 
Erk2 substrates [5]. Briefly, HEK 293 cells overexpressing HA-NDR1(M166G) are 
treated with OA for 45 min before harvesting in order to accumulate active NDR (Fig. 
2). Then the HA-tagged protein is immunoprecipitated using covalently coupled anti-
 55 
HA antibodies in low-stringency buffer where we would expect many NDR-binding 
proteins to remain associated. The HA-immunocomplexes are then directly assayed 
on the PrA-beads in reaction buffer containing [γ−32P] N6-(benzyl)-ATP in 
combination with or without the orthogonal inhibitor 1NM-PP1. Other co-
immunoprecipitated kinases would be able to use “cold” ATP to phosphorylate 
substrates. However, only the analog-sensitive HA-NDR1(M166G) should be able to 
use the radiolabeled ATP analog, therefore directly labeling substrates. The proteins 
are separated by SDS-PAGE and the labeled bands are visualized by exposure to a 
phosphorimager screen, which will show bands responsive to the inhibition of 
NDR1(M166G) by 1NM-PP1 (Fig. 2).  
Figure 2. Experimental outline for kinase assays on HA-NDR1(M166G) immunocomplexes. HEK 293 cells 
expressing HA-NDR1(M166G) are treated with OA before lysis in low stringency buffer. Subsequently, NDR1 
associated proteins are immunoprecipitated using anti-HA antibody covalently coupled to beads. After several 
washes in low-stringency buffer, kinase assays using radiolabeled [γ-32P] N6-(benzyl)-ATP are performed on 
beads in the presence or absence of the orthogonal inhibitor 1NM-PP1. Labeled proteins are then visualized by 
SDS-PAGE and exposure to a Phosphorimager screen. 
 
 
Congruently, HA-tagged NDR1(M166G) and NDR2(M167G) from unstimulated 
or OA-treated HEK 293 cells were immunoprecipitated and associated proteins were 
labeled in an in vitro kinase assay using [γ−32P] N6-(benzyl)-ATP with or without the 
orthogonal inhibitor 1NM-PP1 (Fig. 3A). The kinase assay on immunoprecipitates 
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Figure 3. Kinase assays on NDR1(M166G) immunocomplexes. (A) A distinct pattern of labeled bands is 
observed after immunocomplex kinase assays. After immunoprecipitation in IP buffer (without NaCl) with anti-
HA antibody of HEK 293 cells overexpressing HA-NDR1 or HA-NDR2 treated or untreated with OA for 45 
min kinase assay reactions were performed in the presence of [γ-32P] N6-(benzyl)-ATP and with or without 
1NM-PP1. Labeled bands were visualized using a Phosphorimager screen. (B) The pattern of the specifically 
labeled band is reproducible in more stringent IP buffer. Immunoprecipitation of HA-NDR1(M166G) was 
performed in IP buffer containing 50 mM NaCl before kinase assays using [γ-32P] N6-(benzyl)-ATP. In parallel 
complexes were assayed using anti-HA and anti-T444-P antibodies. (C) The labeled bands are specific for HA-
NDR1(M166G) activity. Lysates of HEK 293 cells overexpressing HA-NDR1(wt) or HA-NDR1(M166G) were 
subjected to immunoprecipitation in IP buffer containing 50 mM NaCl before kinase assays on 
immunocomplexes using [γ-32P] N6-(benzyl)-ATP were performed. Labeled bands were visualized using a 
Phosphorimager screen. In parallel complexes were analyzed using anti-HA and anti-T444-P antibodies. 
 57 
from transfected control cells showed negligible background phosphorylation (Fig. 
3A, lanes 1-4). Interestingly, the kinase assays of HA-NDR1(M166G) 
immunocomplexes from OA-stimulated cells generated a distinct pattern of labeled 
bands at high and low molecular masses (Fig. 3A, lane 7). Significantly, the signals 
were responsive to the inhibition by 1NM-PP1, indicating that these proteins were 
directly phosphorylated by HA-NDR1(M166G) (Fig. 3A, lane 8). We observed 
similar results when kinase assays of HA-NDR2(M167G) immunoprecipitates were 
analyzed (Fig. 3A, lanes 11 and 12). However, the signals were significantly weaker 
as in the case of NDR1 probably due to differences in expression levels. Therefore, 
we used HA-NDR1(M166G) for further experiments.  
We then increased the stringency of our immunoprecipitation and washing 
protocol by using IP buffer containing 50 or 150 mM NaCl. The obtained pattern of 
labeled bands was highly reproducible in buffer containing 50 mM NaCl (Fig. 3B, 
lanes 4 and 5). However, the signals were greatly diminished using buffer containing 
150 mM NaCl (data not shown). Therefore, we used buffer with 50 mM NaCl also to 
decrease background by proteins binding unspecifically to the beads.  
In order to show that the labeling of these bands is derived from NDR1(M166G) 
activity, we performed kinase assays on immunocomplexes of HA-NDR1(wt) from 
OA-stimulated cells in parallel (Fig. 3C). Whereas we observed again a similar 
pattern of bands in the kinase assay using HA-NDR1(M166G) immunocomplexes 
(Fig. 3C, lanes 4 and 5), the reaction with HA-NDR1(wt) immunoprecipitates 
generated only signals resembling background phosphorylation of transfected control 
cells (Fig. 3C, lanes 1-3) despite similar amounts of active HA-tagged NDR species 
were being immunoprecipitated (Fig. 3C, bottom panels).  
 
 58 
In order to identify ERK2 substrates, FLAG-tagged ERK2 was used which facilitated 
the elution of immunocomplexes and subsequent mass spectrometrical analysis [5]. 
Thus, we repeated our experiments with FLAG-tagged NDR1(M166G) followed by 
elution using 3xFLAG peptide. Despite efficient elution from FLAG-NDR1(M166G) 
of the beads, we did not observe a distinct pattern of bands except for the 
autophosphorylation of NDR1(M166G) (Figure 4). 
Figure 4. Kinase assays on FLAG-NDR1(M166G) immunocomplexes do not result on a distinct pattern of 
bands. Complexes from HEK 293 cells overexpressing FLAG-NDR1(M166G) treated with or without OA, were 
immunoprecipitated using anti-FLAG antibody in IP buffer containing 50 mM NaCl. Kinase assay reactions 
were performed in the presence of [γ-32P] N6-(benzyl)-ATP, with or without 1NM-PP1. Then, proteins were 
eluted using 3xFLAG peptide and analyzed by SDS-PAGE. Elution efficiency was assessed by immunoblotting 
using anti-FLAG antibody. Labeled bands were visualized using a Phosphorimager screen. E, eluate, B, beads. 
 59 
 In conclusion, after switching from recombinant analog-sensitive NDR kinase to 
assays using HA-NDR immunocomplexes from OA treated cells we were actually 
able to reproducibly obtain a distinct pattern of bands directly phosphorylated by HA-
NDR1(M166G). Unfortunately, we were not able to use FLAG-NDR1(M166G) 
which would have facilitated elution and further analysis by mass spectrometry.  
 
3.2.3. Discussion 
 
The molecular regulation and the functions of NDR1/2 kinases in apoptosis and 
centrosome duplication [11-21] are well described. However, downstream 
mechanisms of NDR functions remained elusive and only recently the first substrate 
of human NDR kinases was identified, the cyclin-CDK inhibitor p21 (Cornils and 
Kohler. see Appendix).  
Hence, we aimed to identify novel NDR substrates using a chemical genetic approach 
originally developed by Shokat and colleagues [1]. We established recombinant 
sources of analog-sensitive NDR1(M166G) kinase (Fig. 1). Comparing the activity of 
NDR1(M166G) variants either purified from E.Coli or Sf9 cells, we could show that 
recombinant NDR1(M166G) purified using the baculovirus system displayed 
significantly higher basal activity (Fig. 1B). Recombinant analog-sensitive kinases 
such as CDK1, CDK2 or CDK7 need to be activated by pretreatment with upstream 
kinases prior to use for labeling direct substrates [3, 4, 10].Accordingly, we were able 
to increase the activity of the polyhistidine-tagged dimeric NDR1/hMOB complexes 
by 100-fold following preincubation with GST-MST3 (Fig. 3C). This highly active 
analog-sensitive NDR/hMOB1A complex was subsequently used for screening cell 
extracts and subcellular fractions for direct NDR substrates (Fig. 1D). Unfortunately, 
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the addition of activated NDR1(M166G)/hMOB complexes to whole cell lysates or 
subcellular fractions such as membranous fraction did not result in labeling of 
proteins except for the observed autophosphorylation of NDR itself (Fig. 1D, lane 2). 
The labeling of substrates using recombinant analog-sensitive kinases and cell lysates 
or cellular fractions worked exceptionally well with CDKs such as CDK1, CDK2 and 
CDK7 [3, 4, 10]. However, with mammalian kinases of other classes such as PKA, 
JNK or RAF-1, the clear-cut substrate labeling in lysates was more difficult to achieve 
[22-24].  
 Several hypothetical explanations can be thought of to justify the ineffective 
labeling of substrates in cell lysates in vitro: saturation of phosphosites by endogenous 
protein kinases; association of substrates with endogenous kinases, therefore blocking 
access for phosphorylation; reduced activity and substrate specificity of the 
recombinant analog-sensitive kinase; missing co-factors in the dimeric 
NDR1(M166G)/hMOB1 complex; limited abundance of direct substrates in cell 
lysates; complexity of the lysates/fractions.  
 Binding partners of a kinase are potential substrates, therefore 
immunoprecipitation of the overexpressed analog-sensitive kinase under low-
stringency conditions should leave binding partners associated and thus make them 
available for labeling [5]. We adapted this method and observed for the first time a 
reproducible pattern of labeled bands when immunocomplexes of HA-tagged 
NDR1(M166G) from OA-treated HEK 293 cells were assayed in the presence of 
radiolabeled ATP analog (Fig. 3). The bands are likely to be direct targets of 
NDR1(M166G) since the signals were abolished when the orthogonal inhibitor 1NM-
PP1 was added. Furthermore, the signals were not visible in HA-tagged NDR1(wt) 
complexes (Fig. 3C). However, assays performed on FLAG-NDR1(M166G) 
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immunocomplexes did not result in the previously labeled bands (Fig. 4). Therefore, 
the identification of the nature of those bands was largely impaired.  
In order to validate the result obtained with HA-tagged NDR1(M166G) the 
reactions should be tested for the abundance of phosphorylated p21, the recently 
described first substrate of NDR kinases (Cornils and Kohler, see Appendix). The 
assays could be performed as described but after labeling, instead of analysis by SDS-
PAGE, the reaction are boiled in SDS and immunoprecipitation of p21 is performed 
followed by analysis by western blot and autoradiography. Moreover, a combined 
approach of immunocomplex kinase assays and covalent capture of phosphoproteins 
as described in [10] could help to identify substrates of NDR1(M166G).  
In conclusion, we have established a recombinant source of active analog-sensitive 
NDR1/hMOB1A complex yet only the immunoprecipitated HA-NDR1(M166G) 
yielded a specific and reproducible pattern of bands. However, these results should 
open avenues for the discovery of novel direct substrates of human NDR1/2 kinases 
and for further chemical genetic analysis of NDR kinase function.  
 
 
3.2.4. Materials and Methods 
 
Construction of Plasmids and recombinant Baculoviruses. Human NDR1 and 
NDR2 cDNAs were subcloned into pcDNA3-HA or pcDNA3-FLAG using BamHI 
and XhoI restriction sites. The generation of a constitutively active NDR1 kinase by 
exchanging the C-terminus of NDR1 by the hydrophobic motif of PRK2 has been 
described earlier ([12], Kohler R. Masterthesis). The gatekeeper mutations Met166 or 
Met167 to glycine were introduced by site-directed mutagenesis according to the 
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manufacturer’s instructions (Stratagene). The NDR1 PIF M166G cDNA was 
subcloned into pMAL-2c or pFastBac HTb using BamHI and XhoI sites. Human 
hMOB1A and hMOB2 cDNAs were amplified by PCR, digested by XhoI and SphI 
and inserted into pFastBac Dual or digested by BamHI and XhoI and ligated into 
pFastBac HTb. To generate pFastBac Dual coding for NDR1(M166G) and hMOB1A 
or hMOB2, NDR1(M166G) cDNA was subcloned into pFastBac HTb using BamHI 
and XhoI restriction sites. Then NDR1 M166G cDNA containing an N-terminal 6x 
His tag followed by an rTEV cleavage site was subcloned from pFastBac HTb using 
RsrII and HindIII restriction sites and ligated into pFastBac Dual constructs. To 
generate pFastBac1-GST, the coding sequence of Glutathione-S-transferase (GST) of 
pGEX-6P-3 including multiple cloning site was amplified by PCR and digested with 
BglII and NotI and inserted into pFastBac1 vector. Human NDR1(wt) or NDR1(kd) 
and NDR2(wt) or NDR2(kd) were subcloned into pFastBac1-GST using BamHI and 
XhoI restriction sites. All constructs were confirmed by sequence analysis.  
Recombinant baculoviruses were generated using the Bac-to-Bac baculovirus 
system (Invitrogen). Briefly, pFastBac plasmids were transformed into DH10Bac to 
generate bacmid DNA. Correct insertion of coding sequences in bacmid DNA was 
verified by PCR. To generate recombinant baculovirus, individual bacmids were 
transfected into Sf9 cells and high titer viruses were harvested after several rounds of 
amplification. 
Expression and Purification of Recombinant Proteins. To produce recombinant 
protein using the Bac-to-Bac system, Sf9 cells (20 x 106 cells/15-cm dish) were 
infected with the respective high-titer baculovirus stock and cells were harvested 48 
or 72 h after infection. Recombinant proteins containing a polyhistidine tag were 
purified according to manufacturer’s instructions (Invitrogen). Briefly, Sf9 cells were 
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lysed in binding buffer (50 mM NaH2PO4, 500 mM NaCl, 1% NP-40, 1 mM Na3VO4, 
1 mM benzamidine, 4 μM leupeptin, 0.5 mM phenylmethylsulfonyl fluoride (PMSF) 
and 1 μM microcystine at pH 8.0) containing 10 mM imidazole and 6x His tagged 
proteins were bound to Ni-NTA agarose. After extensive washes with binding buffer 
containing 20 mM imidazole, proteins were eluted using 250 mM imidazole followed 
by dialysis vs. 20 mM Tris at pH 7.5 containing 20 % glycerol. Purified recombinant 
proteins were stored at – 80°C.  
Active recombinant NDR kinases containing N-terminal Glutathione-S-
Transferase (GST) tags in complex with hMOB1A were purified on GS-4B beads 
according to the manufacturer’s instructions (GE Lifesciences). Briefly, Sf9 were co-
infected with baculoviruses encoding GST-NDR1/2 variants and 6xHis-hMOB1A and 
harvested 72 hours after infection. To activate NDR kinases, cells were treated with 
0.1 μM okadaic acid (OA) 4 hours before harvest. Complexes were purified on GS-
4B beads. 
To make bacterially synthesized NDR1 PIF M166G, transformed BL21/DE3 E. 
Coli were induced with IPTG for 3 hours and MBP-tagged proteins were purified 
using amylose resin according to the manufacturer’s instruction (New England 
Biolabs). 
The purification of GST-MST3 from OA-treated HEK293 cells was described 
previously [12].  
Cell Culture, Transfections and Chemicals. Sf9 cells were maintained in 
Grace’s insect medium containing penicillin and streptomycin and 10% fetal calf 
serum in a humidified incubator at 25°C. HEK 293 cells were maintained in 
Dulbecco’s modified eagle medium (DMEM) supplemented with 10% fetal calf 
serum. Exponentially growing HEK 293 cells were transfected in solution at 
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consistent confluence (5 x 106 cells/10-cm dish) using jetPEI (Polyplus Transfections) 
according to the manufacturer’s instructions. The orthogonal inhibitor 4-amino-1-
(tert-butyl)-3-(1′-naphthylmethyl) pyrazolo [3,4-d] pyrimidine (1NM-PP1) was 
purchased from Calbiochem and okadaic acid (OA) was from Alexis Biochemicals 
(Enzo Life Sciences). 
Generation of [γ-32P] N6-(benzyl)-ATP. 100 units of Nucleoside diphosphate 
kinase (NDPK, S. Cerevisiae, Sigma) and 400 μCi of [γ−32P] ATP (Hartmann 
Analytic) were added in a 100-μl reaction containing HBS (150 mM NaCl, 20 mM 
HEPES, pH 7.4, and 5 mM MgCl2). The NDPK was allowed to autophosphorylate at 
30°C for 5 min. 32P-labeled NDPK was purified from free [γ−32P] ATP by 
centrifugation through a Probequant G50 micro column (Amersham Bioscience) at 
735 x g for 2 min. 1 nmole of N6-(benzyl)-ADP (Biolog) in HBS was added to the 
32P-labeled NDPK, and the reaction was incubated for 20 min at 30°C. After the 
reaction, [γ−32P] N6-(benzyl)-ATP was purified from NDPK using a Microcon-YM10 
(Millipore) at 13000 rpm for 15 min. This procedure usually resulted in production of 
~200 μCi of purified [γ−32P] N6-(benzyl)-ATP. 
Antibodies. The generation and purification of anti-T444-P, anti-NDRNT, anti-
NDRCTD, anti-hMOB1A/B and anti-hMOB2 antibodies has been described previously 
[17, 19-21]. Anti-GST antibody was purchased from Santa Cruz. Anti-HA 12CA5 and 
42F13 were used as hybridoma supernatants. Anti-FLAG M2 and 3xFLAG peptide 
were purchased from Sigma.  
Immunoblotting. Immunoblotting experiments were performed as described [13]. 
Fractionation of Cells. Cytosolic, nuclear and membrane-associated proteins were 
separated by fractionation as described [13]. 
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Peptide Kinase Assays. Purified recombinant NDR1(M166G) kinase variants 
(500 ng) were incubated in reaction buffer (20 mM Tris/HCL pH 7.5, 10 mM MgCl2, 
1 mM benzamidine, 4 μM leupeptin, 1 μM microcystin, 1 mM DTT, 1 μM cyclic 
AMP-dependent protein kinase inhibitor peptide) containing 500 μM ATP for 90 min 
at 30°C before 1mM NDR substrate peptide (KKRNRRLSVA) and 2.5 μCi [γ−32P] 
N6-(benzyl)-ATP were added. After 30 min at 30°C reaction was stopped by adding 
50 mM EDTA. 20 μl of the reaction mix was then spotted onto squares of P-81 
phosphocellulose paper (Whatman) and washed four times for 10 min each in 1% 
phosphoric acid and once in acetone before counting in a liquid scintillation counter 
was performed. Experiments were performed in duplicates. 
In vitro Activation of NDR1(M166G) Kinases by MST3. 500 ng of purified 
6xHis-tagged NDR1(M166G) in complex with hMOB1A or hMOB2 was incubated 
with or without ~1 μg GST-MST3 for 90 min at 30°C in 60 μl reaction buffer 
containing 1mM ATP. 
Protein Phosphorylation in Cell Extracts. 100 μg cytosolic, nuclear or 
membrane extracts in 20 mM Tris/HCl pH 7.5 supplemented with protease inhibitors, 
phosphatase inhibitors (80 mM sodium-glycerophosphate, 50 mM NaF, 1 mM 
Na3VO4) and an ATP regenerating system (40 mM creatine phosphate, 0.2 mg/ml 
creatine phosphokinase) were mixed with 0.5 – 1 μg of activated NDR1(M166G)/ 
hMOB complexes and 5 μCi [γ−32P] N6-(benzyl)-ATP in a final volume of 70 μl. 
After 30 min at 30°C reactions were stopped by the addition of 20 μl 5x SDS-PAGE 
loading buffer and boiling at 95°C for 5 min. Reactions were analyzed on a 12% 
SDS-PAGE gel and labeled bands were visualized by exposure to film or 
Phosphorimager screen. 
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Immunoprecipitation and Protein Phosphorylation on Immunocomplexes. For 
immunoprecipitation and phosphorylation, cells were treated with 1 μM OA for 45 
min, harvested, pelleted at 1000 g for 3 min, and washed with cold PBS before lysis 
in low-stringency immunoprecipitation buffer (IP buffer) (20 mM Tris, 10% glycerol, 
1% NP-40, 5 mM EDTA, 0.5 mM EGTA, 20 mM β-glycerophosphate, 50 mM NaF, 1 
mM Na3VO4, 1 mM benzamidine, 4 μM leupeptin, 0.5 mM phenylmethylsulfonyl 
fluoride (PMSF), 1 μM microcystine and 1mM dithiothreitol (DTT) at pH 8.0) 
containing no or 50 mM NaCl. Lysates were centrifuged for 10 min at 16000 g at 4°C 
and split in two before preclearing with protein A (PrA)-Sepharose followed by 
immunoprecipitation with anti-HA 12CA5 antibody covalently coupled to PrA-
sepharose. Beads were washed four times with IP buffer and two times in 20 mM 
Tris/HCl containing 1 mM benzamidine, 4 μM leupeptin, 0.5 mM PMSF and 1mM 
DTT at pH 7.5. Immunocomplexes were assayed by resuspention in 30 μl reaction 
buffer containing 1mM ATP and 5 μCi [γ−32P] N6-(benzyl)-ATP supplemented with 
or without 10 μM 1NM-PP1. After 30 min incubation at 30°C reactions were stopped 
by adding 5x SDS-PAGE loading buffer and boiling at 95°C for 5 min. Labeled bands 
were visualized by SDS-PAGE and exposure to a Phosphorimager screen.  
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4. General Discussion 
The aim of the thesis was to investigate the functional role of all human MOB 
proteins in the regulation of human NDR kinases. During the course of this study we 
were able to identify a novel role for hMOB2. In contrast to hMOB1A/B proteins, 
hMOB2 has endogenous inhibitory properties towards NDR1/2 kinases.  
 Furthermore, the basis for the identification of novel substrates of human NDR1/2 
kinases was established. Applying a chemical genetic strategy to NDR1, we observed 
proteins specifically phosphorylated by NDR1(M166G) in immunocomplex kinase 
assays. In addition, while investigating the role of NDR in cell cycle regulation, we 
identified the first in vivo substrate of NDR1/2 kinases, the cyclin-dependent kinase 
inhibitor p21. 
 
Differential regulation of NDR kinases by MOB proteins 
MOB proteins are essential components of the NDR-MOB signaling modules 
across species [6]. Going from unicellular to multicellular species, there is a 
progressive expansion of the MOB family from two MOB proteins in yeast (Mob1p 
and Mob2p) to six MOB proteins in human (hMOB1A/B, hMOB2 and 
hMOB3A/B/C). We observed differential interactions with the human NDR kinase 
family NDR1/2 and LATS1/2. Three out of the six MOB proteins analyzed did not 
bind to or activate NDR1/2 or LATS1/2 kinases. Therefore, the binding partners of 
hMOB3 proteins remain to be identified. Furthermore, we could show that hMOB2 is 
a NDR1/2-specific binder of human NDR kinase family members. Interestingly, 
hMOB2 binds to the same region as shown for hMOB1A/B, the NTR, and we could 
for the first time show competitive binding of two MOB proteins. Moreover, hMOB2 
was observed in an inactive complex with NDR1/2 and reduction of hMOB2 by 
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RNAi resulted in increased NDR kinase activity. In agreement with this finding, 
overexpression of hMOB2 impaired NDR function and activation in the context of 
FAS-mediated apoptosis and centrosome duplication. In summary, this data indicate a 
negative role for hMOB2 in NDR1/2 kinase regulation (Figure 5). 
 In yeast, the MOB proteins are essential for activity and function of NDR kinases 
and, in Drosophila, Mats/dMOB1 is essential for Wts activity and is required for Trc 
function [45-47]. Interestingly, one study already indicated that dMOB2 might act as 
an inhibitor of Trc since overxpression of a dMOB2 truncation mutant sharing high 
sequence similarity with hMOB2 resulted in a weak phenotype as observed in Trc-DN 
mutant flies [47]. In mammals, hMOB1A/B are established activators of human 
NDR1/2 kinases [8, 35, 36, 39, 113] and hMOB2 was 
previously shown to activate NDR1/2 in vitro [37, 49]. 
However, these studies lack a specific substrate for 
NDR and none of the effects were confirmed in vivo 
while our study included analysis using specific 
substrate, a phospho-specific antibody and investigated 
cellular functions of NDR1/2 [50]. Nevertheless, our 
study demonstrates that hMOB2 can act as a negative 
regulator. We speculate that in an overexpression 
setting hMOB2 out-competes endogenous 
hMOB1A/B leading to the accumulation of hMOB2-
NDR1/2 complexes. These inactive complexes 
cannot be activated by upstream effectors such as 
MST1 since the activation by MST1 of NDR requires 
hMOB1A/B binding. Ultimately, the downstream 
Figure 5. Model summarizing 
the role of hMOB2 in regulation 
of human NDR1/2 kinases. 
hMOB2 directly competes with 
hMOB1 proteins for NDR/1/2 
binding and impairs hMOB1 and 
MST1-dependent activation and 
functions of NDR1/2 kinases in 
apoptosis and centrosome 
duplication. Arrowed or blunted 
ends indicate activation or 
inhibition, respectively. 
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signaling is inhibited resulting in impaired functions of NDR1/2 when hMOB2 is 
overexpressed (Figure 6A). Besides inhibition of NDR1/2 kinases via competition 
with hMOB1 proteins, it is also likely that binding of hMOB2 to the NTR of NDR 
kinases leads to a distinct conformational change in the kinase domain. Residues in 
the NTR essential for interaction with hMOB1 are known and binding the NTR 
stimulates autophosphorylation of NDR1/2 probably by release from autoinhibiton [8]. 
Since hMOB2 binds the NTR distinctly from hMOB1A/B, it is likely that hMOB2 
induces an inactive conformation of the kinase domain of NDR1/2 kinases or induces 
autoinhibition by the AIS. Therefore, structural analysis of active hMOB1-NDR in 
comparison to inactive hMOB2-NDR complexes is highly recommended. 
Based on our data and previously published work on NDR activation by 
hMOB1A/B, we propose the following model of subunit exchange during NDR 
activation (Figure 7B). We found that in cycling cells NDR1/2 is present in an 
inactive complex with hMOB2 and active complexes with hMOB1 proteins. Initially, 
hMOB1A/B, but not hMOB2, is phosphorylated by MST1/2 which increases its 
affinity towards NDR1/2 [51, 113]. Phosphorylated hMOB1A/B is then capable to 
replace hMOB2 from the inactive hMOB2-NDR1/2 complex thereby facilitating 
binding and phosphorylation of the hydrophobic motif by MST1 resulting in an active 
hMOB1A/B-NDR1/2 complex (Figure 6B). The large scaffold protein Furry might 
also be involved in governing the subunit exchange during NDR activation. In 
Drosophila, Furry is essential for Trc activity and functions [56, 61] and it was 
recently reported that hMOB2 and NDR1/2 interact with a mammalian Furry protein 
[37]. However, further work is needed to establish Furry as an essential contributor of 
NDR activation in the context of apoptosis and centrosome duplication. 
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Active kinases are usually targeted by the ubiquitin-proteasome system for 
degradation [114]. Therefore, hMOB2 might protect NDR kinases from degradation 
by competing with hMOB1A/B proteins for binding to NDR1/2 thereby sequestering 
NDR1/2 into an inactive complex. Indeed, we observed that hMOB2 depletion by 
RNAi leads to a decrease in total NDR protein and hMOB2 overexpression drastically 
stabilizes NDR1/2 (D. Schmitz, R. Kohler, unpublished observation). Hence, it is 
tempting to speculate that hMOB2 functions in controlling NDR protein levels. 
However, this observation requires further investigation. It is also quite peculiar that 
human NDR1/2 kinases are the only NDR family members that were shown to exist 
in functionally distinct complexes with different MOB proteins. Nevertheless, the 
reason why human NDR1/2 acquired this additional level of regulation in contrast to 
Figure 6. Model of the effect of overexpression of hMOB2 on NDR-hMOB1 signaling and of the 
role of hMOB2 in physiological NDR activation. (A) Overexpressed hMOB2 displaces hMOB1 from 
NDR1/2 kinases leading to the accumulation of inactive hMOB2-NDR complexes which cannot be 
activated by upstream kinases such as MST1. The signaling downstream of NDR and therefore the 
functions in apoptosis and centrosome duplication are impaired. (B) MST1 phosphorylates hMOB1 
proteins thereby increasing affinity for interaction with human NDR1/2 and replacing hMOB2 from 
the inactive hMOB2-NDR complex. hMOB1-NDR complexes can then be activated by upstream 
kinases such as MST1 which leads to the phosphorylation of downstream targets and apoptotic 
progression and centrosome duplication. 
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LATS1/2 which restrictively bind to hMOB1A/B has yet to be investigated. Perhaps 
the hMOB2-NDR1/2 complex serves additional functions such as an adaptor-like or 
scaffold-like protein. We could also speculate that, under specific conditions, even 
this complex can be activated and is required for a yet unknown function of human 
NDR kinases especially since the related MOB2p proteins are essential for the activity 
and functions of NDR kinases in yeast. Therefore, genetically modified mice 
harboring targeted deletion or overexpression of mammalian MOB2 would 
complement ongoing research in tissue cultured cells in order to decipher the 
physiological roles of MOB2 proteins in mammals.  
 
The future of human NDR kinase substrates identification 
 Recently, substrates for almost all NDR kinase family members from yeast to men 
were discovered (Table 2). However, most substrates, if not all, were identified by a 
candidate substrate approach via which a protein implicated in the same process is 
tested as a direct substrate in vitro and then verified in vivo [112]. To date, no 
unbiased approach to discover novel substrates was reported to be applied on NDR 
kinases. Although analog-sensitive alleles of yeast NDR kinases (Cbk1p-as and 
Orb6p-as) have been established, these strains have not yet been used to discover 
novel substrates [43, 70] as reported for other analog-sensitive yeast kinases [115-
117]. Therefore, we aimed to identify targets of human NDR1/2 kinases by creation 
of an analog-sensitive NDR based on the chemical genetic approach developed by 
Shokat and colleagues [118]. 
 Analogous to how novel Cdk7 substrates were identified [119] we established a 
recombinant source of highly active analog-sensitive NDR1(M166G)-hMOB1A 
complexes. However, when we performed kinase assays on cellular fractions in the 
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presence of radiolabeled analog-ATP we did not observe any specifically labeled 
bands. Hence, we adopted another method using analog-sensitive NDR1(M166G) 
previously used to identify ERK2 substrates [120]. By using immunoprecipitated 
NDR1(M166G) and subsequent in vitro kinase assays on immunocomplexes we 
observed for the first time a reproducible pattern of labeled bands responsive to the 
addition of the ortholog inhibitor 1NM-PP1. Therefore, we established a basis for the 
identification of novel substrates of human NDR kinases using a chemical genetic 
approach which should be followed up by mass spectrometric analysis of 
phosphoproteins. 
 More recently, we identified p21 as the first in vivo substrate of human NDR1/2 
kinases (see Appendix and Table 2). NDR1/2 phosphorylate p21 on Ser146, a residue 
previously shown to have a destabilizing effect on p21 [121], resulting in NDR-
mediated degradation of p21. As hypothesized earlier and similar to the peptide 
substrate of NDR1/2 [21], the phosphorylation site Ser 146 is preceded by four 
positively charged residues: RKRRxxS146. Does the identification of the first 
downstream target of human NDR1/2 impede the unbiased search for novel 
substrates? The discovery of p21 as an in vivo substrate might prove immensely 
valuable for further development and improvement of a chemical genetic approach. 
Significantly, known substrates serve as essential positive controls when novel 
methods are applied to protein kinases [115, 119, 122]. Thus, having p21 as a direct 
target, we are now able to validate the functionality of the analog-sensitive 
NDR1(M166G) in our assays. Furthermore, one should try to find phosphorylated p21 
in the established immunocomplex assays by a second immunoprecipitation step or by 
direct immunoblotting with antibodies directed against p21 and p21-pSer146. 
Furthermore, the knowledge of a phosphorylation motif for human NDR1/2, 
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RKRRxxS in p21, can complement the search for substrates via a chemical genetic 
approach. Putative interactors identified by the immunocomplex assay can be scanned 
for a similar motif and tested in vitro. Therefore, the discovery of p21 as a first 
substrate might actually accelerate the identification of novel targets. 
 In addition, the availability of MEFs lacking both NDR1 and NDR2 can also 
facilitate substrate identification. By complementation of NDR1/2 null MEFs with an 
analog-sensitive NDR variant, one will be able to apply total cell phosphoproteomics 
to cells treated with or without the orthogonal inhibitor 1NM-PP1 for instance upon 
FAS-mediated apoptosis, therefore identifying putative downstream effectors of NDR 
in its role in apoptotic progression.  
Overall, with the identification of the first in vivo substrate and the development of 
an unbiased approach for substrate identification, we have now the basis to dissect the 
downstream signaling of mammalian NDR kinases. Importantly, uncovering the 
targets of NDR1/2 signaling will help to gain more detailed understanding of the 
functions of NDR in tumor suppression, apoptosis and centrosome duplication. 
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6. Appendix 
This section contains two additional manuscripts which I have contributed to during 
the course of the thesis. The manuscripts contain work on NDR kinases in the context 
of cell cycle regulation and centrosome duplication which is discussed in the main 
text and put in relation to the work obtained during this thesis. 
The first manuscript describes a novel role of human NDR1/2 in regulation of 
G1/S cell cycle progression. Work on this manuscript lead to the identification of the 
first in vivo substrate of human NDR kinases, the cyclin-dependent kinase inhibitor 
p21. This result is intensively discussed in the main text of this thesis. Further, this 
study was a close collaboration between Hauke Cornils and me which resulted in co-
first authorship. 
The second manuscript describes the essential role of hMOB1 and MST1 proteins 
regulating NDR kinase phosphorylation in the context of centrosome duplication. This 
study showed that binding to hMOB1 is crucial for activation of NDR kinases and 
subsequent centrosome duplication. This result was incorporated and discussed in the 
manuscript in which we describe a negative role for hMOB2 in NDR kinase 
regulation.  
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The G1 phase of the cell cycle is an important integrator of internal and external cues, allowing a cell to
decide whether to proliferate, differentiate, or die. Multiple protein kinases, among them the cyclin-dependent
kinases (Cdks), control G1-phase progression and S-phase entry. With the regulation of apoptosis, centrosome
duplication, and mitotic chromosome alignment downstream of the HIPPO pathway components MST1 and
MST2, mammalian NDR kinases have been implicated to function in cell cycle-dependent processes. Although
they are well characterized in terms of biochemical regulation and upstream signaling pathways, signaling
mechanisms downstream of mammalian NDR kinases remain largely unknown. We identify here a role for
human NDR in regulating the G1/S transition. In G1 phase, NDR kinases are activated by a third MST kinase
(MST3). Significantly, interfering with NDR and MST3 kinase expression results in G1 arrest and subsequent
proliferation defects. Furthermore, we describe the first downstream signaling mechanisms by which NDR
kinases regulate cell cycle progression. Our findings suggest that NDR kinases control protein stability of the
cyclin-Cdk inhibitor protein p21 by direct phosphorylation. These findings establish a novel MST3-NDR-p21
axis as an important regulator of G1/S progression of mammalian cells.
The G1 phase of the cell cycle is a crucial integrator of
internal and external cues, allowing cells to grow, process out-
side information, or repair damage before entering S phase
(32). Entry into S phase is mediated by the action of cyclin-
dependent kinases (Cdk) complexed with their respective cy-
clin subunits. Initially cyclin D-Cdk4/6 and later cyclin E-Cdk2
complexes phosphorylate the retinoblastoma (Rb) tumor sup-
pressor protein, allowing dissociation of Rb from E2F tran-
scription factors and subsequent transcription of genes re-
quired for S phase entry (17). The activity of Cdks is controlled
on multiple levels (44). The association of Cdks with cyclin
subunits is a prerequisite for Cdk activation. This process is
initially controlled by the availability of the cyclin subunit,
whose abundance is regulated by both transcriptional and post-
transcriptional processes (44). Furthermore, cyclin-Cdk inhib-
itor (CKI) proteins of the Cip/Kip (e.g., p21 and p27) and
INK4 (e.g., p16) families control cyclin-Cdk activity by differ-
ent mechanisms. Cip/Kip proteins associate with and inhibit
cyclin E-Cdk2 complexes, and INK4 proteins inhibit cyclin
D-dependent Cdks by sequestering Cdk4/6 into binary Cdk-
INK4 complexes, thereby blocking assembly of active cyclin
D-Cdk4/6 complexes. Multiple signaling pathways have been
shown to directly or indirectly affect the activity of cyclin-Cdk
complexes, thereby controlling the G1/S transition. Since the
correct regulation of the G1/S transition is essential for mam-
malian cells, much research has been invested in understand-
ing this process. However, investigations of the complex regu-
lation of Cdk activity are still needed.
Members of the nuclear-Dbf2-related (NDR) family of Ser/
Thr kinases are highly conserved from yeast to human and
have been implicated in the regulation of a variety of biological
processes (24). NDR family kinases in Saccharomyces cerevi-
siae have distinct roles in the regulation of mitotic exit by
Dbf2p (38, 51) and the control of polarized cell growth by
Cbk1p (3, 53). Similarly, in Schizosaccharomyces pombe, Sid2p
has a role in cytokinesis (16) and Orb6p functions in cell
polarity and morphogenesis (11, 25). In Drosophila melano-
gaster the roles of NDR kinases also differ substantially. Warts
regulates cell proliferation and apoptosis (26), and tricornered
regulates cell morphogenesis and dendritic tiling (13, 18).
These findings indicate that two distinct branches of NDR
signaling exist across species. Nevertheless, in a subset of those
functions NDR kinases in yeast and flies can function cooper-
atively (14, 40). With the regulation of mitotic exit, cell growth,
proliferation, centrosome duplication, and morphogenesis,
NDR family kinases across species have been shown to func-
tion in processes tightly linked to the cell cycle (24). The
human genome encodes for four different NDR kinase family
members, NDR1/2 and LATS1/2 (20). The kinases LATS1/2
function as part of the HIPPO pathway controlling the local-
ization and function of the YAP oncogene (56). Furthermore,
roles for LATS1 and LATS2 in controlling mitotic exit and
genomic stability have been described (4, 34). Although they
are well characterized in terms of biochemical regulation, func-
tions for the other two NDR family kinases in the human
genome, NDR1 and NDR2, have only recently started to be
unraveled. In cellular systems, NDR kinases have been impli-
cated in the regulation of centrosome duplication, apoptosis,
and the alignment of mitotic chromosomes (7, 23, 50). Fur-
thermore, a recent study indicated a tumor-suppressive func-
tion, by controlling proper apoptotic responses, for NDR1/2 in
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mice (10). NDR1/2 activity is regulated by phosphorylation of
the hydrophobic motif (HM) through the mammalian Ste20-
like kinases MST1, MST2, and MST3 (7, 22, 47, 50). Whereas
NDR kinase activation during apoptosis and centrosome du-
plication is mediated by MST1 (22, 50), MST2 regulates NDR
in the context of mitotic chromosome alignment (7). However,
the functional context of NDR kinase activation by MST3 has
not been reported so far. Furthermore, although functions and
regulators of NDR1/2 were defined recently, downstream signal-
ing remained elusive. Here we addressed NDR1/2 activation
throughout the cell cycle. We show that NDR1/2 are selectively
activated in G1 phase by MST3, establishing the first functional
context for NDR kinase regulation by MST3. More importantly,
with the direct regulation of p21 stability by phosphorylation on
Ser 146, we define here the first downstream signaling mecha-
nisms by which NDR kinases can control G1/S progression.
MATERIALS AND METHODS
Construction of plasmids. The construction of plasmids encoding cDNAs and
retroviral constructs for tagged variants of NDR1, NDR2, MST1, MST2, and
MST3 has been described elsewhere (19, 22, 50). RNA interference (RNAi)
rescue constructs for NDR2 were obtained by introducing silent mutations into
the short hairpin RNA (shRNA) target sites using PCR mutagenesis. For con-
structs expressing cDNAs fused to an internal ribosome entry site-green fluo-
rescent protein (IRES-GFP), the IRES-GFP cassette was excised from the
pMIG-vector using XhoI/SalI digestion and inserted into pcDNA3 containing
the indicated cDNAs using XhoI. Constructs for pGEX2T-GSTp21, pcDNA3-
p21, and pcDNA-myc-p21 were obtained by PCR cloning attaching BamHI/XhoI
sites to p21-cDNA (a kind gift from N. Lamb, Institut de Ge´ne´tique Humaine,
Montpellier, France) and insertion into the BamHI/XhoI sites of the respective
vector. Mutation of T145, S146, and T145/S146 to alanine was done by PCR
mutagenesis. cDNA encoding c-myc was a kind gift from N. Hynes (Friedrich
Miescher Institute, Basel, Switzerland), and hemagglutinin (HA)-tagged c-myc
was obtained similarly to myc-p21 by PCR cloning into a pcDNA3-HA vector.
HA-tagged variants of c-myc containing only the first 215 amino acids (c-myc-
C) or the last 234 amino acids (c-myc-N) were obtained by PCR cloning.
Deletion of the MB1 or MB2 domain was performed by PCR mutagenesis.
Primer sequences are available upon request. Vectors encoding cDNA for FBW7
or ubiquitin (Ub) were kind gifts from B. Clurman (Fred Hutchinson Cancer
Research Center, Seattle, WA) and W. Filipowicz (Friedrich Miescher Institute,
Basel, Switzerland). For production of recombinant protein, kinase-dead NDR1
(NDR1kd) (K118R) cDNA was cloned in the pMal-C2 vector.
Cell culture, transfections, and treatments. All cell lines used in this study
were maintained in Dulbecco modified Eagle medium (DMEM) supplemented
with 10% fetal calf serum (FCS). Cells were transfected using Fugene 6 (Roche),
Lipofectamine 2000 (Invitrogen), or jetPEI (Polyplus Transfection) as described
by the manufacturer. For small interfering RNA (siRNA)-mediated knockdown
of MST1, MST2, MST3, or p21, cells were transfected with predesigned siRNA
(Qiagen) using Lipofectamine 2000. For si_p21-mediated rescue experiments,
cells were transfected twice at 24-h intervals. HeLa cells expressing tetracycline
(TET)-inducible shRNA against NDR1 and NDR2 and U2OS cells stably ex-
pressing shRNA against NDR1 together with a wild-type NDR1 (NDR1wt)
rescue construct have been described elsewhere (23, 50). HeLa and U2OS cells
stably expressing shRNA against NDR1 or NDR2 alone were generated as
described previously (23, 50). To determine protein stability, cells were treated
with 50 g/ml cycloheximide (CHX) or 10 M MG132.
Reagents and antibodies. The generation of antibodies against T444-P, NDR1,
NDR2, and NDR1/2 has been described previously (50). Antibodies against
cyclin A, cyclin E, cyclin B1, cdc2, p27, GFP, c-myc (N262), HA (Y11), and actin
were from Santa Cruz. Antibodies to detect p21, cyclin D1, Cdk4, MST1, MST2,
MST3, and myc-tagged proteins (71D10) were from Cell Signaling. Antibodies
against HA tag (12CA5 and 42F13), tubulin (YL1/2), and c-myc (9E10) were
used as hybridoma supernatants. Additional antibodies used included anti-p21-
pS146 (Abgent), anti-P-MST4-T178/-MST3-T190/-STK25-T174 (referred to as
P-MST3) (Epitomics), anti-MST3 (BD Biosciences), and anti-FLAG (M2)
(Sigma). Nocodazole, thymidine, propidium iodide (PI), and cycloheximide were
from Sigma. Okadaic acid (OA), SB203580, and SB202190 were from Alexis
(Enzo Life Sciences). MG132 was from Calbiotech. Bromodeoxyuridine (BrdU)
and anti-BrdU antibody were from BD Biosciences.
Protein extraction, immunoprecipitation, immunoblotting, and ubiquitination
analysis. Protein extraction from cultured cells, immunoprecipitation, and im-
munoblotting were done as described previously (19). The following antibodies
were used for immunoprecipitation: anti-HA (12CA5), anti-c-myc (9E10 and
N262), anti-p21, anti-MST3, and a mixture of NDR1- and NDR2-specific anti-
bodies to assess endogenous NDR species. For quantification using the Li-Cor
Odyssey system, Western blots were incubated with secondary antibodies con-
jugated with fluorescent dyes. Quantifications were carried out using the Li-Cor
Odyssey software. Analysis of c-myc ubiquitination was performed as described
previously (41).
Cell cycle analysis. HeLa and HeLa S3 cells were synchronized using either a
double thymidine block with subsequent nocodazole arrest and mitotic shake-off
(48) or a single treatment with 100 ng/ml nocodazole for 14 h. Cells were washed
free of nocodazole with ice-cold phosphate-buffered saline (PBS) and released
into fresh medium for the indicated times before harvesting. Cell cycle distribu-
tion was assessed using either BrdU labeling as described by the manufacturer or
PI staining as described previously (23). To detect cells blocked in G1, a method
described by Mikule et al. was used (35). In short, cells were seeded at defined
densities into 10-cm dishes, and 24 h later 2.5 g/ml nocodazole was added and
left for 14 to 16 h to terminally arrest cells at the G2/M border. Cells were
harvested by trypsinization and processed for fluorescence-activated cell sorter
(FACS) analysis.
Kinase assays. Methods to determine the activity of endogenous NDR kinases
have been described earlier (50). To assay p21 phosphorylation by NDR1/2 in
vitro, HEK293 cells were transfected with cDNAs encoding HA-tagged NDR
kinase isoforms and mutants. Cells were stimulated with 1 M okadaic acid for
60 h prior to lysis and immunoprecipitation. In vitro kinase assays using purified
glutathione S-transferase (GST)-tagged p21 isoforms were performed as de-
scribed previously (19) with minor modifications. Before addition of [-32P]ATP
and GST-p21, the immunoprecipitated kinases were preincubated for 90 min at
30°C in reaction buffer without 32P-labeled ATP. The labeling reaction was
stopped after 60 min by boiling the samples in sample buffer for 5 min at 95°C.
Samples were resolved on SDS-PAGE, stained with Coomassie blue, and ex-
posed to a phosphorimager (Amersham Biosciences). Kinase activity of endog-
enous MST3 species was assessed by immunoprecipitation of endogenous MST3
and by using recombinant maltose binding protein (MBP)-tagged NDR1 K118R
as a substrate in an in vitro kinase assay as described earlier (47).
Proliferation assays. For the analysis of cell proliferation, cells were seeded at
defined densities in triplicates. For experiments including inducible shRNAs,
fresh tetracycline was added each day, starting with cell seeding. After the
indicated times, cells were harvested by trypsinization and counted using a
ViCell-XR automated cell counter (Beckman Coulter). The decrease in prolif-
eration of HeLa shNDR1/2 cells with or without TET was calculated using the
formula y  100  (cell count on day 6 with TET)/(cell count on day 6 without
TET). The result represents the mean of triplicates for three different clones.
RNA isolation, quantitative real-time PCR, and luciferase assays. Total RNA
from cells was isolated with TRIzol reagent (Invitrogen) and further purified
using an RNeasy kit (Qiagen). cDNA was generated from 2 g of total RNA
using Moloney murine leukemia virus (M-MuLV) reverse transcriptase (NEB)
and oligo(dT) primers. Quantitative RT-PCR to detect p21, p27, and c-myc
(primer sequences are available upon request) was carried out using SYBR
green technology in an ABI Prism 7000 detection system (Applied Biosystems).
Luciferase assays using the wild-type (LDH-WT) or E-box-mutated (LDH-MT)
version of the LDA-H promoter (a kind gift from C. V. Dang, Johns Hopkins
University, Baltimore, MD) (45) were performed using the dual-luciferase re-
porter assay from Promega.
Statistical analysis. Statistical analyses were performed with Student’s t test
for the comparison between two samples.
RESULTS
NDR kinases are activated in G1 by MST3. Mammalian
NDR kinases are implicated in the regulation of cell cycle-
dependent processes such as centrosome duplication and the
alignment of mitotic chromosomes (7, 22). To better define the
cell cycle function(s) of NDR kinases, we analyzed NDR ki-
nase activity during cell cycle progression. Hydrophobic motif
(HM) phosphorylation of NDR1 and NDR2, as an indicator of
NDR kinase activity (47), was nearly absent in M phase, in-
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FIG. 1. NDR kinases are activated by MST3 in the G1 phase of the cell cycle. (A) NDR kinases are activated in a cell cycle-dependent manner.
Synchronized HeLa S3 cells were harvested after mitotic shake-off and replated in fresh medium for the indicated times. Activation of NDR1/2
was assessed using anti-T444-P, -NDR1, and -NDR2 antibodies. Cell cycle distribution was assessed using propidium iodide (PI) staining and
FACS analysis. (B) Endogenous NDR kinase activity is increased in G1 phase. HeLa cells were arrested at the G2/M border using nocodazole
treatment for 14 h and released for the indicated times before harvesting. Lysates were subjected to immunoblotting and immunoprecipitation of
endogenous NDR species using a mixture of isoform-specific antibodies. NDR kinase activity was assessed using peptide kinase assays (n  3; P 
0.002). (C) Depletion of MST1/2/3 kinases using isoform-specific siRNAs. HeLa cells were transfected with control siRNA (si_Con) or siRNAs
targeting MST1/2/3 kinases (si_MST1, si_MST2, and si_MST3) and 48 h later were arrested with nocodazole for 14 h. Arrested cells were harvested
or released into G1 for 8 h before harvesting. NDR activation was assessed using T444-P antibody. Cell cycle phases were confirmed by analyzing
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creased 3 h after mitotic shake-off upon entry into G1 phase,
and peaked at around 6 to 8 h in G1 phase. Activation of NDR
persisted into S phase (12 to 14 h) and started to decrease 14 h
after shake-off (Fig. 1A). Analysis of cell cycle markers by
immunoblotting and FACS staining of the cell population (vi-
sualized by a plotted graph) confirmed that NDR activation
peaked in G1 phase with the activation persisting into S phase.
G1 activation of NDR1/2 was confirmed by analyzing endoge-
nous NDR1/2 activity using a peptide kinase assay (Fig. 1B).
Since three members of the mammalian Ste20-like kinases
(MST1/2/3) can regulate NDR kinases by phosphorylation of
the HM of NDR (7, 22, 47, 50), we tested which MST kinase
was important for NDR1/2 activation in G1. To this end, we
analyzed NDR phosphorylation in G1 upon siRNA-mediated
knockdown of MST1 to -3 (Fig. 1C). Although depletion of
MST1 and MST2 hardly affected NDR activation, knockdown
of MST3 expression significantly reduced NDR phosphoryla-
tion in this setting. This finding was confirmed using overex-
pression of dominant negative (DN) variants of MST1 to -3
(data not shown), suggesting that MST3 is the main upstream
kinase in this cell cycle phase. Interestingly, we observed an
increase in phosphorylated MST3 in G1-phase cells versus M-
phase-arrested cells, indicating that MST3 activity is increased
in G1 phase of the cell cycle (Fig. 1D). We then addressed
whether increased MST3 phosphorylation reflected an in-
crease in kinase activity. Endogenous MST3 kinase was immu-
noprecipitated in cells arrested in M phase or released into G1
phase. The increase in phosphorylation of MST3 in G1 was
paralleled by approximately 2-fold-increased kinase activity
when an in vitro kinase assay on kinase-dead NDR1 (MBP-
NDR1 K118R) was performed (Fig. 1E), therefore demon-
strating that kinase activity of MST3 is increased in G1. Collec-
tively, these results revealed that NDR kinases were activated in
G1 phase of the cell cycle, with the activation persisting into S
phase. Furthermore, our experiments revealed MST3 as the
responsible upstream kinase for NDR1/2 in this setting,
thereby providing the first functional link between NDR1/2
and MST3.
Depletion of NDR kinases results in G1 arrest and subse-
quent proliferation defects. To analyze whether the activation
of NDR kinases contributed to cell cycle progression and pro-
liferation, we generated HeLa cells expressing inducible
shRNA against NDR1 and NDR2 (Fig. 2A). Both isoforms
were simultaneously targeted to avoid any compensatory ef-
fects as described earlier for NDR1-deficient mice (10).
Knockdown of NDR kinases consistently resulted in decreased
proliferation of around 50%, which was not observed in con-
trol clones expressing shRNA against firefly luciferase (Fig. 2B
and C). Single knockdown of NDR kinase isoforms also re-
sulted in a significant decrease in proliferation (data not
shown). Accordingly, depletion of MST3 by RNAi resulted in
reduced proliferation similar to that after knockdown of
NDR1/2 (Fig. 2D). Reduced proliferation in NDR-depleted
cells was accompanied by an increase in cells in G1 and a
decrease in cells in S phase (Fig. 2E). G1 phase arrest was
confirmed by treating cells with nocodazole to accumulate cy-
cling cells at the G2/M border (Fig. 2F). Briefly, at 3 days after
induction of shRNA expression, the cells were treated with
nocodazole to depolymerize microtubules, activating the spin-
dle assembly checkpoint and arrest cells at the G2/M border.
(35). Therefore, cells blocked in G1 will not proceed to G2/M
border, and as was apparent, cells depleted of NDR1/2 were
retained in the G1 peak (Fig. 2F, TET). Since depletion of
NDR can result in centrosome defects (23), we asked next
whether the G1 arrest was due to activation of the p38-p53 cen-
trosome integrity checkpoint (35, 46). NDR1/2-depleted cells
were treated with p38 inhibitors (SB203580 and SB202190) prior
to G1 arrest assessment (Fig. 2G), revealing that inhibition of
p38 had no detectable effect. These results suggest that p38-
p53 signaling does not contribute to the cell cycle arrest upon
NDR1/2 depletion. Therefore, we analyzed the mechanisms
underlying the G1 block by investigating expression levels of
other known G1/S regulators (Fig. 3A). Interestingly, the ex-
pression of p21 and p27 was elevated in NDR1/2 knockdown
cells without a significant decrease in the expression of cyclins
and Cdks (Fig. 3A). In addition, the expression of the c-myc
proto-oncogene was reduced. These results were confirmed in
HeLa cells expressing shRNA against NDR1 and NDR2 alone,
as well as in transiently transfected HCT116 cells (data not
shown). Furthermore, stable expression of shRNA-resistant
NDR1wt in U2-OS cells counteracted p21 and p27 upregu-
lation and restored cell proliferation (data not shown). This
suggested that the observed G1 block upon depletion of
NDR1/2 might be due to the inhibition of cyclin-Cdk complexes
by increased levels of p21 and p27. In addition, we analyzed the
effects of MST3 depletion on p21, p27, and c-myc levels (Fig. 3B).
As found upon NDR depletion, we also observed upregulation of
p21 and p27, while c-myc levels were reduced in MST3-depleted
cells (Fig. 3B). These experiments suggest the existence of an
MST3-NDR axis as regulator of cell proliferation.
It has been shown that c-myc is able to repress p21 and p27
expression (9, 54). Therefore, we tested whether depletion of
NDR1/2 would result in increased expression of p21 and p27
mRNAs. Strikingly, although p27 mRNA levels were clearly
increased, we did not observe any elevation of p21 mRNA in
our settings (Fig. 3C). In addition, NDR depletion did not
affect c-myc mRNA expression, suggesting that NDR kinases
cyclin B1 and p27 expression (*, unspecific band). Phospho-T444 levels after G1 release were compared to those in control samples and analyzed using
the Li-Cor Odyssey system. (D) Reduction of MST3 impairs G1 activation of NDR. HeLa cells were transfected with control siRNA (si_Con) or siRNA
against MST3 (si_MST3) and treated and analyzed as described for panel C. MST3 activation was assessed using a P-MST4-T178/-MST3-T190/-STK25-
T174-specific antibody (anti-P-MST3). Note that the P-MST3 signal disappears in the siMST3-treated samples. (E) Kinase activity of MST3 is increased
in the G1 phase of the cell cycle. HeLa cells were arrested at the G2/M border using nocodazole treatment for 14 h and released for 8 h before harvesting.
Lysates were subjected to immunoblotting and in parallel to immunoprecipitation (IP) of endogenous MST3 species using anti-MST3 or control
antibodies. Endogenous MST3 kinase activity was assessed by an in vitro kinase assay using recombinant MBP-NDR1 K118R as a substrate. Reactions
were analyzed by SDS-PAGE followed by immunoblotting against phosphorylation of Thr 444 in NDR1 and in parallel by exposure to a phosphorimager
screen. NDR phosphorylation was quantified and normalized to the activity of MST3 in M phase.
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FIG. 2. shRNA-mediated knockdown of NDR1/2 results in cellular proliferation defects due to a G1 block. (A) Characterization of T-Rex-
HeLa cells stably expressing shRNA against NDR1 and NDR2. Cells were seeded in 10-cm dishes, and shRNA expression was induced by the
addition of tetracycline (TET) for the indicated times. Lysates from harvested cells were analyzed for NDR1 and NDR2 expression using
isoform-specific antibodies (*, unspecific band). (B) NDR1/2 depletion results in proliferation defects. HeLa cells expressing shRNA against
NDR1/2 (shNDR1/2) or firefly luciferase (shLUC) as a control were seeded in triplicates, and tetracycline was added to induce shRNA expression.
After the indicated times, cells were harvested by trypsinization and counted using a ViCell automated cell counter. (C) Validation of proliferation
defects in different clones stably expressing shNDR1/2 or shLUC (n  3; P  0.001). Experiments were performed as for panel B, and differences
in proliferation were calculated as the percentage of cells without tetracycline to cells with tetracycline counted on day 6 after induction of shRNA
expression. (D) Depletion of MST3 results in proliferation defects similar to those observed in NDR-depleted cells. HeLa cells were transfected
with control siRNA (si_Con) or siRNA against MST3 (si_MST3); 24 h later, cells were seeded at defined densities in triplicates and cell counts
were analyzed as for panel B. (E) Depletion of NDR1 and NDR2 results in an increase in G1 phase cells accompanied by a decrease in S phase
cells. HeLa cells expressing shRNA against NDR1/2 were induced for 4 days with tetracycline. BrdU was added directly to the cell medium and
left for 30 min before harvesting and processing for FACS analysis (n  3). (F) Depletion of NDR1/2 results in G1 arrest. Knockdown of NDR1/2
was induced for 4 days using tetracycline. At 14 h before harvesting and processing for FACS analysis, cells were treated with 2.5 g/ml nocodazole
to induce G2/M accumulation. Fixed cells were stained with PI and analyzed by FACS. Histograms were overlaid to allow better comparison of
cells in a given cell cycle phase. (G) Treatment of NDR1/2-depleted cells with inhibitors against p38 does not suppress G1 arrest. HeLa cells
expressing shRNA against NDR1/2 were induced for 4 days with tetracycline. At 24 h before analysis, SB203580 or SB202190 (10 M final
concentration) was added to the cells. G1 arrest analysis was performed as for panel F.
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regulated p21 and c-myc protein levels posttranscriptionally
(Fig. 3C).
NDR kinases regulate c-myc protein levels by direct binding
and interfering with FBW7-mediated ubiquitination. A recent
report analyzing posttranscriptional modifiers of c-myc in hu-
man B cells proposed that NDR1 could regulate c-myc protein
stability (52). In full agreement with this previous report, c-myc
protein levels were rescued by the addition of the proteasomal
inhibitor MG132 in NDR1/2-depleted HeLa cells (data not
shown). In addition, we could confirm that NDR1 and c-myc
interacted on both overexpressed and endogenous levels (data
not shown). Furthermore, NDR2 bound to c-myc with similar
affinity as NDR1 (data not shown). Next, we analyzed the
currently unknown determinants for NDR binding to c-myc.
Using coimmunoprecipitation experiments, we found that c-
myc interacted mainly with the N-terminal region (NTR) (res-
idues 1 to 82) of NDR1 (Fig. 4A). In addition, interaction was
shown to be modulated by HM phosphorylation (Thr 444)
(Fig. 4B). Both the NTR and the HM phosphorylation site
have been shown to be essential for full kinase activity of NDR
(2, 36, 47), suggesting that NDR might bind to c-myc in an ac-
tive conformation. Nevertheless, kinase-dead NDR1 (NDR1kd)
associated with c-myc similarly to NDR1wt (Fig. 4B). Both
NDR1wt and NDR1kd significantly stabilized c-myc levels
(Fig. 4C). NDR1 mutants defective in or with reduced c-myc
interaction (NDR1-NTR and NDR1-TA) had minor effects
on c-myc stability, indicating that binding of NDR1 to c-myc is
required to stabilize c-myc levels. Furthermore, increasing HM
phosphorylation of overexpressed NDR by coexpression of
MST3 increased complex formation and c-myc stability (Fig.
4D and data not shown). The effects of overexpression and
HM phosphorylation of NDR1 on endogenous c-myc levels
were also tested. Strikingly, overexpression of NDR1wt and
NDR1kd increased endogenous c-myc levels, which could
be further increased by stimulating HM phosphorylation
through coexpression of MST3 (data not shown). Besides
stabilizing c-myc protein levels, NDR1wt but not NDR1TA
(T444A) overexpression stimulated c-myc-mediated transcrip-
FIG. 3. Depletion of NDR1/2 kinases results in an increase in p21 and p27 protein levels and a decrease in c-myc protein level. (A) Reduced
NDR kinase levels increase p21 and p27 and decrease c-myc. Knockdown of NDR1/2 was induced for 4 days, and cell lysates were analyzed for
the expression of the indicated cell cycle regulators using Western blotting. (B) Depletion of MST3 increases p21 and p27 and decreases c-myc
similarly to knockdown of NDR kinases. HeLa cells were transfected with control siRNA (si_Con) or siRNA against MST3 (si_MST3). After 3
days, cell lysates were analyzed by Western blotting (*, p27). (C) NDR1/2 depletion results in increased p27 mRNA levels, whereas changes in
c-myc and p21 are observed only at the protein level. Knockdown of NDR1/2 was induced for the indicated times, and RNA extracts were prepared
to analyze p21, p27, and c-myc mRNAs by quantitative RT-PCR. Values for p21, p27, and c-myc mRNAs are given as fold change relative to
untreated samples (n  3). In parallel, the samples were analyzed for the levels of the indicated proteins by Western blotting.
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tion (reference 45 and data not shown). This suggests that
NDR expression and phosphorylation can positively affect c-
myc protein levels and activity.
Degradation of c-myc is tightly regulated by the ubiquitin-
proteasome system (49), and hence we tested whether NDR
expression affected c-myc ubiquitination. Indeed, we observed
that the stabilizing effect of NDR1 overexpression on c-myc
was due to impaired c-myc ubiquitination (Fig. 5A). The
FBW7 E3 ubiquitin ligase complex has been shown to mainly
regulate c-myc ubiquitination and degradation (49). We tested
the effect of NDR overexpression on FBW7-mediated ubiq-
uitination (Fig. 5B). Ubiquitination of c-myc by FBW7 was
impaired by NDR1wt overexpression, although NDR1 did not
compete with FBW7 for c-myc interaction (Fig. 5C). Collec-
tively, our analysis suggests a role for NDR kinases in the
regulation of c-myc protein stability by interfering with FBW7-
mediated ubiquitination. Interestingly, NDR kinases inter-
acted with c-myc supported by HM phosphorylation, but inde-
pendent of NDR kinase activity.
G1 arrest upon depletion of NDR is not dependent on c-myc.
Depletion of NDR1/2 results in G1 arrest accompanied by
an increase in the p21 level and a decrease in c-myc. To test
the potential contribution of a reduced c-myc level to the G1
arrest observed in NDR-depleted cells, we restored the c-
myc level by exogenous expression (Fig. 6). Although restor-
ing c-myc prevented, as expected, accumulation of p27, it
failed to rescue cells from G1 arrest in this setting. These
experiments therefore indicated that the increased levels of
p21 might mediate the observed G1 arrest in NDR kinase-
depleted cells.
NDR kinases regulate p21 stability by phosphorylation of
S146 on p21. Since restoration of c-myc level was not sufficient
FIG. 4. NDR1/2 in an active conformation stabilizes c-myc. (A) c-myc binds to the N-terminal region of NDR1. HEK293 cells were transfected
with c-myc together with the indicated HA-tagged NDR1 constructs. NDR1 species were immunoprecipitated, and c-myc binding was analyzed
by SDS-PAGE. (B) Binding of NDR1 to c-myc is modulated by hydrophobic motif phosphorylation (T444). HEK293 cells were transfected with
the indicated NDR1 constructs (NDR1TA, T444A; NDR1-3xA, T74, S281, and T444A). c-myc was immunoprecipitated, and bound NDR1 species
were analyzed by immunoblotting. (C) Overexpression of NDR1wt and NDR1kd stabilizes c-myc. HEK293 cells were transfected with c-myc and
the indicated NDR1 cDNA; 24 h later, cells were treated with cycloheximide (CHX) for the indicated times and c-myc levels were analyzed using
the Li-Cor Odyssey system. (D) Hydrophobic motif phosphorylation of NDR increases binding of NDR to c-myc. HEK293 cells were transfected
with c-myc and the indicated NDR1 cDNAs together with a vector encoding FLAG-MST3, and complex formation was analyzed.
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to compensate for NDR depletion and release of the subse-
quent G1 arrest, we addressed the well-known cell cycle regu-
lator p21 in our setting. NDR depletion results in increased
p21 protein levels, without accompanying upregulation of p21
mRNA (Fig. 3). This indicates that NDR kinases could affect
p21 protein stability. Indeed, knockdown of NDR1/2 signifi-
cantly increased p21 protein stability (Fig. 7A). No binding of
NDR1/2 to p21 could be detected (data not shown), suggesting
a mechanism distinct from the regulation of c-myc by NDR.
Earlier studies have implicated several phosphorylation sites
on p21 in regulating p21 stability (8), which suggested p21 as a
potential NDR kinase substrate. Recombinant NDR2 kinase
was able to phosphorylate GST-p21 in an in vitro kinase assay
(Fig. 7B). Strikingly, purified NDR1 and NDR2wt phosphor-
ylated p21 in vitro, while NDR1/2kd did not (Fig. 7C and data
not shown). Although no substrates of NDR1/2 have been
described, one study reported that NDR1 prefers a stretch of
positively charged basic amino acids in the vicinity of the
phosphorylation site (36). Intriguingly, the p21 primary se-
quence contains a stretch of four basic amino acids up-
stream of the known phosphorylation sites T145 and S146
(43), GRKRRQT145S146MT (G, glycine; R, arginine; K, lysine;
Q, glutamine; T, threonine; S, serine; and M, methionine).
Therefore, T145 or S146 alanine mutants were subjected to
kinase assays (Fig. 7D and E). Phosphorylation of p21 by
NDR1/2 was abolished when Ser 146 was mutated to alanine
but not when Thr145 was mutated (Fig. 7D and data no
shown). These findings were confirmed using a phospho-spe-
cific antibody for phosphorylation on Ser 146 (anti-p21-pS146)
(Fig. 7E). Therefore, our analysis showed that NDR1/2 phos-
phorylates p21 mainly on S146.
NDR kinases are efficiently activated by okadaic acid (OA)
treatment. Indeed, overexpression of NDR1wt but not kinase-
dead NDR1 or an HM mutant increased phosphorylation of
p21 upon OA treatment (Fig. 8A). Similar results were
obtained when NDR2wt or kinase-dead NDR2 was used
(Fig. 8B). Furthermore, reduction of NDR kinases in cells
by shRNA reduced OA-mediated as well as steady-state phos-
phorylation of p21 on S146 (Fig. 8C). Significantly, steady-state
phosphorylation of endogenous p21 on S146 was reduced upon
FIG. 5. NDR overexpression impairs FBW7-mediated c-myc ubiquitination. (A) HEK293 cells were transfected with c-myc and His-tagged
ubiquitin (His-Ub) together with HA-NDR1wt where indicated. Ubiquitinated proteins were pulled down from cell lysates using Ni-nitrilotriacetic
acid (NTA)–Sepharose and analyzed by SDS-PAGE. (B) NDR decreases FBW7-mediated ubiquitination of c-myc. The experiment was performed
as for panel A, but where indicated, GFP-FBW7 was coexpressed. (C) NDR1 does not compete with FBW7 for c-myc binding. HEK 293 cells were
transfected with c-myc, FBW7, and increasing amounts of NDR1wt. c-myc was immunoprecipitated and analyzed for bound FBW7.
FIG. 6. G1 arrest in NDR-depleted cells is not dependent on c-myc.
(A) HeLa cells expressing shRNA against NDR1/2 were induced for
72 h with tetracycline and transfected with vectors expressing c-myc
together with an IRES-GFP as a transfection marker. G1 arrest anal-
ysis was performed as described in the legend to Fig. 2F. Cell cycle
profiles of GFP-positive cells were overlaid to allow for better com-
parison. (B) Analysis of GFP-positive cells in G1 after nocodazole
arrest upon depletion of NDR1/2 and overexpression of c-myc (n 3).
(C) Analysis of c-myc, p21, and p27 in NDR1/2-depleted cells upon
overexpression of c-myc. Cells were treated as described for panel A,
but lysates were prepared before G1 arrest analysis.
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knockdown of NDR1/2 in HeLa cells without OA treatment,
despite an increase in the total level of p21 (Fig. 8D). Since it
has been shown that phosphorylation of S146 destabilizes p21
(42), we tested the effect of overexpressing NDR1 together
with MST3 on the stability of p21 (Fig. 8E). Although overex-
pression of NDR1wt or NDR1kd did not significantly affect
p21 steady-state level, treatment of cells with cycloheximide
(CHX) to inhibit translation revealed that overexpression of
FIG. 7. NDR kinases phosphorylate p21 on S146 in vitro. (A) Depletion of NDR1/2 increases p21 stability. HeLa-shNDR1/2 cells were treated
with tetracycline for 72 h. Prior to harvesting, cells were treated for the indicated times with CHX. p21 levels were analyzed using the Li-Cor
Odyssey system (n  3). p21 levels are depicted as the percentage remaining relative to the level at time zero, and trend lines were added to the
data. r2 values for the trend lines are 0.98 (TET) and 0.92 (TET). Equation for the trend lines are y 100e0.0166x (TET) and y 100e0.0083x
(TET). (B) Recombinant NDR2 phosphorylates recombinant p21. GST-p21 was used in an in vitro kinase assay with polyhistidine-tagged NDR2
from Sf9 cells in the presence of [-32P]ATP. After 30 min, reactions were analyzed by SDS-PAGE and exposure to a phosphorimager. (C) NDR1
and 2 phosphorylate p21 in vitro. HA-tagged NDR1/2wt or HA-NDR1/2kd was immunoprecipitated from okadaic acid-stimulated HEK293 cells
and used for in vitro kinase assays with GST-p21 as a substrate. Reactions were analyzed as for panel B. (D) Ser 146 is the major site of p21
phosphorylated by NDR kinases. GST-p21 with mutated T145, S146, or T145/S146 phospho-acceptor sites was used as a substrate for in vitro kinase
assays as described for panel B. (E) NDR1 and -2 phosphorylate p21 on Ser 146. GST-p21wt or GST-p21 S146A was used as a substrate in in vitro
kinase assays using HA-tagged NDR1/2wt or HA-NDR1/2kd from okadaic acid-stimulated HEK 293 cells. Assays were analyzed by Western
blotting using a phospho-specific antibody of p21 recognizing only if Ser 146 of p21 is phosphorylated.
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NDR1wt but not NDR1kd decreased p21 protein stability in
this setting (Fig. 8E). Taken together, these results show that
NDR kinases directly phosphorylated p21 on S146 in vitro and
in vivo, establishing p21 as the first substrate for mammalian
NDR kinases. Importantly, since phosphorylation on S146 can
negatively affect the protein stability of p21, our results suggest
that loss of NDR activity results in an increase in total p21
level and that increased activity of NDR leads to destabili-
zation of p21.
G1 arrest upon depletion of NDR kinases is dependent on
increased p21 stability. To confirm the effects of NDR on p21,
we performed experiments to rescue the effects of depletion
of NDR by transient overexpression of NDR mutants re-
fractory to shRNA (Fig. 9A). Indeed, whereas overexpres-
FIG. 8. NDR phosphorylates p21 in vivo and regulates p21 stability. (A) Overexpression of NDR1wt increases okadaic acid (OA)-induced
phosphorylation of p21 on S146. HeLa cells were transfected with the indicated HA-tagged NDR1 species together with myc-tagged p21. Samples
were stimulated with OA for 1 h before lysis where indicated. myc-tagged p21 was immunoprecipitated from lysates, and p21-pS146 levels were
analyzed and quantified using the Li-Cor Odyssey system (n 3; P 0.002). p21-pS146 levels were normalized to controls without OA. (B) NDR2
phosphorylates p21 on S146 in vivo. HeLa cells were transfected with the HA-tagged NDR2wt or NDR2kd together with myc-tagged p21. Samples
were stimulated with OA for 1 h before lysis where indicated. myc-tagged p21 was immunoprecipitated from lysates, and p21-pS146 levels were
analyzed and quantified using the Li-Cor Odyssey system (n  3; P  0.0001). p21-pS146 levels were normalized to controls without OA.
(C) Depletion of NDR1/2 decreases phosphorylation of p21 on S146. HeLa-shNDR1/2 cells were induced for 72 h with tetracycline and transfected
with cDNA encoding myc-tagged p21. At 24 h after transfection, cells were stimulated with OA for 1 h and lysed. p21-pS146 levels were analyzed
as for panel B (*, unspecific band). p21-pS146 levels were normalized to the untreated control sample. (D) Depletion of NDR results in a reduction
of phosphorylated p21. HeLa-shNDR1/2 cells were induced for 72 h with tetracycline before lysis and immunoprecipitation of endogenous p21
were performed. p21-pS146 levels were analyzed by Western blotting. (E) Overexpression of NDR decreases p21 stability. HeLa cells were
transfected with empty vector (EV) or with cDNAs encoding HA-NDR1wt or HA-NDR1kd in the presence of HA-MST3. Prior to lysis, cells were
treated with CHX for 60 min where indicated (*, HA-MST3; **, HA-NDR).
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sion of NDR2wt in this setting rescued both the effects on
c-myc and p21 levels, overexpression of NDR2kd only restored
c-myc levels. Importantly, NDR2TA failed to rescue either of
the effects. Additionally, reexpression of refractory NDR1wt in
U2OS shNDR1 cells rescued the effect on p21 levels upon
NDR1 knockdown (data not shown). These observations fully
confirm our previous findings, namely, that NDR can regulate
c-myc stability irrespective of kinase activity, while the effect of
NDR kinases on p21 levels is dependent on NDR kinase ac-
tivity.
Next we analyzed whether altered p21 levels mediated the
G1 arrest upon depletion of NDR. Indeed, siRNA-mediated
depletion of p21 was fully sufficient to result in a significant
restoration of NDR1/2-depleted cells from G1 blockade (Fig.
9B to D). Furthermore, we have confirmed this finding by the
use of a second, independent siRNA against p21 (data not
shown). In full agreement with this finding, p21 levels were
shown to correlate with G1 arrest in shNDR1/2 cells. Pro-
longed depletion of NDR1/2 resulted in an increasing amount
of cells in G1 and correspondingly in an accumulation of p21
protein, whereas p27 levels did not correlate (Fig. 9E). Collec-
tively, these experiments revealed that p21 is a key mediator of
the G1 arrest observed in NDR kinase-depleted cells.
DISCUSSION
In eukaryotes NDR kinases have been shown to function in
processes tightly linked to the cell cycle, such as mitotic exit,
cell growth, proliferation, centrosome duplication, and mor-
phogenesis (24). Here we identify human NDR kinases as
novel regulators of cell cycle progression. NDR kinases are
activated in G1, with the activation persisting into S phase (Fig.
1), in full accordance with NDR kinase function in centrosome
duplication (23). Conversely, knockdown of NDR1/2 results in
G1 arrest (Fig. 2). Importantly, although depletion of NDR
kinases can result in centrosome duplication defects (22, 23),
our experiments show that the G1 arrest is completely inde-
FIG. 9. G1 arrest after NDR kinase knockdown is rescued by reducing p21 levels. (A) The effects of NDR kinase depletion can be rescued
depending on the NDR mutant. HeLa cells expressing shRNA against NDR2 were treated for 48 h with tetracycline and subsequently transfected
with the indicated NDR2 mutants refractory to shNDR2 (*, HA-tagged NDR2). p21 levels were quantified using the Li-Cor Odyssey system.
(B) HeLa cells expressing shRNA against NDR1/2 were treated with tetracycline for 48 h before being transfected with siRNA against p21 on two
consecutive days. The cells were treated for G1 arrest analysis as described in the legend for Fig. 2F at 24 h after the second transfection.
(C) Quantification of cells in G1 after nocodazole treatment (n 3; P 0.002). (D) Cells obtained from the experiment for panel B were analyzed
for the expression of p21 and NDR1/2 (*, unspecific band). (E) p21 levels correlate with G1 arrest in NDR1/2-depleted cells. HeLa cells expressing
shRNA against NDR1/2 were induced with tetracycline for the indicated times before harvest and lysis. Cells used for cell cycle analysis were
treated with 2.5 g/ml nocodazole for 14 h before harvest.
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pendent of the reported p38-p53 centrosome integrity check-
point (35, 46).
Although they are well described in terms of upstream
regulation and biochemical activation, signaling mechanisms
downstream of mammalian NDR kinases remained elusive.
Here we describe a novel function for NDR kinases in regu-
lating the G1/S transition, identify c-myc and p21 as down-
stream signaling targets for mammalian NDR kinases, and
provide detailed mechanistic insight into this regulation:
whereas NDR kinases regulate c-myc protein stability by direct
interaction independent of kinase activity (Fig. 4 and 5), p21 is
directly phosphorylated by NDR kinases on Ser 146, thereby
regulating p21 stability (Fig. 7 and 8). Furthermore, knock-
down of NDR1/2 resulted in G1 arrest and was dependent on
increased p21 stability but not on c-myc (Fig. 9).
NDR1 has been shown previously to bind to c-myc and
increase its stability; however, mechanistic insight into this
regulation has not been reported so far (52). Here we confirm
the binding of NDR kinases to c-myc (Fig. 4 and data not
shown). Strikingly, we find that both binding and stabilization
of c-myc by NDR are independent of NDR kinase activity (Fig.
4), indicating a novel adaptor-like function for NDR kinases.
We observed distinct effects on NDR–c-myc interaction upon
point mutation of the hydrophobic motif phosphorylation site
T444 or deletion of the C terminus. The C-terminal deletion
mutant still interacted with c-myc, whereas point mutants
(T444A, T444D, or T444E) displayed reduced or no interac-
tion (Fig. 3 and data not shown). Since we found the N termi-
nus of NDR to be responsible for the interaction with c-myc,
deletions or mutations of the C terminus might have distinct
conformational consequences for the structure of the N-terminal
region of NDR. Therefore, future structural analysis of NDR
kinases bearing mutations or deletions will be required to put
these findings into the context of how NDR–c-myc interaction is
modulated and hence how exactly NDR stabilizes c-myc.
c-myc protein levels are tightly regulated in cells. Apart from
a pronounced regulation at the transcriptional level, protein
levels of c-myc are controlled by ubiquitin ligases such as
FBW7 (49). Here we show that NDR kinases do not compete
with FBW7 for c-myc binding. Nevertheless, NDR kinases can
inhibit c-myc ubiquitination by FBW7 (Fig. 5), indicating a
novel mechanism by which NDR kinases interfere with c-myc
degradation. Potentially, NDR kinases bound to c-myc inhibit
ubiquitination directly or facilitate recruitment of deubiquiti-
nating enzymes. Future studies to further define the effects of
NDR kinases on c-myc stability are warranted.
Various mechanisms control expression of the Cdk inhibitor
p21. The transcriptional regulation of p21 is well described and
includes p53-dependent and p53-independent mechanisms
(15). Here we show that the deregulation of p21 levels upon
knockdown of NDR is not based on changes in transcription of
the p21 gene (Fig. 3), indicating a novel aspect of p21 regula-
tion on a posttranscriptional level by NDR kinases. Degrada-
tion of p21 is mediated by both ubiquitin-dependent and -in-
dependent mechanisms (1). In addition, phosphorylation of
p21 has been shown to modulate a variety of p21 functions by
affecting p21 localization, complex formation, and degradation
(8). We show here that NDR1 and NDR2 phosphorylate p21
on S146 in vitro and in vivo, identifying p21 as the first in vivo
substrate for human NDR1/2 (Fig. 7 and 8). Direct substrates
of NDR/LATS orthologs in yeast and flies and also of mam-
malian LATS1/2 kinases have been discovered (6, 12, 28, 29,
33, 37). Interestingly, the aforementioned reports also defined
consensus phosphorylation motifs for NDR/LATS kinases in
yeast, flies, and mammals: for human LATS1/2 and fly warts,
HXRXXS; for yeast Dbf2p and Sid2p, RXXS; and for yeast
Cbk1p, HXR/K
R/KXS (H, histidine; R, arginine; K, lysine; S,
serine; and X, any amino acid). Interestingly, NDR1/2 kinases
seem to have a less stringent consensus, since they prefer a
stretch of positively charged basic amino acids N terminal of
the phosphorylation site (36). Nevertheless, the p21 phosphor-
ylation site of NDR, GRKRRQTS146M, matches a minimal
consensus for NDR kinases across species, RxxS. However,
further research in this area in order to define a precise con-
sensus phosphorylation motif of mammalian NDR1/2 kinases
is warranted.
Interestingly, endogenous p21 phosphorylation is reduced
upon knockdown of NDR kinases despite an increase in total
levels of p21 (Fig. 8). Phosphorylation of p21 on S146 has been
reported to both increase and decrease p21 protein stability,
depending on the cellular context and whether endogenous or
overexpressed p21 was analyzed (30, 39, 42, 55). In our setting
we could confirm the destabilizing effect of phosphorylated
S146 on p21 protein turnover (Fig. 8). Even more importantly,
our results show that increased p21 stability and subsequent
accumulation of p21 correlated with the increase of cells in G1
(Fig. 9). Furthermore, in rescue experiments using siRNAs
targeting p21 in cells depleted of NDR kinases, we observed a
significant release from G1 arrest compared to that in control
cells (Fig. 9) Therefore, p21 indeed is the main regulator of the
G1 arrest observed in NDR kinase-depleted cells.
Previous reports revealed a role for NDR kinases in regu-
lating mitotic chromosome alignment, centrosome duplication,
and apoptosis (7, 22, 50). In these contexts, however, NDR
kinases have been shown to function downstream of MST1 and
MST2 kinases (7, 22, 50), which have been established as
tumor suppressors as part of the HIPPO pathway (21, 56). A
third member of the MST kinase family, MST3, has also been
reported to act as an upstream kinase for NDR kinases (47),
but the biological significance of this MST3-NDR axis has
remained elusive. Here we identified MST3 as the main up-
stream kinase responsible for NDR activation in G1 (Fig. 1). In
addition, we observed an increase of active MST3 in G1 com-
pared to M phase, showing that MST3 activity can change in a
cell cycle-dependent manner. Furthermore, our experiments
confirmed a role of MST3 signaling in cell cycle regulation, as
depletion of MST3 resulted in effects on proliferation similar
to those observed for NDR kinases (Fig. 2D and 3B). MST3
signaling has been implicated in the regulation of axon out-
growth, cellular migration, and stress-induced apoptosis (5, 27,
31); however, any involvement of MST3 in cell cycle progres-
sion has not been described so far. Now, given our findings
regarding this novel role of MST3 in the control of cell cycle
progression, future research addressing the molecular activa-
tion mechanisms of MST3 is warranted.
Together, the findings described in this report lay a new
foundation for research addressing functions of NDR kinases
in cell cycle control. In combination with previous reports
regarding apoptotic signaling (10, 50), our results actually in-
dicate a potential dual role for NDR kinases in regulating cell
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proliferation and apoptosis. Intriguingly, the different and par-
tially opposing functions of mammalian NDR kinases seem to
depend on the MST kinase input: whereas NDR kinase func-
tion in apoptosis, tumor suppression, and centrosome duplica-
tion is dependent on MST1 (10, 22, 50), NDR kinases regulate
mitotic chromosome alignment downstream of MST2 (7). In
line with these findings, the regulation of cell proliferation by
NDR kinases described here depends not on MST1 or MST2
but on MST3. In conclusion, the MST3-NDR axis reported
here can promote cell proliferation via direct phosphorylation
of p21, thereby restricting p21 levels. Therefore, our work
might provide a platform for establishing a dual and most likely
cell context-dependent role for NDR kinases in normal and
cancer cell biology.
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 Figure S1. Single depletion of NDR kinase isoforms results in proliferation 
defects and G1-arrest independent of the centrosome checkpoint. (A) Knock-
down of NDR1 alone results in proliferation defects. HeLa cells expressing shRNA 
against NDR1 alone were seeded in triplicates and treated with tetracycline for the 
indicated time. Cells were either processed for immuno-blotting (left panel) or 
counted using a Vicell-automated cell counter. (B) Knock-down of NDR2 alone 
results in proliferation defects. HeLa cells expressing shRNA against NDR2 alone 
were treated and analyzed as in (A). (C) Validation of proliferation defects in different 
clones stably expressing shNDR1, shNDR2 or shNDR1/2 or shLUC (n=3; *, P < 
0.005). Experiments were performed as in (A) and differences in proliferation were 
calculated as percentage of cells without tetracycline to cells with tetracycline counted 
on day 6 after induction of shRNA expression. 
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 Figure S2. Validation of the effects of depletion of NDR kinases on 
proliferation, p21, p27 and c-myc levels. (A) Analysis of p21, p27 and c-myc levels 
in a different HeLa clone expressing shRNA against NDR1/2. shRNA expression was 
induced for 72h before harvest and analysis. (B) Analysis of p21, p27 and c-myc upon 
knock-down of NDR1 alone. Experiment was performed as in (A). (C) Analysis of 
p21, p27 and c-myc upon knock-down of NDR2 alone. Experiment was performed as 
in (A). (D) Analysis of p21, p27 and c-myc in a control clone expressing shLUC. 
Experiment was performed as in (A). (E) Validation of findings in HCT116 cells. 
Cells were transiently transfected with vectors expressing shLUC or shNDR1/2. 
Protein lysates were obtained 3 days after transfection. Cells were seeded in triplicates 
and counted after the indicated time using a Vicell-automated cell counter. (F) Effects 
of NDR1 depletion on p21 and p27 level and on proliferation are rescued by re-
expression of an NDR1wt rescue construct. U2OS cells expressing shNDR1 and 
rescue constructs were described and validated in Hergovich et al., 2007. Protein 
lysates were obtained 72h after tetracycline induction and cell counts were obtained as 
described in (E).  
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 Figure S3. NDR1 and NDR2 interact with and stabilize c-myc. (A) Effects of 
NDR depletion on c-myc levels can be rescued by proteasome inhibition. Knock-
down of NDR1/2 was induced for 48h. To inhibit proteasome-dependent degradation 
of c-myc, MG132 was added for the indicated time. (B) Endogenous NDR kinases 
and c-myc interact. NDR species or c-myc were immunoprecipitated from HeLa cell 
lysates using the indicated antibodies and complex formation was analyzed using 
SDS-PAGE. (C) Overexpressed NDR1 interacts with c-myc. HEK cells were 
transfected with cDNAs for c-myc and HA-NDR1wt and HA or myc precipitates 
were analyzed for interaction. (D) Both NDR1 and NDR2 interact with c-myc. HEK 
cells were transfected with HA-NDR1, HA-NDR2 and c-myc and complexes were 
analyzed as in (C). (E) Overexpression of NDR1wt and NDR1kd stabilizes c-myc. 
HEK cells were transfected with c-myc and the indicated NDR1 cDNAs. 24h later 
cells were treated with CHX for the indicated time and c-myc levels were assessed by 
SDS-PAGE and LICOR Odyssey system. (F) Hydrophobic-motif phosphorylation of 
NDR increases c-myc stability. HEK293 cells transfected with c-myc and NDR1 
constructs in the presence of absence of FLAG-MST3 were treated with CHX for 
120min and lysates were analyzed for the expression of c-myc, as compared to 
untreated samples, using the LI-COR Odyssey system. (G) NDR overexpression 
stabilizes endogenous c-myc levels. HEK293 cells were transfected with HA-tagged 
variants of NDR1 together with HA-MST3 where indicated and lysates were analyzed 
for the expression of endogenous c-myc 24h later (*, HA-MST3; **, HA-NDR). (H) 
NDR overexpression promotes c-myc dependent transcription. HEK293 cells were 
transfected with the indicated constructs and c-myc dependent transcription of the 
LDH-A promoter was analyzed (n = 3; P < 0.001). 
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 Figure S4. Validation of p21-Ser146 phosphorylation for both NDR1 and 
NDR2 in vitro. (A) Both NDR1 and NDR2 phosphorylate p21 in vitro. HA-tagged 
NDR2wt or HA-NDR2kd was immunoprecipitated from okadaic acid-stimulated 
HEK293 cells and after pre-incubation with cold ATP used for in vitro kinase assays 
with GST-p21 as substrate. (B) NDR1 phosphorylates p21 on S146. In vitro kinase 
assay to determine NDR phosphorylation site on p21. GST-p21 with mutated T145, 
S146 or doubly mutated T145/S146 phospho-acceptor sites were used as substrates 
for in vitro kinase assays as described in (A). Here NDR1 was immunoprecipitated 
from cells.  
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 Figure S5. G1-arrest after NDR kinase knock-down is rescued by reducing 
p21 levels using an additional independent siRNA targeting p21. (A) HeLa cells 
expressing shRNA against NDR1/2 were treated with tetracycline for 48h before 
being transfected with siRNA against p21 on two consecutive days. The cells were 
treated for G1-arrest analysis as described 24h after the second transfection. 
Quantification of cells in G1 after nocodazole treatment (n=3; P < 0.0025). (B) Cells 
obtained in (A) before nocodazole treatment were analyzed for the expression of p21 
and NDR1/2.  
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 Figure S6. NDR1 T444D and T444E display loss or reduced binding to c-myc. 
HEK 293 cells were transfected with c-myc together with the indicated HA-tagged 
NDR1 constructs. HA-tagged NDR1 species were immunoprecipitated and c-myc 
binding was analyzed by SDS-PAGE. 
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 Figure S7. Expression of DN-MST3 reduces G1-activation of NDR. HeLa cells 
were transfected with HA-tagged dominant-negative (DN) variants of MST1, MST2 
or MST3 and 24h later arrested with nocodazole for 14h. Arrested cells were 
harvested or released into G1 for 8h before harvesting. NDR activation was assessed 
using T-444-P antibody. Cell cycle phases were confirmed by analyzing Cyclin B1 
and p27 expression. Phospho-T444 levels after G1 release were compared to control 
samples and analyzed using the LI-COR Odyssey system. 
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Summary
Background: Human MST/hSAV/LATS/hMOB tumor suppres-
sor cascades are regulators of cell death and proliferation;
however, little is known about other functions of MST/hMOB
signaling. Mob1p, one of two MOB proteins in yeast, appears
to play a role in spindle pole body duplication (the equivalent
of mammalian centrosome duplication). We therefore investi-
gated the role of human MOB proteins in centrosome duplica-
tion. We also addressed the regulation of human centrosome
duplication by mammalian serine/threonine Ste20-like (MST)
kinases, considering that MOB proteins can function together
with Ste20-like kinases in eukaryotes.
Results: By studying the six human MOB proteins and five
MST kinases, we found that MST1/hMOB1 signaling controls
centrosome duplication. Overexpression of hMOB1 caused
centrosome overduplication, whereas RNAi depletion of
hMOB1 or MST1 impaired centriole duplication. Significantly,
we delineated an hMOB1/MST1/NDR1 signaling pathway
regulating centrosome duplication. More specifically, analysis
of shRNA-resistant hMOB1 and NDR1 mutants revealed that
a functional NDR/hMOB1 complex is critical for MST1 to phos-
phorylate NDR on the hydrophobic motif that in turn is required
for human centrosome duplication. Furthermore, shRNA-
resistant MST1 variants revealed that MST1 kinase activity is
crucial for centrosome duplication whereas MST1 binding to
the hSAV and RASSF1A tumor suppressor proteins is dispens-
able. Finally, by studying the PLK4/HsSAS-6/CP110 centriole
assembly machinery, we also observed that normal daughter
centriole formation depends on intact MST1/hMOB1/NDR
signaling, although HsSAS-6 centriolar localization is not
affected.
Conclusions: Our observations propose a novel pathway in
control of human centriole duplication after recruitment of
HsSAS-6 to centrioles.
Introduction
Centrosomes function as the main microtubule-organizing
centers in animal cells. Each centrosome is composed of
two centrioles surrounded by pericentriolar material [1–3].
They play an important part in organizing the bipolar spindle
during mitosis, ensuring equal distribution of genetic material
between the two daughter cells. Centrosomal components are
further required for the assembly and maintenance of cilia and
flagella, two structures with essential functions in mammalian
development and physiology [4, 5]. Therefore, the doubling of
centrosomes during S phase (termed centrosome duplication)
*Correspondence: hergo@fmi.chis under strict control. Studies with mammalian cells have
shown that centriole duplication is orchestrated by different
protein kinases, such as polo-like kinase 4 (PLK4), cyclin-
dependent kinase 2 (Cdk2), and NDR kinases [6–9].
The NDR/LATS family is a subgroup of AGC serine/threonine
protein kinases and consists of four related kinases (NDR1/
STK38, NDR2/STK38L, LATS1, and LATS2) in the mammalian
genome [10]. Although members of the NDR family have
been detected on spindle pole bodies (SPB) and centrosomes,
only human NDR1/2 kinases have been attributed a role in
centrosome duplication [11]. Although LATS1/2 kinases are
found on centrosomes, they are not involved directly in the
regulation of centrosome duplication in human cells [9]. In
multicellular organisms, LATS kinases play a central role in
Hippo/SWH (Salvador/Warts/Hippo) signaling, which coordi-
nates cell proliferation and apoptosis [12–14]. Initially delin-
eated in flies as the Hpo/Sav/Lats/dMOB1/Yki network,
mammalian MST/hSAV/LATS/hMOB/YAP tumor suppressor
signaling was also defined recently [15]. In mammalian cells,
this machinery regulates tissue homeostasis by balancing
cell proliferation and apoptotic events, where hSAV, MST1/2,
LATS1/2, and hMOB1 form complexes (summarized in [11]).
However, very little is known about other molecular functions
of MST/hMOB signaling.
Intriguingly, one study has already suggested that Mob1p
(the yeast counterpart of human hMOB1A/B proteins) plays
a role in SPB duplication [16]. Therefore, we analyzed in this
study all six human MOB proteins (hMOBs: hMOB1A,
hMOB1B, hMOB2, hMOB3A, hMOB3B, and hMOB3C) for a
potential involvement in centrosome duplication. Given that
MOB proteins can function together with Ste20-like kinases
in yeast, fly, and human cells [10], we further expanded our
study by addressing all human mammalian serine/threonine
Ste20-like kinases (MSTs: MST1, MST2, MST3, MST4, and
SOK1) in centrosome duplication. Significantly, we found that
MST1/hMOB1 signaling is required for centrosome duplica-
tion. Furthermore, we show here that centriole formation
depends on intact MST1/hMOB1/NDR signaling, although
the association of HsSAS-6 with centrioles appears to be
normal.
Results
Overexpression of hMOB1A/B Results in Centrosome
Overduplication
Given the intriguing observation with Mob1p [16], we initially
addressed hMOBs in human centrosome duplication by over-
expression studies (Figure 1). All six human MOB proteins
were overexpressed and the numbers of centrosomes per
mononucleated cell were determined by immunofluorescence
microscopy (Figure 1A). Except for hMOB2, all hMOBs were
detected mainly in the cytoplasm (Figure 1A). Overexpression
of hMOB1A/B caused a significant increase in cells displaying
extra centrosomes (three or more centrosomes per cell),
whereas expression of hMOB2, hMOB3A, and hMOB3B had
no effect (Figure 1B). Overexpression of hMOB3C resulted in
slightly increased centrosome amplification in U2-OS cells
(Figure 1B) but did not cause centrosome amplification in
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(A and C) U2-OS expressing indicated human MOB proteins (1A, 1B, 2, 3A, 3B, or 3C) for 48 hr were processed for immunofluorescence (A) or immunoblot-
ting (C) with the indicated antibodies.
(A) Insets show enlargements of centrosomes in green. DNA is stained blue.
(B) Histograms showing percentages of cells with excess centrosomes (more than three per mononucleated cell;R3). Cumulative data from two indepen-
dent experiments with at least two replicates of 100 cells counted per experiment. Error bars indicate standard deviations.
(D) Histograms showing percentages of cells with supernumerary centrosomes in HeLa cells. Cells were incubated with aphidicolin (2 mg/ml) for 8 hr before
being transfected with indicated cDNAs. Cells were incubated for a further 48 hr before processing for immunofluorescence. Cumulative data from two
independent experiments with at least two replicates of 100 cells counted per experiment. Error bars indicate standard deviations.
(E) Staining of U2-OS cells expressing HA-hMOB1A(wt) with antibodies against Cep170 (green), centrin (red), and HA (blue). Enlargements of centrioles
are shown.
(F) Quantification analysis of the experiment shown in (E). Cumulative data from three independent experiments with at least 100 cells counted per
experiment. Error bars indicate standard deviations.HeLa cells (Figure 1D). Notably, of the six hMOBs, expression
levels of hMOB1A and hMOB1B were consistently the lowest
for unknown reasons (Figure 1C; data not shown).
To investigate whether the generation of supernumerary
centrosomes resulting from hMOB1A/B overexpression is
a consequence of centriole/centrosome overduplication or
failure of cytokinesis, we arrested HeLa cells in S phase by
aphidicolin treatment and compared the induction of centro-
some amplification to that in untreated normally cyclingcells. Significantly, hMOB1A/B overexpression triggered
centrosome amplification regardless of the presence or
absence of aphidicolin (Figure 1D; data not shown). Centro-
somes do not overduplicate spontaneously during prolonged
S phase arrest in HeLa [17, 18], so these data suggest that
hMOB1A/B overexpression causes centrosome amplification
by an overduplication mechanism. To verify this finding, we
analyzed hMOB1A-overexpressing cells with increased
centrosome number for Cep170 staining (Figure 1E). If
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the majority of cells should contain only one Cep170-positive
centriole, whereas failure of cell division would cause the
accumulation of at least two mature Cep170-positive centri-
oles [19]. As seen in Figures 1E and 1F, the majority of
hMOB1A-expressing cells with supernumerary centrioles dis-
played only one Cep170-positive centriole, suggesting that
hMOB1A/B overexpression causes centrosome overduplica-
tion in our experimental system.
Endogenous hMOB1A/B Is Required for Centrosome
(Over)duplication
To study endogenous hMOB1A/B, centrosome overduplica-
tion assays [20] were performed in U2-OS cells depleted of
hMOB1A/B (Figure 2). In parallel to the generation of a
hMOB1A/B antibody that selectively recognized hMOB1A
and hMOB1B (Figure S1 available online), stable cell lines
were generated expressing tetracycline-inducible short hairpin
RNA (shRNA) directed against hMOB1A/B (Figure 2A). Of note,
hMOB1A and hMOB1B mRNAs had to be targeted simulta-
neously by two different shRNAs, to allow efficient knockdown
of total hMOB1A/B protein levels (Figure 2A). Significantly,
centrosome amplification was altered in hMOB1A/B-depleted
cells upon S phase arrest (Figures 2B and 2C). To ensure the
specificity of our RNAi experiments, wild-type hMOB1A cDNAs
refractory to shRNA were introduced into U2-OS cells express-
ing inducible vector-based RNAi (Figure 2D). Expression of
shRNA-resistant hMOB1A restored centrosome overduplica-
tion upon depletion of endogenous hMOB1A/B (Figure 2E),
indicating that the failure of hMOB1A/B-depleted cells to
efficiently overduplicate centrosomes is due to specific
knockdown of endogenous hMOB1A/B.
To address hMOB1A/B in normal centriole duplication, we
analyzed centriole numbers at the end of the centriole duplica-
tion cycle [9, 21]. Nearly 50% of hMOB1A/B-depleted cells
lacked at least one centriole in early mitotic stages (Figures
2F and 2G; control: 9.3% 6 1.7%; hMOB1A/B knockdown:
47.2% 6 8.7%). About 34% of hMOB1A/B-depleted cells
displayed bipolar spindles containing only three centrioles
instead of the normal four centrioles per cell (untreated control
background: 8%), and 13% of hMOB1A/B-depleted cells con-
tained only one or two centrioles (control: 2%). Depletion of
endogenous hMOB1A/B in HeLa and diploid untransformed
RPE1 cells also resulted in decreased centriole numbers
(Figure S2). U2-OS cells expressing shRNA-resistant hMOB1A
did not display a significant loss of centrioles upon depletion of
endogenous hMOB1A/B (Figure 2G; control: 10.2% 6 2.9%;
hMOB1A/B knockdown with shRNA-resistant hMOB1A:
13.5% 6 4%), suggesting that endogenous hMOB1A/B
contributes to normal centriole duplication in human cells.
hMOB1A/B Regulates Hydrophobic Motif Phosphorylation
of NDR Kinase
hMOB1A/B proteins have already been reported to interact
with NDR kinases [22–27]; hence, NDR1/2 protein levels were
analyzed in hMOB1A/B-depleted cells upon S phase arrest.
Significantly, phosphorylation of NDR1/2 on Thr444 (the
hydrophobic motif of NDR1) was strongly diminished upon
hMOB1A/B knockdown (Figure 2A) and partially restored by
expression of shRNA-resistant hMOB1A (Figure 2D). This
finding was surprising, because recombinant hMOB1A did
not cause an increase in NDR1/2 phosphorylation on Thr444
in vitro [22] and hMOB1A/B is not required for hydrophobic
motif phosphorylation of LATS1 in cells [26]. Nevertheless,our findings suggest that hMOB1A/B regulates the phosphor-
ylation of NDR1/2 on Thr444 by upstream kinase(s) upon S
phase arrest of cells.
hMOB1/NDR Complex Formation Is Essential for Efficient
Centrosome Duplication and NDR Phosphorylation
Before addressing the nature of the upstream kinase(s), we
determined whether the interaction of hMOB1A/B with NDR1/
2 is required for the regulation of centrosome duplication. First,
the effects of selected NDR1 mutants (initially defined in
[22, 25]) on the centrosome cycle were examined (Figure 3).
These NDR1 mutants displayed intact hMOB2 binding,
although interactions with hMOB1A/B (also termed hMOB1)
were undetectable (Figure S3; data not shown). All NDR1 vari-
ants expressed at comparable levels and displayed similar
subcellular distribution (Figures 3A and 3B; data not shown).
However, only overexpression of NDR1(wt) resulted in centro-
some amplification (Figure 3C). Overexpression of NDR1
kinase-dead (kd) or NDR1 deficient in hMOB1 binding did not
increase centrosome numbers (Figure 3C). Expression of
shRNA-resistant NDR1 mutants did not restore centrosome
overduplication upon depletion of endogenous NDR1 (Fig-
ure 3E). These mutants also displayed dramatically decreased
phosphorylation on Thr444 (Figure 3D), suggesting that NDR1/
hMOB1 complex formation is required for Thr444 phosphoryla-
tion and centrosome amplification.
To further address the role of hMOB1/NDR complex forma-
tion, we generated a hMOB1A(E51K) mutant deficient in
NDR1/2 binding (Figure S4). Overexpression of hMOB1A(E51K)
did not lead to centrosome overduplication, even though
expression and localization were not significantly changed
(Figure S5). Moreover, shRNA-resistant hMOB1(E51K) did not
compensate for the depletion of endogenous hMOB1A/B (Fig-
ure S5). Furthermore, although NDR1 expression and subcel-
lular localization were not obviously affected upon knockdown
of hMOB1A/B, NDR1-driven centrosome overduplication was
impaired in hMOB1A/B-depleted cells (Figure S6; data not
shown). Inversely, centrosome amplification resulting from
overexpression of hMOB1A was decreased in NDR1-depleted
cells (Figure S6; data not shown). Overall, the findings
described in Figure 3 and Figures S5 and S6 strongly suggest
that a functional hMOB1/NDR complex is indispensable for
centrosome overduplication.
MST1Kinase Regulates Centrosome (Over)duplication and
NDR Phosphorylation in a hMOB1A/B-Dependent Manner
Our data shown in Figure 2 and Figure S5 suggested that
hMOB1A/B regulates the phosphorylation of NDR1/2 by
upstream kinase(s). Therefore, we investigated whether any
of the postulated upstream activators (the entire group of
MST kinases [10]) is responsible for Thr444 phosphorylation
in a hMOB1A/B-dependent manner (Figure 4). In U2-OS cells,
overexpression of MST1(wt) increased phosphorylation of
endogenous NDR1/2 the most efficient (Figure 4A and
Figure S7), although MST1, MST2, and MST3 can phosphory-
late NDR1/2 on Thr444 in vitro [27, 28]. This increase in
NDR1/2 phosphorylation was dependent on MST1 kinase
activity (Figure 4A) and was blocked in hMOB1A/B-depleted
cells but restored by expression of shRNA-resistant
hMOB1A(wt) upon hMOB1A/B knockdown (Figure 4B). In full
agreement with our previous observations (Figure 2 and
Figure S5) these results suggest that MST1 phosphorylates
NDR1/2 on Thr444 in a hMOB1A/B-dependent manner.
Furthermore, they suggest that MST1 kinase might be involved
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1695Figure 2. Endogenous hMOB1A/B Is Required for Centrosome Duplication
(A and B) U2-OS cells stably expressing tetracycline-regulated short-hairpin RNA (shRNA) directed against hMOB1A/B were incubated for 72 hr without (2)
or with (+) tetracycline (2 mg/ml) and for a further 72 hr with aphidicolin (2 mg/ml), before processing for immunoblotting (A) or immunofluorescence (B) with
the indicated antibodies.
(B) DNA is in blue. Insets show centrosome enlargements in red.
(C) Histograms showing percentages of cells with excess centrosomes (R3) incubated without (2) or with (+) tetracycline, followed by incubation with aphi-
dicolin. Cumulative data from three independent experiments with at least two replicates of 100 cells counted per experiment. Error bars indicate standard
deviations.
(D) U2-OS stably expressing shRNA against hMOB1A/B were infected with empty vector (lanes 1–4) or HA-hMOB1A wild-type cDNA (lanes 5–8) that is
refractory to shRNA [wt_9N]. After incubation for 72 hr with (+) or without (2) tetracycline and for an additional 72 hr with aphidicolin, cells were processed
for immunoblotting with the indicated antibodies.
(E) In parallel, cells were processed for immunofluorescence to determine centrosome numbers per cell. Histograms show the percentage of cells with
excess centrosomes (R3) incubated without (2) or with (+) tetracycline, followed by incubation with aphidicolin. Cumulative data from two independent
experiments with at least two replicates of 100 cells counted per experiment. Error bars indicate standard deviations.
(F) U2-OS cells expressing shRNA directed against hMOB1A/B were incubated without (2) or with (+) tetracycline for 96 hr, before processing for immuno-
fluorescence with centrin (green) and a-tubulin (red) antibodies. DNA is shown blue.
(G) Histograms showing percentages of mitotic cells in prophase and prometaphase that displayed the loss of at least one centriole (%3 centrioles per cell)
in the presence (+) or absence (2) of tetracycline. Cumulative data from three independent experiments with at least 100 cells counted per experiment. Error
bars indicate standard deviations.
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(A and B) U2-OS cells expressing HA-NDR1 wild-type(wt), kinase-dead(kd), or hMOB1A/B binding mutants (Y31A, R41A, or T74A) for 48 hr were processed
for immunoblotting (A) or immunofluorescence (B) with the indicated antibodies.
(B) Insets show enlargements of centrosomes in green. DNA is stained blue.
(C) Histograms showing percentages of cells with excess centrosomes (R3). Cumulative data from three independent experiments, with at least 150 cells
counted per experiment. Error bars indicate standard deviations.
(D and E) U2-OS cells stably expressing tetracycline-regulated short-hairpin (shRNA) directed against human NDR1 were infected with empty vector (lanes
1–3), HA-NDR1 wild-type (lanes 4 and 5), or hMOB1A/B binding mutants (lanes 6–11) that are refractory to shRNA [HA-NDR1(6N)]. After incubation for 72 hr
without (2) or with (+) tetracycline and for a further 72 hr with aphidicolin, cells were analyzed by immunoblotting with the indicated antibodies (D) or by
immunofluorescence for centrosome numbers (E).
(E) Histograms showing percentages of cells with excess centrosomes (R3). Cumulative data from two independent experiments, with at least two
replicates of 100 cells counted per experiment. Error bars indicate standard deviations.in the regulation of centrosome (over)duplication and Thr444
phosphorylation upon S phase arrest.
To address this experimentally, stable cell lines were
generated expressing tetracycline-inducible shRNA directed
against MST1 (Figure 4C). Phosphorylation of NDR1/2 onThr444 was decreased in MST1-depleted cells (Figure 4C), indi-
cating that MST1 is the main upstream kinase under these
conditions. Significantly, centrosome overduplication was
decreased upon MST1 knockdown (Figure 4D). By analyzing
the number of centrioles at the end of the centriole duplication
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(A) U2-OS transfected with indicated cDNAs for 20 hr were processed for immunoblotting with the indicated antibodies.
(B) U2-OS stably expressing shRNA against hMOB1A/B (lanes 1–3), or the same cells infected with empty vector (lanes 4–6) or shRNA-resistant HA-hMOB1A
(wt_9N) (lanes 7–9) were incubated without (2) or with (+) tetracycline for 72 hr before being transfected with HA-MST1(wt) overnight. Subsequently, cells
were processed for immunoblotting with the indicated antibodies.
(C) U2-OS cells stably expressing tetracycline-regulated short-hairpin RNA (shRNA) directed against human MST1 were incubated for 72 hr without (2) or
with (+) tetracycline and for a further 72 hr with aphidicolin, before processing for immunoblotting.
(D) In parallel, cells were analyzed by immunofluorescence microscopy. Histograms show the percentages of cells with excess centrosomes (R3) incubated
without (2) or with (+) tetracycline, followed by incubation with aphidicolin. Cumulative data from three independent experiments with at least two replicates
of 100 cells counted per experiment. Error bars indicate standard deviations.
(E) U2-OS stably expressing shRNA against MST1 were analyzed after 96 hr with (+) or without (2) tetracycline. Histograms show the percentage of mitotic
cells in prophase and prometaphase that lost at least one centriole (%3 centrioles per cell). Cumulative data from three independent experiments with at
least 100 cells counted per experiment. Error bars indicate standard deviations.
(F and G) U2-OS cells expressing the indicated cDNAs were processed for immunoblotting (F) or immunofluorescence (G) with indicated antibodies.
(G) Insets show centrosome enlargements in green. DNA is shown blue.
(H) Histograms showing percentages of cells with excess centrosomes (R3). Cells expressing the indicated kinase-dead(kd) MST kinases were incubated
with aphidicolin for 72 hr. Cumulative data from four independent experiments with at least two replicates of 100 cells counted per experiment. Error bars
indicate standard deviations.cycle (see Figure 2F), we found that 32%of MST1-depleted cells
lacked at least one centriole (Figure 4E; control: 10.1%6 0.7%;
MST1 knockdown: 32.3%6 4.5%). Knockdown of endogenousMST1 in HeLa and RPE1 cells also caused loss of centrioles
(Figure S2), indicating that endogenous MST1 contributes to
normal centriole duplication in different human cells.
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(kd) overexpression (Figures 4F–4H), because MST1(kd) can
function as a dominant-negative kinase [29]. Significantly,
centrosome overduplication was impaired in U2-OS cells ex-
pressing MST1(kd), whereas overexpression of MST2(kd),
MST3(kd), MST4(kd), or YSK1/SOK1(kd) had no effect, despite
similar expression and subcellular localization patterns (Fig-
ures 4F–4H; data not shown). Because MST2(kd), MST3(kd),
MST4(kd), and SOK1(kd) can also function as dominant-nega-
tive kinases [30], these findings suggest that mainly MST1
contributes to centrosome overduplication in our settings.
However, although MST1 plays a role in NDR1/2 phosphoryla-
tion and centrosome duplication (Figure 4), these findings did
not necessarily demonstrate that NDR-driven centrosome
duplication requires MST1. Thus, we determined the effect of
NDR1(wt) or hMOB1A overexpression on centrosome amplifi-
cation in MST1-depeleted cells, revealing that NDR1- or
hMOB1A-driven centrosome overduplication was impaired in
MST1-depleted cells (Figure S8). Therefore, it is very likely
that centrosome duplication is regulated by MST1/hMOB1/
NDR signaling in our experimental systems.
MST1 Kinase Activity, but Not RASSF1A or hSAV Binding,
Is Required for Centrosome Amplification
MST1 kinase is controlled by various mechanisms [30], most
importantly by binding to RASSF1A, hSAV, or to itself via a
C-terminally located SARAH (Sav/Rassf/Hippo) domain [31–
35]. Therefore, we generated a C-terminally truncated form of
MST1 (residues spanning 1–433; termedDC) that was deficient
in hSAV-, RASSF1A-, and homodimer-complex formation
(Figure S9). Surprisingly, overexpressed MST1(DC) phosphor-
ylated NDR1/2 on Thr444 similarly to MST1(wt) kinase
(Figure S9).
Given this observation, we introduced MST1(wt), (kd), and
(DC) cDNAs refractory to shRNA into U2-OS-expressing induc-
ible vector-based RNAi against MST1 (Figure 5A). Although
expression of shRNA-resistant MST1(wt) restored centrosome
overduplication and Thr444 phosphorylation of NDR1/2 in
MST1-depleted cells, shRNA-resistant MST1(kd) did not
compensate for MST1 depletion, despite similar localization
and expression levels (Figure 5; data not shown). Significantly,
expression of shRNA-resistant MST1(DC) supported centro-
some amplification upon depletion of endogenous MST1
(Figure 5B) and phosphorylation of Thr444 (Figure 5A). These
data show that binding of MST1 to RASSF1A, hSAV, or homo-
dimer formation through the SARAH domain is dispensable for
centrosome overduplication, whereas MST1 kinase activity is
crucial.
The MST1/hMOB1/NDR Cascade Is Required for Human
Centriole Duplication, but Dispensable for Centriolar
‘‘Seed’’ Formation
To understand in more detail the role of MST1/hMOB1/NDR
signaling in human centriole duplication, we investigated
whether the MST1/hMOB1/NDR machinery is required for
PLK4-driven centriole biogenesis (Figure 6). As already
reported [21], overexpression of PLK4 is sufficient to trigger
centriole amplification, where two types of procentriole
arrangements have been observed: centrioles arranged either
in (1) flower-like structures around parental centrioles, or (2)
clusters of centrioles after disengagement [36]. Significantly,
PLK4-driven centriole amplification was impaired in
hMOB1A/B-, MST1-, or NDR1-depleted cells, although PLK4
expression and centriole localization were not obviouslyaffected (Figure 6; Figure S10; data not shown). Moreover, no
significant differences in cell cycle profiles were observed
upon depletion of MST1/hMOB1/NDR signaling components
and/or PLK4 overexpression (Figure 6D; Figures S10 and
S11), suggesting that the observed defect in centriole amplifi-
cation is not simply a consequence of a general cell cycle
arrest. Overall, reduction of MST1/hMOB1/NDR signaling
appears to negatively affect PLK4-driven centriole biogenesis
without any direct effect on PLK4 expression, subcellular local-
ization, and cell cycle profiles.
Next, we addressed whether MST1/hMOB1/NDR signaling
might play a role in other steps of the centriole assembly
pathway conserved from lower to higher eukaryotes [37–52].
In human cells, after the activation of PLK4 on the parental
centriole, g-tubulin, CPAP, Cep135, and HsSAS-6 are rapidly
recruited to the centriole [36]. Then, CP110 forms a cap on
the newly forming procentriole, and finally, the centriole grows
by addition of tubulin. To determine any involvement of MST1/
hMOB1/NDR signaling in this pathway, we focused our anal-
ysis on centrosomes and centrioles at the end of the centriole
duplication cycle (as already defined in Figure 2F). Cell lines
expressing inducible shRNA directed against hMOB1A/B,
MST1, or NDR1 were cultured in the absence or presence of
tetracycline without apparent changes in cell cycle profiles
and protein expression, except for the targeted proteins of
interest (Figures 7A and 7B; Figures S11 and S12). As expected
[53, 54], normal prophase cells (with condensed DNA and
Figure 5. MST1 Kinase Activity, Not the SARAH Domain, Is Required for
Centrosome Overduplication in Human Cells
(A) U2-OS stably expressing shRNA against MST1 were infected with empty
vector (lanes 1–3), HA-MST1 wild-type (lanes 4–6), kinase-dead (lanes 7–9),
or a C-terminally truncated mutant cDNA (DC; lanes 10–12) that is refractory
to shRNA [wt_7N, kd_7N, or DC_7N]. After incubation for 72 hr with (+) or
without (2) tetracycline and for an additional 72 hr with aphidicolin, cells
were processed for immunoblotting with indicated antibodies.
(B) In parallel, the number of centrosomes per cell was determined. Histo-
grams show the percentage of cells with excess centrosomes. Cumulative
data from three independent experiments with at least two replicates of
100 cells counted per experiment. Error bars indicate standard deviations.
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two CP110 signals at each spindle pole (Figures 7C and 7E).
Interestingly, the association of HsSAS-6 with prophase
centrosomes was not altered upon hMOB1A/B, MST1, or
NDR1 depletion (Figure 7C; data not shown). Irrespective of
the decreased centriole number per spindle pole, HsSAS-6
associated with centriole pairs or single centrioles (Figure 7D;
data not shown).
Next, to address in more detail whether the cell cycle-
dependent centriole localization of HsSAS-6 [54] relies on
MST1/hMOB1/NDR signaling components, we determined
the cell cycle stages of individual cells by PCNA staining (Fig-
ures S13 and S14). In full agreement with existing literature
[54], HsSAS-6 was not detected on centrioles in most U2-OS
cells during G1 phase, but was present on the majority of
centrioles in S and G2 phase (Figure S14). It is noteworthy
that depletion of hMOB1A/B, MST1, or NDR1 did not affect
this cell cycle-regulated HsSAS-6 localization pattern (Fig-
ure S14; data not shown). Taken together, these findings
suggest that the initiation of procentriole formation (also
termed centriolar ‘‘seed’’ formation; see [36, 54]) is indepen-
dent of MST1/hMOB1/NDR signaling.
In contrast, despite unaffected DNA condensation and
centrosome separation, a significant portion of hMOB1A/B-,
MST1-, or NDR1-depleted cells lacked at least one CP110
centriole signal in prophase (Figure 7E; control [without
Figure 6. PLK4-driven centriole biogenesis is
impaired upon hMOB1A/B or MST1 depletion
(A and B) U2-OS stably expressing shRNA
against hMOB1A/B (lanes 1–3), or MST1 (lanes
4–6) were incubated without (2) or with (+) tetra-
cycline for 72 hr before being transfected with
GFP-PLK4(wt) overnight. Subsequently, cells
were processed for immunoblotting (A) or immu-
nofluorescence (B) with the indicated antibodies.
(B) Insets show enlargements of centrioles. GFP-
PLK4 is in green and centrioles are shown in red.
DNA is stained blue.
(C) Histograms showing percentages of cells with
excess centrioles (R5). Cumulative data from
two independent experiments, with at least two
replicates of 100 cells counted per experiment.
Error bars indicate standard deviations.
(D) In parallel, cells from the same samples were
analyzed for DNA content by FACS.
tetracycline induction], 8% [n = 130];
hMOB1A/B knockdown, 44% [n = 142];
control, 7% [n = 121]; MST1 knockdown,
30% [n = 127]; control, 9% [n = 131];
NDR1 knockdown, 41% [n = 116]). As
already described for centrin-2 (see
Figures 2F, 2G, and 4E), CP110 signals
displayed reduced numbers of centri-
oles in depleted cells (Figure 7F; data
not shown). Two additional centriole
markers (glutamylated-tubulin and
acetylated-a-tubulin) further confirmed
that centriole numbers are decreased
upon hMOB1A/B, MST1, or NDR1
depletion (Figure S15; data not shown).
Overall, the analysis of depleted
cells with five independent centriole
markers—HsSAS-6, CP110, centrin-2,
glutamylated-tubulin, and acetylated-a-tubulin—revealed
that MST1/hMOB1/NDR signaling is required for normal
centriole duplication in human cells, although the association
of HsSAS-6 with centrioles does not appear to be affected.
Discussion
Taken together, our findings indicate that MST1/hMOB1/NDR
signaling contributes to centriole duplication in human cells.
Endogenous hMOB1A/B and MST1 are required for normal
centriole duplication (Figures 2, 4, and 5). The association of
hMOB1A/B with NDR1/2 kinases is essential for centrosome
duplication (Figure 3; Figure S5). Moreover, centrosome over-
duplication requires MST1 kinase activity but is independent
of the SARAH domain of MST1 (Figure 5). Because MST1
binding to hSAV, RASSF1A, NORE1, and CNK1 depends on
the SARAH domain of MST1 [30], this suggests that all
currently known activators/inhibitors of MST1 are unlikely to
contribute to MST1 signaling in centrosome duplication.
Our data would indicate that MST1 kinase activity plays
a role in human centrosome duplication, although MST1 is
best known as a proapoptotic kinase [30] whose activity is
enhanced by RASSF1A/MST1 complex formation [34].
RASSF1A binding to MST1 through the SARAH domain also
increased NDR1/2 kinase activity in apoptotic cells [27]. In
contrast, MST1 signaling in centrosome duplication is SARAH
Current Biology Vol 19 No 20
1700domain independent (Figure 5). This suggests that the SARAH
domain of MST1 might exemplify the means by which human
cells utilize similar signaling systems for the regulation of
very different biological processes (e.g., programmed cell
death versus centrosome duplication in the case of MST1/
hMOB1/NDR signaling). Considering further that centrosome
duplication occurs in S phase, it is tempting to speculate
that MST1 kinase regulates NDR1/2 kinases in a cell cycle-
dependent manner. Intriguingly, we could confirm the reported
[55] S-phase-induced phosphorylation of MST1 (Figure S16),
suggesting that MST1 kinase activity could oscillate during
the cell cycle. As a result, a new line of research will be required
to elucidate how MST1 activity is regulated (in)dependently of
its SARAH domain during the cell cycle. Hence, future research
addressing the role of MST1/hMOB1/NDR signaling in cell
cycle progression is warranted.
Our data suggest that MST1 regulates human centrosome
duplication through the phosphorylation of endogenous
NDR1/2 in S phase (Figures 4 and 5). However, human
LATS1/2, histone 2B (H2B), and FoxO have also been identified
as MST1 substrates [56–58]. In this context, it is noteworthy
that LATS1/2 are not involved in centrosome duplication [9].
Of further importance, caspase-cleaved MST1 phosphorylates
H2B in the nucleus, whereas full-length MST1 targets cytosolic
Figure 7. Centriole Localization of CP110, but
Not of HsSAS-6, Depends on MST1/hMOB1
Signaling
(A and B) U2-OS cells expressing shRNA directed
against hMOB1A/B (lanes 1 and 2) or MST1 (lanes
3 and 4) were incubated without (2) or with (+)
tetracycline for 96 hr before processing for
immunoblotting (A) or DNA content analysis by
FACS (B).
(C–F) In parallel, U2-OS cells expressing shRNA
directed against hMOB1A/B were processed for
immunofluorescence with indicated antibodies.
g-tubulin (centrosome) and acetylated-a-tubulin
(centriole) stainings are in red. DNA is shown
blue. Insets show enlargements of centro-
somes/centrioles. Schemes on the right indicate
HsSAS-6 and CP110 localization on centrioles
in green.
FoxO1 in a SARAH domain-dependent
manner [59]. Therefore, considering
that cytoplasmic MST1 lacking the
SARAH domain is capable of driving
centrosome overduplication (Figure 5;
data not shown), it is rather unlikely
that the phosphorylation of H2B or
FoxO by MST1 plays a role in the centro-
some cycle. Taking into further account
that shRNA-resistant NDR1(T444A)
cannot restore centrosome overduplica-
tion in NDR1-depleted cells (Figure S17),
our data indicate that the phosphoryla-
tion of NDR1/2 on Thr444 by MST1 is
a key event in the regulation of centro-
some duplication in this setting.
We also found that hydrophobic motif
phosphorylation of NDR1/2 requires
endogenous hMOB1A/B in addition to
MST1 (Figures 2 and 4). The analysis of
NDR1 and hMOB1A mutants (Figure 3;
Figure S5) showed that a functional NDR/hMOB1 complex is
critical for the phosphorylation of NDR on the hydrophobic
motif by MST1, which in turn is required for human centrosome
duplication (Figure S18).
Significantly, we also addressed at which step MST1/
hMOB1/NDR signaling controls centriole duplication in human
cells. Although PLK4-driven centriole amplification is impaired
upon depletion of MST1/hMOB1/NDR components, the asso-
ciation of PLK4 with centrioles is not affected (Figure 6). The
recruitment of HsSAS-6 to centrioles is also independent of
the MST1/hMOB1/NDR cascade (Figure 7). Therefore, the
two first steps of the human centriole assembly pathway [36,
54], namely PLK4 and HsSAS-6 localization to centrioles,
appear to be normal upon knockdown of MST1/hMOB1/NDR
signaling components. However, recruitment of centrin-2
and CP110 to procentrioles appears to depend on an intact
MST1/hMOB1/NDR cascade (Figures 2, 4, and 7). Although
the incorporation of CP110 and centrin-2 into nascent procen-
trioles occurs rapidly [36], we observed that a significant
fraction of MST1/hMOB1/NDR knockdown cells displayed
reduced centriole staining (Figures 2, 4, and 7). Collectively,
these observations suggest that MST1/hMOB1/NDR signaling
is important for efficient centriole duplication (daughter
centriole formation), even though the initiation of procentriole
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centrioles) appears to be normal (Figure S18).
The stabilization of a first centriolar seed is very likely to be
a rate-limiting step in human centriole duplication [36, 54].
However, our data would suggest that human centriole dupli-
cation can also be regulated after the initiation step involving
PLK4/HsSAS-6. Currently, we do not know precisely at which
step centriole duplication is blocked in MST1-, hMOB1-, or
NDR1-depleted cells (Figure S18). Most likely, a combination
of live cell imaging and electron microscopy will be required
to decipher exactly at which stage daughter centriole forma-
tion depends on MST1/hMOB1/NDR signaling. Given that the
MST1/hMOB1/NDR cascade also plays a role in the regulation
of apoptosis [27], future research will also be needed to
address how MST1/hMOB1/NDR signaling can be fine-tuned
to allow the regulation of different biological aspects by the
same signaling modules. In this context, another future chal-
lenge will be the identification of NDR substrates that play
a direct role in centriole duplication and/or apoptosis. A further
challenge will be to test how far the role of MST1/hMOB1/NDR
signaling in centrosome duplication is conserved from yeast to
man. Taken together, the elucidation of a role for the MST1/
hMOB1/NDR pathway in centrosome duplication reported
here might open novel avenues in the pursuit of centriole dupli-
cation signaling as well as molecular function(s) that might
contribute to tumor-suppressing activities of MST1 and
hMOB1.
Experimental Procedures
Cell Culture, Transfections, and Chemicals
U2-OS, HeLa, PT67, COS-7, and RPE1-hTert cells were maintained in
DMEM supplemented with 10% fetal calf serum. U2-OS, HeLa, COS-7,
and RPE1-hTert cells were plated at a consistent confluence and trans-
fected with Fugene 6 (Roche), jetPEI (PolyPlus Transfection), or Lipofect-
amine 2000 (Invitrogen) as described by the manufacturer. Aphidicolin
was from Calbiochem.
Generation of Stable Cell Lines
To generate tetracycline-inducible cell lines, U2-OS T-Rex cells were trans-
fected with pTER constructs [60] expressing shRNA against hMOB1A/B or
MST1. Cell clones were selected and maintained as described previously
[9]. Retroviral pools of rescue cell lines were generated as described else-
where [9]. U2-OS Tet-On cells expressing tetracycline-regulated shRNA
against NDR1 have been described already [9].
Immunoblotting, Immunoprecipitation, Cell Fractionation,
Immunofluorescence Microscopy, and FACS
Immunoblotting, coimmunoprecipitation, and cell fractionation experi-
ments were performed as described [25]. Cells were processed for FACS
and immunofluorescence as defined elsewhere [9].
Supplemental Data
Supplemental Data include Supplemental Experimental Procedures
(construction of plasmids; antibody sources) and 21 figures and can be
found with this article online at http://www.cell.com/current-biology/
supplemental/S0960-9822(09)01698-4.
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